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Abstract
Apoptosis is a complex and ubiquitous physiological program for the deletion of cells in
which caspases typically direct morphological and biochemical changes leading to safe clearance by
phagocytes. However, a growing body of evidence now suggests that not all forms of cell death
require caspases, and that caspases themselves can participate in cellular events that do not ultimately
lead to the demise of the cell.
Maintenance of platelet number, thrombostasis, is an essential element for the preservation of
haemostasis, and thus the existence of a complex metazoan. The platelet is a small anucleate cell
found only in the circulation and is primarily responsible for maintaining the integrity of the vascular
system. This is achieved by aggregating to one another and to exposed ECM to form part of the
physical barrier to prevent blood loss, and by directing repair to the damaged endothelium. Platelets
are formed in the bone marrow by a poorly understood cellular fragmentation of their progenitor, the
megakaryocytes, and thus megakaryocyte proliferation has been the focus of study in understanding
the control of platelet numbers.
This thesis reports that thrombostasis is potentially maintained by the relative level of two
opposing and different cell death programs within megakaryocytes and platelets. Firstly, platelet
formation from megakaryocytes occurs by a unique, compartmentalised form of caspase-dependent
apoptosis that results in the formation of multiple functional anucleate progeny. However, whilst the
megakaryocyte cell body contains active caspases and displays nuclear condensation and
fragmentation typical of apoptosis, the forming platelets retain functional mitochondria, do not
contain active caspases, and are not phagocytosed, emphasising an atypical compartmentalised
mitochondrion-independent apoptotic program. Platelet formation from megakaryocytes could be
significantly augmented by ligation of the Fas death receptor, and reduced by treatment with caspase
inhibitors.
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Secondly, this thesis reports a constitutive but caspase-independent program for the specific
phagocytic clearance of intact effete platelets. Platelets aged in vitro exhibited increased expression
of proapoptotic Bak and Bax, underwent diminution of function, and displayed cytoplasmic
condensation and plasma membrane changes that lead to recognition by phagocyte scavenger
receptors. However, although platelets contained the effector caspase-3 they lacked caspase-9, a key
component of the apoptosis initiator complex the apoptosome. Intriguingly, megakaryocytes
contained both caspase-3 and -9, suggesting sequestration of the enzyme by the progenitors during
platelet formation, again underscoring the compartmentalised death of megakaryocytes and thus
explaining the inability of platelets to activate caspases during constitutive death, and hence their
commitment to undergo a caspase-independent death.
In summary, this study demonstrates that platelet numbers may in part be controlled by the
level ofmegakaryocyte apoptosis within the bone marrow, and hence number of platelets released into
circulation, and inversely by a constitutive death program within the platelet leading to biochemical
changes resulting in their clearance and hence removal from the circulation. Although limited in its in
vivo relevance, the study also emphasises that diseases of thrombostasis may reflect abnormalities in
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Chapter 1 - Introduction
i
Apoptosis and cell death
1.1 Historical Background
There is an ancient samurai saying from the Hagakure that says, "once we are in the land of
the living, we will eventually die" (Tsunetomo 1716). This is of course true not only for humans but
also for the cells from which we are made. We are all derived from one single egg, which after
repeated cell division becomes the billions of cells that constitute our bodies. During this process
many damaged, unwanted, or harmful cells must be removed in a safe and efficient way. The study of
cell death - including apoptosis - now holds near to 100,000 publications, but although biologists have
assumed the field to have first appeared in the 1970s, as with most science we have spent much of our
time reinventing the wheel, the true "birth" of cell death being in the late nineteenth century. One of
the earliest recorded investigations comes from the German development biologist Vogt who
characterised the natural death of notochordal and cartilaginous cells during development (1842).
However not until forty years later was unmistakable evidence of what we now refer to as apoptosis
seen, with Flemming's study of regressing ovarian follicles containing hand drawn microscope
transcriptions of cells showing clear margination of chromatin (1885). After a promising start the
field changed direction to study the removal of cell corpses, with the Russian emigre Ilya Mechnikov
winning a Nobel Prize for his discovery of phagocytosis (1908). Perhaps in some ways this reflects
the paradigm shift seen at present with the final stage, and as many would argue the most important
step of apoptosis, the phagocytic clearance, emerging to take centre stage once again.
However, it was not until the early 1970s when the true extent of the implications of
apoptosis, and at that time coined "shrinkage necrosis", was appreciated. Following the union of "the
grandfathers of apoptosis", John Kerr, Andrew Wyllie and A.R. Currie in Aberdeen, the three
published their seminal paper (1972). This described the key observations that dying cells were in
fact following a specific and conserved pathway, and most importantly that the program was a
biological phenomena "as natural as mitosis, secretion, or glycolysis". In addition, they extended
2
their findings to the wide-ranging implications that the regulated kinetics of such a program would
have on the control of an animal's total cell population - tissue homeostasis. Following consultation
with James Cormack, a professor of Ancient Greek, the term "apoptosis" was coined, deriving from a
Greek word describing the "falling off' of petals from a flower, or leaves from a tree. Given a
publication on the role of defender against apoptotic death protein (DAD1), expressed in mammalian
and plant cells, which was shown to be down-regulated during senescence of flower petals (Orzaez
and Granell 1997), the term apoptosis represents either extreme serendipity, or immense foresight by
the authors in the extent to which apoptosis plays a role.
1.2 Basics of Cell Death
1.2.1 Apoptosis vs. Necrosis
Until the realisation that cells could engage a natural cell death program, death was thought
to occur as a result of a pathological condition. This form of "misguided" cell death, termed necrosis,
tends to affect "fields" of cells and occurs in response to a number of noxious stimuli such as
ischemia, hypothermia, hypoxia, complement attack, metabolic poisons, and direct mechanical cell
trauma (Wyllie 1980). An understanding of the mechanisms and processes of necrosis is undoubtedly
required to appreciate the need for such a distinct and defined program as apoptosis. Early necrosis
proceeds through swelling of the cytoplasm and organelles, especially the mitochondria. When
hydrostatic pressure reaches a critical point, structural integrity cannot be maintained and the cell
lyses releasing its contents. Due to this release inflammation develops in surrounding tissue in
response to the released contents (Wyllie et al 1980). Apoptosis on the other hand tends to affect
single scattered cells in response to many environmental and developmental prompts such as
genotoxic insult, factor deprivation, virus infection, glucocorticoid treatment, and heat shock (Wyllie
1980). Regardless of the wide-ranging set of insults, apoptosis proceeds in a predictable fashion with
a conserved chain of observable morphological changes. The cell's cytoplasm begins to condense
along with margination of the chromatin, with many cell types undergoing blebbing of the plasma
















Figure 1.1: The morphological features of apoptosis and necrosis. Adapted from Kerr et al (1972)
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containing intact organelles and nuclear material. These are recognised, ingested, and degraded by
neighbouring cells - a process named phagocytosis. A basic schematic of these two processes are
outlined in Figure 1.1. Since apoptosis remains a relatively contained process with no leakage of
cytoplasmic components, and hence little bystander cell death and inflammation, the process remains
fairly inconspicuous within tissue histology, which is thought to reflect the true efficacy with which
phagocytes remove apoptotic cells in vivo.
1.2.2 Better to be dead than wrong
Given the advantages of a refined form of cell death such as apoptosis compared to necrosis,
one might ask what is the point of naturally occurring cell death at all. Cells that die during normal
development and tissue homeostasis have been shown to fit into five broad categories, according to
the extensive work by Ellis et al (1991): (1) cells that have no function and thus can be eliminated,
(2) cells that are generated in excess, some of which may be eliminated, (3) cells that develop
incorrectly, (4) cells that have fulfilled their function, and (5) cells that are harmful and must be
eliminated to protect the organism. From this we can see that apoptosis plays important roles ranging
from embryogenesis (i.e. sculpting of organs and tissues: "cell division forms the clay, whilst cell
death sculpts the clay into the desired form", in the words of Michael Hengartner, personal
communication), to tumour regression by acting as "anti-cancer" machinery (Neubauer et al 1996),
and particularly striking as the mechanism for clonal deletion of undesirable T-cells activated to self-
antigens (Wu et al 1993). Therefore it could be said that apoptosis is the "workhorse" to attain and
maintain a normal organism in homeostasis.
1.2.3 Away from the nucleus
As apoptosis is an active conserved chain of events it was believed that RNA and protein
synthesis would be required, in contrast to the passive "accidental" death by necrosis (Schwartzman
and Cidlowski 1993). In fact, initiation of apoptosis by many stimuli occurs in the presence of protein
or RNA synthesis inhibitors, Fas-mediated being the archetypal case (Yonehara et al 1989; Itoh et al
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1991). In addition, it was shown many biochemical and morphological changes could take place in
enucleated cells (Jacobson et al 1994; Schulze-Osthoff et al 1994), leading to the key conclusion that
all of the cell death machinery required is ready within the cytoplasm of most cells, and could
therefore proceed without any need for nuclear factors (Weil et al 1996). It could be considered that
these key findings helped "redirect" the field away from the nucleus, with its easily visualised
morphological changes, to the cytoplasm and other organelles to search for more distinct biochemical
changes. Much of the field of cell death has concentrated on the mechanisms of caspases and their
activation by the mitochondrial pathway, however many other organelles and cellular components
have been implicated to undertake important roles in cell death. Specifically, the Golgi apparatus
(Bennett et al 1998), lysosomes (Ishisaka et al 1998), the cytoskeleton (Brancolini et al 1997), the
endoplasmic reticulum (Ng et al 1997), the nucleolus (Stegh et al 1998), the plasma membrane
(Fadok et al 1992a), etc, etc. Looking at a list like this can only bring one conclusion to mind.
Organelles should not be singled out for their relative importance in cell death, since overall the entire
cell is subjected to and must participate in the changes ultimately leading to its safe self-degradation
and removal.
1.3 Mechanisms of Cell Death
The rapid advances in biochemical techniques and support technology over the last decade
have allowed a rapid advancement in the elucidation of the molecular machinery responsible for
implementing biochemical changes during cell death. A myriad of publications have documented the
importance of a number of key molecular players and proposed hypothetical models incorporating
them, including the Bcl-2 family members and their interaction with the mitochondria, caspases,
endonucleases, kinases, death receptors, oncogenes, and tumour suppressors. Many have divided the
death pathway into hypothetical stages. For example Kroemer has suggested three stages comprising
pre-mitochondrial, mitochondrial, and post-mitochondrial (1997a), to clearly over-emphasise the
central role of this organelle, but given the number of possible alternative pathways this represents
somewhat of a bias. Given the somewhat unusual scope of the current thesis a more holistic and
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liberal division is proposed, also encompassing the consequences of death. Therefore death is divided
into three stages: initiation, execution and resolution.
Initiation represents the triggering of death by a wide range of stimuli followed by the
"decision" to die and commitment to death. What ultimately represents the final On/Off switch, if
such a point exists, is still not known, although many changes can be considered biochemically
irreversible such as release of cytochrome-C from the mitochondria (Liu et al 1996), or the clearly
irreversible proteolytic cleavage of the caspases (Thornberry et al 1992). The execution phase
corresponds to the degradation of a discrete subset of signalling, transcriptional, and structural
proteins, as well as the genetic material itself, by a cascade of proteases and eventual endonuclease
activation. Finally, during the resolution stage cells expose or alter cell surface markers to states or
conformations that ultimately result in recognition, uptake, and degradation by neighbouring cells, a
process termed phagocytosis. The entire chain of events occurs without the release of intracellular
components from the dying cell, and hence prevents a deleterious inflammatory response. In the
following sections a more in depth focus on these processes will be presented.
1.4 Caspases - Homicidal Proteases
1.4.1 A family ofcysteine proteases
Caspases are cysteinyl-proteases with a specificity to cleave proteins to the carboxy-side of
aspartic acid residues (Thornberry et al 1992; Nicholson et al 1995), and are recognized as the major
executioners of cell death responsible for driving the apoptotic cell death phenotype. The name
caspase derives from the cysteine residue within the catalytic diad active site and substrate specificity,
hence Cysteine aspases. This ability to cleave to the carboxyl-side of aspartic acid is extremely
unusual for proteases allowing caspases to function with high specificity during cell death*, and hence
helps protect against non-specific protease cleavage initiating cell death (Kidd et al 1998; Thornberry
* The only other eukaryotic protease known to have a similar specificity is the serine protease
granzyme B, a mediator of granule-dependent cytotoxic T lymphocyte mediated apoptosis.
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and Lazebnik 1998). This specificity is also reflected in the observation that apoptosis is not
accompanied by indiscriminate protein degradation, but rather the select cleavage of a subset of
proteins in a coordinated manner. There are currently fourteen mammalian caspases, including two
murine family members, caspase-11 and -12, for which human homologues have yet to be found
(Thornberry and Lazebnik 1998). In addition to the primary specificity is a requirement for at least
three amino acids to the amino side of the cleavage site, known as the P2-P4 positions. In contrast to
the stringent P, requirement, the P4 position was identified as the next most important determinant in
defining the distinct substrate preferences of the various caspase sub-species (Thornberry et al 1997).
From this caspases can be divided into three major specificity groups. Group I enzymes (caspase-1, -
4, and -5) prefer the sequence WEHD but may be considered "promiscuous" compared to others.
Group II enzymes (caspase-2, -3, and -7) favour DEXD, and display high selectivity. Group III
enzymes (caspase-6, -8, -9, and -10) utilise the consensus sequence (L/V)EXD (Table 1.1). This
broadly categorises them according to whether they function as initiators of a caspase cascade, group
III, as effectors, group II, or are involved in inflammatory processes, group I.
Specificity group P4-P1 specificity Consensus Proposed function
Group 1
Caspase-1 WEHD maturation of
Caspase-4 (W/L)EHD WEHD pro-inflammatory
Caspase-5 (W/L)EHD Cytokines
Group II
Caspase-2 DEVD effectors, i.e. cleavage
Caspase-3 DEVD DEXD of DXXD-containing
Caspase-7 DEHD "death" substrates
Group III
Caspase-6 VEHD initiators, i.e. cleavage
Caspase-8 LETD (l/V/L)EXD of group II caspases
Caspase-9 LEHD and non-DXXD substrates
Table 1.1: Specificities and proposed biological functions of caspases. X represents any
amino acid. Adapted from Thornberry et al (1997).
Interestingly, all amino acids can be divided into aromatic, aliphatic, acidic and basic.
Taking this, the amino acid in the P4 position of all group I caspases is an aromatic, all group II have
acidic at P4, whilst all group III caspases have aliphatic amino acids at P4. Assuming this is not an
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incredible coincidence, could we be missing an entire family of caspases with basic residues at the P4
position? Analysis of the SwissProt database for the sequence (H/K/R)EXD reveals many potentially
interesting substrates for such putative caspases, including many membrane specific proteins,
including most members of the ABC transporter family.
1.4.2 Activation by proteolysis
The majority of caspases are found as latent proforms within the cytoplasm, and are usually
converted to an active enzyme by proteolytic processing. This can occur by either another protease or
by autocatalysis, triggered by binding of cofactors or removal of inhibitors (Thornberry and Lazebnik
1998), and hence allows the accumulation of large amounts of precursor in advance that can be
activated on demand. All pro-caspases contain three domains: an NH2 terminal domain, a large
subunit of ~20kDa, and a small subunit of ~10kDa. Activation occurs by sequential processing
between the subunits (Thornberry and Lazebnik 1998). Initially the enzyme is cleaved into large and
small subunits, followed by removal of the NH2 domain from the large domain. The large and small
domains form a heterodimer that, as evidenced by the crystal structures for active caspase-1 and -3,
associates two heterodimers to form a tetramer containing two independently functional active sites
(Rotonda et al 1996). The large and small subunits are intimately associated and both contribute
residues to form the active site. This specific arrangement of all procaspases conveys two important
mechanistic implications. Firstly, the NH2 domain displays marked variation in sequence and length
between caspases and is involved in the regulation of activation. Secondly, all cleavage sites within
the pro-enzymes represent caspase consensus sequences, explaining the premise that these enzymes
are activated either autocatalytically, or in a cascade by enzymes with similar specificities. This led to
postulation, and later proof, that a hierarchical relationship must exist between "initiator" caspases,
containing much larger NH2 domains, and "effector" caspases that result in the cell disassembly.
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1.4.3 The role ofcaspases in cell death
The notion of a proteolytic cascade is central to the activation of caspases and hence control
of cell death, providing multiple points of regulation to prevent unwanted activation of effector
caspases. In fact, given that caspases mediate such a drastic process as cell death the complexity of
their regulation rivals that of the complement or coagulation cascades. Multiple apoptotic stimuli
result in the activation of initiator caspases, which in turn activates effector caspases. Different
initiator caspases mediate distinct signals from apoptotic stimuli. For example, caspase-8 mediates
activation of effector caspases in response to Fas ligation (Ashkenazi and Dixit 1998), whilst caspase-
9 is involved in death induced by cytotoxic agents (Hakenr et al 1998) explaining how a range of
stimuli can induce the same biochemical and morphological changes. The ultimate objective of
effector caspase-mediated proteolysis is the disassembly of the cell, and to mediate changes resulting
in the eventual safe clearance by phagocytes. Although over one hundred different caspase substrates
have been identified (Stroh and Schulze-Osthoff 1998), mainly through protein database analysis of
caspases consensus recognition residues, only a small proportion of these are understood in their
relationship to cell death at any level. Caspase-mediated cleavage of substrates can be considered to
result in either a gain of function, such as the loss of a regulatory domain from a catalytic subunit, or a
loss of function, such as cleavage to inactivate an enzyme or the disassembly of structural proteins.
One role of caspases is to inactivate proteins that serve to protect living healthy cells from
effecting apoptosis. The archetypal example of this is cleavage of ICAD, an inhibitor of the caspase-
activated deoxyribonuclease (CAD) responsible for oligonucleosomal DNA fragmentation. In
nonapoptotic cells CAD is present as an inactive complex with ICAD. During apoptosis the caspase
cascade activates caspase-3 resulting in cleavage and inactivation of ICAD, allowing CAD to function
as a DNAse (Liu et al 1997; Sakahira et al 1998). Several members of the Bcl-2 family of anti-
apoptotic regulators are also cleaved by caspases (Xue and Horvitz 1997; Cheng et al 1997). Caspase
cleavage not only prevents their anti-apoptotic capability, but also produces fragments that actually
promote apoptosis, effectively giving positive feedback to ensure the inevitability of death (Cheng et
al 1997).
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The major morphological changes witnessed during apoptosis are also caspase mediated.
Destruction of the nuclear lamina, a rigid structure underlying the nuclear membrane and involved in
chromosomal organisation, occurs through cleavage of lamins at a single site. Lamins represent
intermediate filaments that polymerise to form nuclear lamina, which on cleavage cause the structure
to collapse and contribute to chromatin condensation (Lazebnik et al 1995; Rao et al 1996). Indirect
reorganisation of cell architecture occurs through caspase cleavage of many proteins directly
responsible for cytoskeletal regulation, including gelsolin (Kothakota et al 1997), focal adhesion
kinase (FAK) (Wen et al 1997), p21-activated protein kinase (PAK2) (Rudel and Bokoch 1997), and
fodrin/spectrin (Wang et al 1998). In general, cleavage of these proteins results in deregulation.
However, in the case of gelsolin, a protein that severs actin in a Ca 2+ controlled manner, cleavage
produces a constitutively active fragment (Kothakota et al 1997).
The third major targets of the caspases are proteins involved in repair and homeostatic
functions such as DNA-PKcs (Casciola-Rosen et al 1995), U1-70K (Casciola-Rosen et al 1994), PKC8
(Emoto et al 1995; Song et al 1996). Taken together it can be seen that caspases act as the major
"workhorses" of apoptosis, acting with swift military precision. They cut off contacts with
surrounding cells, shut down DNA replication and repair, reorganise the cytoskeleton, interrupt
splicing, disrupt nuclear structure, destroy DNA, fragment the cell into apoptotic bodies (Coleman et
al 2001; Sebbagh et al 2001) and in many cases mediate surface changes, such as exposure of
phosphatidylserine (PS), to allow phagocytic clearance (Fadok et al 1992a).
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1.4.4 APAFs and the apoptosome - the intrinsic pathway
The intrinsic pathway is a term reflecting a cell death decision triggered internally in
response to a number of cellular insults and stresses including growth factor withdrawal, chemical
treatment (e.g. staurosporine), or DNA damage to the cell. Activation of this death pathway is
thought to converge on the mitochondria, which has been demonstrated to act as a central control
point. The first insight was the requirement for a mitochondria-enriched fraction to enable cytosolic
extracts to induce apoptosis in isolated Xenopus eggs (Newmeyer et al 1994). The elucidation of the
pathway proceeded through the intense study of the activation of caspase-3 by the Apoptotic Protease
Activating Factors (APAFs). A series of groundbreaking papers from Xiaodong Wang and colleagues
used protein purifications of cell extracts to identify three key factors (APAFs) capable of activating
caspase-3 in a cell free system, in the presence of dATP. In the first of the papers Liu et al (1996)
purified a factor they termed APAF-2, which surprisingly turned out to be cytochrome-C. Normally
present on the outer surface of the inner-mitochondrial membrane, cytochrome-C serves as a shuttle
for electrons between complex III and complex IV of the mitochondrial electron transport chain
(Brierley and Murer 1964). Subsequent work by two independent groups demonstrated the anti-
apoptotic effect of Bcl-2 on the mitochondria was mediated by acting to prevent apoptosis induced
cytochrome-C release, and hence prevent caspase activation (Kluck et al 1997; Yang et al 1997).
In the second of the papers Zou et al (1997) identified another factor, APAF-1, which on
analysis was shown to be the first mammalian homologue of the C. elegans protein ced-4. The ced-4
domain of APAF-1 is flanked on one side by a region bearing strong homology to the prodomain of
some caspases, CARD domains, and the other side by WD repeats, which were demonstrated to bind
to cytochrome-C (Zou et al 1997). The final instalment by Li et al (1997) demonstrated that the third
factor, APAF-3, was in fact identical to caspase-9. This led to the speculative model that cytochrome-
C binding to the WD repeats of APAF-1 leads to a conformational change exposing its CARD domain
and allowing caspase-9 to bind, resulting in its processing and activation (Li et al 1997; Reed 1997).
This tripartite complex consisting of APAF-1, caspase-9, and cytochrome-C, in the presence of dATP,
has been termed the "apoptosome" (Hengartner 1997). In retrospect, a better term could be the
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"cytoplasmic apoptosome", since the death-induced signalling complex (DISC) involved in mediating
death receptor signalling pathways could be considered a "membrane apoptosome", as both
essentially represent a protein platform that serves to mediate procaspase aggregation and subsequent
activation, coupled to downstream events (see below). A basic schematic of this pathway is outlined
in Figure 1.2. In addition to cytochrome-C, other mediators of apoptosis are released from
mitochondria. In some cells, mitochondria have been demonstrated to contain a pool of caspase-3 that
is liberated into the cytosol on induction of apoptosis (Mancini et al 1998). Another recently
described but phylogenetically ancient apoptotic mediator is the so-called apoptosis-inducing factor
(AIF). On release of AIF from mitochondria it translocates to the nucleus where it mediates large
scale (~50kb) nuclear fragmentation, and is thought to be involved in caspase-independent forms of
cell death (Susin et al 1996; 1997).
1.4.5 Death receptors - the extrinsic pathway
In contrast to the intrinsic, extrinsic pathways represent a death decision that has originated
from outside the cell, normally through the ligation of surface death receptors. Death receptors are
members of the tumour necrosis factor (TNF) / nerve growth factor (NGF) superfamily, and members
include TNF Rl, Fas/Apo-l/CD95, DR-3/Apo-3/TRAMP, DR-4/TRAIL-R1, and DR-5/TRAIL-
R2/TRICK2 (Schmitz et al 2000; Ashkenazi and Dixit 1998, and references therein). The common
feature to all of these members is a characteristic cysteine-rich extracellular motif, and an important
68 amino acid homology region on their cytoplasmic tail named the death domain (DD) (Itoh and
Nagata 1993; Tartaglia et al 1993). In short, death domain signalling proceeds through ligand-
induced receptor trimerisation, recruitment of receptor associating adapter molecules, and subsequent
initiation of a caspase cascade. Receptor ligation is thought to cause a conformational change of the
cytoplasmic DD to allow homotypic interaction with DD containing adapter proteins such as FADD
or TRADD, allowing their recruitment to the death induced signalling complex (DISC) (Chinnaiyan et
al 1995). Fas death receptor signalling recruits FADD, whilst TNF Rl binds FADD through its initial




Figure 1.2: Basic schematic of the intrinsic and extrinsic apoptotic signalling pathways. Ligation
of death receptors, induces processing of caspase-8 and subsequent activation of effector caspases -
the extrinsic pathway. Intracellular changes in Bcl-2 family members mediate mitochondrial
disruption and release of cytochrome-C, resulting in formation of the apoptosome and activation of
caspase-3 - the intrinsic pathway. Caspase-8 cleavage of Bid induces release of cytochrome-C from
the mitochondria, and as such represents a crossover of the pathways. Stress or chemical induced
apoptosis also results in release of cytochrome-C. Adapted from Schulze-Osthoff et al (1998)
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to it containing an N-terminal death effecter domain (DED), which allows interaction and hence
recruitment of DED containing procaspases such as -8 and -10 to the DISC. As a result, procaspases
are proteolytically cleaved into active forms enabling them to cleave downstream caspases
(Srinivasula et al 1996; Muzio et al 1996; 1998). In addition, caspase-8 has been demonstrated to
cleave the BH3 only protein Bid, resulting in its truncated form mediating release of cytochrome-C
from the mitochondria (Luo et al 1998). A basic schematic of this pathway is outlined in Figure 1.2.
Controversy exists as to the relative requirement for cytochrome-C release in death receptor
signalling. Whether a cell requires the "secondary amplification" of caspase activation that
cytochrome-C release provides is thought to be dependent on cell type (Scaffidi et al 1998), and can
be shown by the ability of Bcl-2 to inhibit death (Huang et al 2000). The TNF R1 pathway has also
been shown to activate the TNF R1 associated factor 2 (TRAF2) through TRADD, which has been
shown to be involved in NFkB activation-mediated survival (Ting et al 1996). In addition, receptor
interacting protein kinase (RIP) has been shown to be able to mediate caspase-independent death of T
cells following interaction with FADD after either Fas or TNF R1 ligation (Holler et al 2000).
Regulation of death receptor pathways can occur by cell surface decoy receptors, such as DcR-I, -2, -
3, all of which contain truncated cytoplasmic DD, and cannot mediate FADD or TRADD recruitment,
hence acting as competitive inhibitors for ligands (Pan et al 1997; Marsters et al 1997; Pitti et al
1998). Control of death can also occur due the presence of endogenous FADD-like inhibitory
proteins (FLIPs), which contain DED domains enabling them to interact and hence sequester other
DED containing proteins such as procaspase-8, -10, and FADD (Hu et al 1997; Thome et al 1997;
Tschopp et al 1998). Interestingly many viral immune evasion strategies involve manipulation of
death receptor signalling. The viral protein crmA is an inhibitor specific for caspase-8, -10, and -1,
thereby preventing the host defence strategy of killing the virally infected cell (Ray et al 1992;
Komiyama et al 1994).
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1.4.6 Regulation ofcaspases
Given the irreversibility of caspase activation by cleavage and the fundamental consequences
that ensue, cells have developed many methods to prevent activation, antagonise their activity, and to
promote their removal and destruction. The Inhibitor of Apoptosis (IAP) family of proteins have an
evolutionarily conserved role in regulating apoptosis in species ranging from insects to humans (Clem
and Miller 1994; Roy et al 1995; Rothe et al 1995). All IAPs contain one or more of three baculoviral
inhibitory repeats (B1R), a characteristic cysteine-rich domain of ~80 amino acids (Rothe et al 1995).
The extensively studied XIAP contains all three BIRs followed by a COOH-terminal RING zinc-
finger, whilst the smallest, Survivin, contains a single BIR2 domain (Tamm et al 1998). Using an in
vitro cell free system, XIAP was shown to prevent cytochrome-C induced caspase-3 activation and
nuclear destruction. In addition, it could also inhibit active caspase-3 and the closely related caspase-
7 activity by directly binding to them (Deveraux et al 1997). However, XIAP was demonstrated to
bind weakly to their unprocessed forms, implying that its inhibitory effect on caspase-3 processing
occurred upstream, namely by preventing activity of processed caspase-9 (Srinivasula et al 2001).
Furthermore, it has been shown that XIAP itself can be cleaved by caspases into a BIR1-2 containing
fragment, specific for caspase-3 and 7, and a BIR3-RING zinc-finger fragment, which specifically
inhibits caspase-9 (Deveraux et al 1999). Interestingly, the introduction of mutations into XIAP,
which abrogate its caspase-3 inhibitory activity, does not prevent it from protecting cells as efficiently
as the wild type protein, suggesting its main target to be initiator caspases (Silke et al 2001).
Further investigations have shown the hunter becomes the hunted. XIAP itself has a panel of
inhibitors, able to antagonise its anti-caspase activities by displacing and sequestering it. XIAP-
associated factor 1 (XAF1) is a nuclear protein identified using the yeast two-hybrid system. It was
shown to interact directly with XIAP, resulting in its sequestration in nuclear inclusions, reversing its
protective effect (Liston et al 2001). Importantly, a screen of cancer cell lines found XAF1 to be
absent or present at greatly reduced levels in most tested. In another key paper from Xiaodong Wang
and colleagues, and simultaneously from David Vaux's group, a novel mitochondrial protein capable
of antagonising XIAP was identified. Named either Smac (Du et al 2000) or Diablo (Verhagen et al
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2000), it was demonstrated to be released from the mitochondria concomitant with cytochrome-C, and
to directly bind XIAP through its BIR3 domain (Liu et al 2000). Given its release with cytochrome-
C, its antagonism ofXIAP further helps to amplify the caspase cascade.
Phosphorylation represents another important means by which caspases can be controlled.
Ras activity in cells had been noted to confer resistance to apoptosis caused by stimuli known to
release cytochrome-C (Yang et al 1997). Effectors of the Ras pathway include phosphatidyl-inositol
3-kinase, which generates secondary messengers that activate Akt, a serine-threonine protein kinase
(Khwaja et al 1997). Treatment of Ras-transfected cell cytosols with protein phosphatases restored
cytochrome-C mediated caspases activation. Pro-caspase-9 was shown to contain Akt consensus
phosphorylation sites, which when phosphorylated at Ser196 resulted in conformational change of the
catalytic machinery responsible for its auto-activation when complexed with APAF-1 and
cytochrome-C (Cardone et al 1998). Another example of particular relevance given the context of this
thesis is the inactivation of caspases by the calcium-activated neutral cysteine protease, calpain.
Calcium has long been established as a regulator of apoptosis, and has been shown to promote or
inhibit dependent on cell type. In vitro analysis of calpain activity has shown its cleavage specificities
to be structure and not primary sequence-dependent (Sorimachi et al 1997). Several groups have
demonstrated calpain to be able to cleave a number of caspases including -9, -8, -3, and -7.
Processing occurs at sites that produce truncated forms, unable to activate downstream effectors or
cleave substrates, effectively preventing most caspase cascades (Wolf et al 1999; Chua et al 2000;
Lankiewicz et al 2000). This mechanism is particularly striking in excitotoxic neuron death, whereby
over activation of glutamate receptors lead to neuronal calcium overloading. The apoptosis is initiated
by cytochrome-C release, triggered by mitochondrial uptake of Ca2+, but activation of calpains by the
Ca2+ results in cleavage and inactivation of caspase-9 and -3, effectively converting neuronal death
into a caspase-independent program (Lankiewicz et al 2000).
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1.4.7 Caspase-independent cell death
That cells die by caspase-dependent apoptosis is universally accepted, but do all forms of cell
death utilise caspases as their executioners? Recent evidence indicates a diversification of the
apoptotic program in higher eukaryotes that questions the necessity and role of caspases, and in
particular the many apoptotic-like cell death programs occurring without caspase activation (Lavoie et
al 1998; Mathiasen et al 1999; Foghsgaard et al 2001). Surprisingly, many of these alterations to the
death program do not ultimately affect the final removal of the dying cell (Chung et al 2000; Hirt et al
2000), and thus serve the same purpose as classical apoptosis - the safe non-inflammatory removal of
corpses (Ren and Savill 1998). One could propose that the evolutionary pressure for an organism to
develop several cell death programs reflects the increasing complexity and lifespan of the organism
(Aravind et al 2001). It is well characterised that yeast undergo an apoptosis-like death associated
with DNA fragmentation, zeiosis, PS exposure, and chromatin condensation, despite being devoid of
caspases (Frohlich et al 2000). In addition, caspase coding sequences are conspicuously absent from
the genomes of many non-animal species (Aravind et al 2001), including plants and single-celled
eukaryotes, which have been demonstrated to undergo programmed cell death under conditions of
stress (Ameisen 1996). The revelation of these "back-up" death pathways often occurs following
pharmaceutical inhibition of caspases or genetic ablation, but several lines of evidence from both
normal physiology and pathological conditions underscore the need for such a "second line defence".
For example, caspase pathways can be inhibited by factors such as energy depletion (Leist et al 1997),
nitrative/oxidative stress (Leist et al 1999), other proteases (Lankiewicz et al 2000; Chua et al 2000),
the 1AP family (Strasser et al 2000), and a range of viral proteins able to directly inhibit caspases
(Strasser et al 2000).
A plethora of new terms have now been presented within the apoptosis field, helping to
describe the many variations of cell death that do not match the strict morphological criteria of
caspase-dependent apoptosis. These include; Apoptosis-like cell death, whereby chromatin
condensation is less complete and compact, but recognition molecules for phagocytes are still
displayed before cell lysis (Lavoie et al 1998; Mathiasen et al 1999; Foghsgaard et al 2001);
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necrosis-like cell death, typically used to define cell death that occurs in the absence of any nuclear
condensation, along with a range of accompanying apoptotic-like features including PS exposure
(Vercantmen et al 1998; Holler et al 2000) - a subset of this death type has been characterised as
"aborted apoptosis", that is the initiation of a standard apoptotic program that is blocked at the level of
caspase activation and is finally terminated by caspase-independent routes (Nicotera et al 1999) (Of
particular relevance to chapter 4); paraptosis, characterised by little nuclear condensation, but
extensive cytoplasmic vacuolisation (Wyllie and Golstein 2001), and many more obscure forms
including autophagy (Xue et al 1999) and dark cell death (Turmaine et al 2000)1
1.5 Role of the Bcl-2 family and the Mitochondria
1.5.1 A family ofpro- and anti-apoptotic proteins
The first gene found to be specifically involved in the process of physiological cell death in
mammalians cells was bcl-2 (Vaux et al 1988). This proto-oncogene is located at the break point
region of the t( 14; 18) chromosomal translocation commonly seen as a hallmark of follicular B cell
lymphoma (Yang and Korsmeyer 1996). However instead of inducing cell proliferation, as with most
other oncogenes at that time, it was unusually able to extend cell survival (Vaux et al 1988). An
important discovery of molecular and functional similarity between Bcl-2 and the C. elegans gene
product Ced-9 (Hengartner and Horvitz 1994) led to the finding that overexpression of Bcl-2 in ced-9 "
'' nematodes could partially suppress death (Vaux et al 1992). Bcl-2 was found to be the seminal
example of a continuously expanding family of apoptosis regulatory proteins, including Bcl-XL, Bcl-
Xs, Bcl-W, Bax, Bak, Bad, Bik, Bim, Bid, Mcl-1, Al, Hrk, Bok, Blk, Nip3, Nix and Diva, (Reed
1998; Adams and Cory 1998, and references therein) to name but a few! In addition viral homologues
of Bcl-2 have been found in Adenovirus, Epstein-Barr virus, and African swine fever virus (Chiou et
al 1994; Granville et al 1998; Meinl et al 1998), whereby inhibition of the cells' apoptotic response to
the invading pathogen allows for a more productive and persistent infection. Strangely both pro- and
anti-apoptotic regulators are encoded from the same homologous family of domains. All members
contain a least one of four possible conserved motifs named the Bcl-2 homology domains (BHX)
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(Adams and Cory 1998). The majority of pro-survival members include at least BH1 and BH2, with
those closely related to Bcl-2 containing all four (Bcl-XL, Bcl-W). Two subfamilies of the pro-
apoptotic members contain either BH1 to 3 (Bax, Bak, Bok), or only the single short BH3 domain,
and are referred to as the BH3-only proteins (Bid, Bad, Bik, Blk). Interestingly these BH3-only
proteins share similarity to the C. elegans protein Egl-1, shown to be required for death (Conradt and
Horvitz 1998). Curiously this suggests that many mammalian family members such as Bax or Bak
have no homologue in the worm.
1.5.2 The duelling dimer hypothesis ofdeath
Bcl-2 and Bax were shown to be able to form homodimers with themselves and to
heterodimerise with each other (Oltvai et al 1993). This led to a model whereby the relative levels of
Bcl-2 and Bax would determine whether anti-apoptotic Bcl-2 homodimers, Bcl-2-Bax heterodimers,
or pro-apoptotic Bax homodimers formed (Oltavai and Korsmeyer 1994). Mutagenesis of the BH1-3
domains strongly implicated them in mediating dimerisation, and the crystal structure of Bcl-XL
provided an explanation. Coalescence of the a helices in its BH1-3 domains creates an elongated
hydrophobic cleft into which a BH3 amphipathic a helix can bind (Muchmore et al 1996). This BH3
"cleft-coupling" may account for the ability of all family members to dimerise with each other,
leading to the postulation that Bax and its analogues may have alternative conformations: a Bcl-XL-
like conformation, and another with the BH3 helix rotated outside to allow insertion into the groove of
an anti-apoptotic family member. As well as the promiscuous interactions with themselves, Bcl-2
family members have been shown to interact with a range of proteins including APAF-1,
cFLlP/Casper, Raf-1, R-Ras, calcineurin, and the adenine nucleotide translocator (ANT) of the
mitochondrial inner membrane (Reed 1998). Evidence from the genetically tractable C. elegans
model suggests a requirement for interactions between ced-9 and ced-4 (the APAF-1
homologue)(Ellis et al 1991). Physical interaction between ced-9 and ced-4 has been shown to
correlate with the ability of ced-9 to suppress ced-4 mediated activation of caspases (Spector et al
1997; Wu et al 1997, Chinnaiyan et al 1997). Similarly, in the mammalian system the BF14 region of
Bcl-XL was shown to bind the apoptosome component APAF-1, interacting with the ced-4-like region
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within this protein (Hu et al 1998; Pan et aI 1998). However, although containing a BH4 region Bcl-2
itself binds APAF-1 very weakly in vitro, indicating the anti-apoptotic role of Bcl-2 in mammals is
not APAF-1-directed, but mediated by some other mechanism.
1.5.3 Mechanisms ofaction ofBcl-2 family members
Although Bcl-2 family members have been extensively studied and are implicated in
regulating mitochondrial cytochrome-C release, the precise biochemical foundation for this remains
elusive. There are currently two basic models for possible mechanism, with substantial evidence for
each. The Bcl-2 protein contains a stretch of hydrophobic amino acids at its COOH-terminus
allowing insertion into intracellular membranes, primarily the cytoplasmic face of the mitochondrial
outer membrane, endoplasmic reticulum, and the nuclear envelope (Krajewski et al 1993). However,
despite containing COOH termini only a small fraction of Bcl-XL is present on membranes, whilst
Bax remains cytoplasmic until an apoptotic stimulus occurs (Hsu and Youle 1998). An insight into
the mechanism of Bcl-2 family function arose from the realisation that the Bc1-Xl crystal structure,
and in particular the a 5 and a 6 helices, bore a striking resemblance to pore-forming domains of some
bacterial toxins, for example, diphtheria toxin and the colicins (Muchmore et al 1996; Satler et al
1997). As expected, Bcl-2, Bcl-XLi and Bax all form ion channels when added to synthetic lipid
bilayers, with those created by Bax and Bcl-2 displaying distinct characteristics including ion
selectivity (Schendel et al 1997; Minn et al 1997; Antonsson et al 1997). Evidence for pore formation
in vivo has not been demonstrated, and whether the pores formed are of a sufficient size to allow
passage of cytochrome-C into the cytosol remains unclear. Other proteins released such as
Smac/Diablo exists as a lOOkDa end to end dirner (Chai et al 2000), suggesting a channel formed by
~20kDa proteins are simply not sufficient. The ability of Bax to oligomerise may partly explain this,
with a report of a Bax tetramer able to form a channel in liposomes of around 22 A, and therefore able
to permit cytochrome-C passage (Saito et al 2000). However, small bacterial toxins such as
pneumolysin can oligomerise to form a ring of 30-50 subunits and a channel size of 400 A (Gilbert et
al 1997), although this has yet to be shown with Bcl-2 family members.
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A further proposed model for Bcl-2 family member modulation of cytochrome-C release may
involve a more non-specific disruption of outer mitochondrial membrane. Following alterations in
mitochondrial physiology, as a consequence of apoptotic signalling, a disruption may occur to allow
diffusion of proteins across the lipid bilayer. This non-specific rupture is thought to require the
opening of a large mitochondrial conductance channel termed the permeability transition pore (PTP),
formed from a complex of the voltage dependent anion channel (VDAC), the adenine nucleotide
translocator (ANT), and cyclophilin D (Zamzami et al 1996a; Qian et al 1997; Crompton 1999).
Opening of the PTP allows small molecular weight solutes (<1.5kDa) to diffuse across the inner
mitochondrial membrane resulting in a collapse of the inner mitochondrial membrane potential (Av|/M)
and matrix swelling (Zamzami et al 1996b). Swelling of the mitochondria is thought to result in
rupture of the membrane, enabling release of cytochrome-C and other associated apoptogenic factors
localised within the intermembrane space (Kroemer et al 1997b). It is suggested that Bcl-2 family
members could directly regulate PTP activity to modulate factor release (Marzo et al 1998; Narita et
al 1998). Supporting this model is the observation that inhibitors of PTP opening, such as bongkrekic
acid and cyclosporin, are able to block apoptosis in some (Zamzami et al 1996a), but not all systems
(Eskes et al 1998). Whether mitochondrial depolarisation occurs as a result of PTP opening to initiate
apoptosis, or whether PTP opening occurs as a later event due to apoptotic changes remains highly
controversial.
In another study VDAC alone has been demonstrated to interact with pro-apoptotic members
of the family such as Bax and Bak, to allow formation of the so-called "megapore" (Shimizu et al
1999; 2000). Conversely anti-apoptotic family members such as Bcl-XL may act to promote a closed
conformation of the pore (Shimizu et al 1999). In many ways this "enlarged" VDAC model has more
in common with the channel models discussed above. Studies of the BH3-only members, such as Bid,
suggest they can act alone through a separate as yet undefined pathway, causing release of
cytochrome-C. It is predicted Bid may associated with novel outer mitochondrial membrane proteins
(Wang et al 1996; Luo et al 1998; Li et al 1998).
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1.6 Hiding the evidence, removing the corpse
As mentioned in the historic background, the study of phagocytosis was originally reported
in the late 19th century by Ilya Metchnikoff (1893). Using basic light microscopy he observed
"microphages" (i.e. neutrophils) being "englobed" by macrophages in the experimentally injured fins
of tadpoles, the fundamental biological phenomena we now know as phagocytosis - i.e. cells
consuming other cells. The consumption of microorganisms and other foreign material (non-self) is
an important primary host defence in innate immunity, whilst the phagocytosis of senescent or dead
cells (altered-self) plays a pivotal role in embryogenesis, normal tissue turnover, development,
regulation of the immune system, and in the resolution of inflammation (Hart et al 1996). The critical
and central caveat of these processes is that dying or apoptotic cells are recognised and phagocytosed
prior to them undergoing lysis. Hence avoiding the leakage of potentially deleterious intracellular
components that would result in the damage of adjacent tissue. In short, phagocytic clearance is swift
and efficient, leaving no remains of the apoptotic cell, and thus partly explaining why physiological
cell death was overlooked for so many years. In fact, the classic quote is that on calculation "an entire
tissue could disappear in 20 days with only four apoptotic cells being visible at any one time, in any
given section" (Tidball and Albrecht 1998). Of course one could argue that this represents the
phagocytes ability in vivo to perhaps recognise and clear dying cells before the classic hallmarks of
apoptosis occur.
1.6.1 Phagocytes and their receptors
Phagocytes involved in the process of clearance can be considered to be either professional,
such as macrophages, or semi-professional, such as epithelial cells, fibroblasts, vascular smooth
muscle cells, and Sertoli cells (Chemes 1986). A number of receptors on the phagocyte surface have
been implicated in the binding and uptake of apoptotic cells (Figure 1.3). These include lectin-like
receptors that were suggested to interact with altered sidechains of surface glycoproteins on the
apoptotic cell (Duvall et al 1985). The vitronectin receptor, an avp3 integrin thought previously to be
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primarily involved in anchorage of cells, has been shown to be involved in the phagocytosis of a wide
range of cells (Savill et al 1990). Extending this work, the class B scavenger receptor CD36 was also
implicated in this process through interaction with thrombospondin, a glycoprotein synthesised and
secreted by the macrophage. Thrombospondin is suggested to bind cooperatively with av(33 and CD36
to form a "molecular bridge" between phagocyte and apoptotic cell (Savill et al 1992). Other
molecules implicated on the phagocyte include class A scavenger receptors (Piatt et al 1996), the
ATP-binding cassette transporter ABC1 (Luciani and Chimini 1996), activation of both classical and
alternative complement pathways with subsequent coating of the apoptotic cell with C3bi, followed
by recognition by macrophage complement receptors (Mevorach et al 1998), and CD 14, the bacterial
lipopolysaccharide (LPS) receptor (Devitt et al 1998). Interestingly, interaction between CD 14 and its
prototypical ligand LPS leads to an inflammatory response by the macrophage and subsequent release
of proinflammatory cytokines (Pollack et al 1995), whereas uptake of apoptotic cells does not (Fadok
et al 1998).
1.6.2 "Eat me" signals on the apoptotic cell
In comparison to the surface of the macrophage, much less is known about the molecules on
the apoptotic cell that mediate clearance. In addition to the modification of glycoproteins mentioned
above, the loss of phospholipid asymmetry and exposure of phosphatidylserine (PS) on the outer
leaflet of the plasma membrane has emerged as an important marker of cell death and phagocytic
clearance (Fadok et al 1992a; Martin et al 1995). Subsets of macrophages have been demonstrated to
preferentially use PS as a signal for recognition and uptake (Fadok et al 1992b), however, the identity
of the PS receptor on the phagocyte remained elusive for many years. Although many suggestions of
candidate molecules had been made including annexins, CD36 (Tait and Smith 1999), and scavenger
receptors (Rigotti et al 1995), no conclusive evidence demonstrated them to be the PS receptor.
However, using a phage display screen for the antigen of mAb 217, known to block PS dependent
phagocytosis, Fadok and colleagues (2000) successfully cloned a novel sequence with high
homologies to proteins of unknown function in both C. elegans, and D. melanogaster. This putative
PS-receptor specifically conferred the ability to phagocytose apoptotic cells on expression in Jurkat T
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Apoptotic cell
Figure 1.3: Schematic of the major molecular players involved in phagocytic clearance of apoptotic
cells. Inhibitor studies in assays of the ingestion of apoptotic cells in vitro by phagocytes have
revealed a variety of candidate molecules, many of which have incompletely understood roles or
uncharacterized binding partners. A repertoire of 'eat me' signals (top) interact with receptors on the
phagocyte (bottom), either directly or via serum-derived bridging molecules (middle). LDL,
lowdensity lipoprotein; SRA, class A scavenger receptor; TSP, thrombospondin. Adapted from Savill
and Fadok (2000).
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cells, and displayed the characteristic downregulation of inflammatory function after uptake of
apoptotic cells (Fadok et al 2000). Other molecules implicated on the dying cell's surface include the
immunoglobulin superfamily member ICAM-3 (Moffat et al 1999), and the complement protein Clq
(Botto et al 1998), however many of these proteins function are still yet to be fully understood.
1.6.3 The importance ofbeing eaten
The apparent abundance and redundancy of phagocytic mechanisms is a keen indicator of the
vital importance of phagocytosis in vivo. Acute inflammation, and in particular the participation of
neutrophils, has evolved as a beneficial host response to infection and injury, and normally resolves
with minimal damage to surrounding tissues (Ren and Savill 1998). However, the neutrophil is
essentially a circulating "loaded weapon", with specialised granules full of lytic enzymes and
inflammatory mediators. If these cells die by necrosis and release their contents at an already
inflamed site, the potential to exacerbate local tissue damage is high (Savill et al 1993). The
archetypal example is in the adult respiratory distress syndrome (ARDS), where a large influx of
neutrophils into the lung results in the overwhelming of the clearance system, and subsequent
secondary necrosis and tissue damage (Smith 1994). Therefore, the clearance of effete neutrophils
must be considered an important prerequisite for the resolution of inflammation. In this respect work
by Savill et al (1989) has provided evidence of the close link between the apoptotic fate of neutrophils
and subsequent engulfment by macrophages in situ in the acutely inflamed joints of human patients.
1.6.4 It takes two to tango, the role ofCD3I
The "traditional" and universally accepted model of phagocytic clearance suggests that target
cells undergo biochemical changes of apoptosis leading to the expression of "eat-me" signals on the
surface, marking the cells and allowing engulfment. However, is this model "holistic" enough in an in
vivo context? The observation that apoptotic cells are rarely seen within tissue sections has always
been interpreted as a reflection of the efficacy of phagocytic clearance in vivo. Perhaps, however, the
cellular changes able to mediate phagocytosis occur much earlier within the death program, and
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before the relatively late classical markers of apoptosis, such as nuclear fragmentation and
condensation. Given the deleterious nature of necrosis does it make sense for a cell to become
recognition competent so late in the program? One could argue that a better physiological system
would include some form of cross talk between predator and prey, with the death impending cell able
to "communicate" its need to be cleared, and maybe even a timescale for this. In analogy, maybe a
dying cell has a surface molecular equivalent of a "fuel gauge", able to be read by the phagocyte to
indicate when the cell was likely to be "running on empty". Conversely, could a more viable cell be
capable of registering its condition to the phagocyte, effectively telling it to "get lost"? Recent work
from the group suggests that the relationship between predator and prey may, in some settings, be
more intertwined than previously thought. Using a novel molecular "fishing" approach Brown and
colleagues (2002) identified CD31, otherwise known as PECAM-1, to be able to mediate interactions
between macrophages and neutrophils. Interestingly, fresh viable neutrophils were capable of
mediating an active detachment from the macrophage, whilst apoptotic neutrophils could not, and
hence were unable to escape and were subsequently phagocytosed.
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Platelet structure and function
Platelets are small anucleate cells of discoid shape, measuring 1-3 pm in diameter. Formed
in the bone marrow from the precursor cell, the megakaryocyte (MK)(Radley and Scurfield 1980),
they are found almost exclusively in the circulation throughout their lifespan of ~8 days, and represent
the most abundant blood cell after the erythrocyte, with normal levels ranging from 150-450,000 per
pi of whole blood (Kumar and Clark 1998). Although not containing a nucleus, platelets are capable
of a complex variety of reactions that are essential for haemostasis, vital for healing of damaged blood
vessels, and play an as yet ill-understood part in inflammation. Platelets are extremely metabolically
active utilising both glycolysis and oxidative phosphorylation to support their endocytic and secretory
activities (Doery et al 1970). With virtually all their organelles, proteins and enzymes derived from
the MK, platelets represent a unique "pre-packaged" powerhouse equipped with a full armoury of
specialised factors, and a dedicated internal structure to enable their prime function, the maintenance
of vascular integrity. Examination by TEM reveals platelets to be "jammed full" of granules that have
been termed alpha and dense, dependent on their electron opacity (Figure 1.4). Alpha granules tend to
contain factors involved in coagulation and adhesion, whilst dense granules tend to contain platelet
agonists (Ginsberg et al 1980). In addition, many mitochondria are apparent throughout the
cytoplasm, along with glycogen particles and smaller vesicles shown to contain lysosomal enzymes
(Bentfeld-Barker and Bainton 1975). One of the most unique defining features of the platelet is the
microtubule coil seen to encompass all internal organelles (Figure 1.4). This coil in conjunction with
the actin cytoskeleton maintains the discoid shape. Mechanical or agonist-induced stimulation
depolymerises the microtubules to cause shape change. Another distinctive function-specific platelet
feature is the unusually thick glycocalyx, the "forest" of glycoproteins and receptors at the cell surface
evidenced by fixing in the presence of ruthenium red, which aids the formation of fibrinogen and
fibrin "bridges" between cells during aggregation (Savage and Ruggeri 1991).
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Figure 1.4: Transmission electron micrograph of a typical platelet A typical cross section
through an unactivated platelet showing a typical distribution of dense bodies (DB), alpha granules
(G), microtubule coil (MT), and the open canalicular system (OCS). Scale bar represents 1 pm.
Figure 1.5: A basic schematic of platelets' haemostatic functions. On encountering exposed
basement membrane, platelets adhere and release factors to recruit other platelets, forming a thrombus
which acts as a physical plug.
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1.7 Molecular basis of platelet adhesion
Resting platelets exist in the circulation as singular entities, and are thought to have little
interaction with each other or other cell types. However, in response to appropriate stimuli they
rapidly change to an adhesive state. A very simplified scenario of platelet adhesion to vessel wall is
outlined in Figure 1.5. Damage to the endothelial cell lining of the vasculature, by for example the
rupture of an atherosclerotic plaque, exposes underlying basement matrix proteins that support initial
platelet attachment. Platelets flatten and spread (shape change) across the surface forming multiple
tight interactions with the matrix and between each other. Spreading, in conjunction with other
agonists released in the microenvironment, induce platelets to secrete granule contents causing
additional resting platelets within the circulation to adhere, forming an aggregate that acts as an
effective plug or seal to prevent excessive blood loss. Obviously this series of functional platelet
responses, although essential for haemostasis, can be devastating if the platelet-rich thrombus formed
occludes the blood vessel leading to thrombosis. Conversely, syndromes causing defects in these
adhesive reactions, and usually of a genetically acquired origin (e.g., Glanzmann's thrombasthenia or
Bernard-Soulier syndrome), can be equally as dangerous leading to latent bleeding episodes.
1.7.1 The endothelium and matrix proteins mediate platelet attachment and spreading
In an elegantly simple system the major components of the subendothelial matrix support
platelet attachment and spreading (Table 1.2). With an intact endothelium creating an effective
barrier, circulating platelets are kept away from the matrix preventing thrombus formation. On
damage, these proteins become exposed initiating platelet attachment and spreading. In addition to
creating an effective physical barrier, endothelial cells contribute to a non-thrombogenic surface by
synthesising an elaborate array of molecules able to inhibit factors or directly effect aggregation and
coagulation responses, notably nitric oxide (Radomski et al 1987), prostaglandin I2, ecto-ADPase
(CD39) (Marcus et al 1997), heparin sulphate proteoglycans (which are secreted directly into the
subendothelium), thrombomodulin (Esmon 1995). However, damaged endothelium rapidly
downregulates these anticoagulant functions to become procoagulant. Even in the absence of
endothelial damage inflammatory mediators can tip the equilibrium to a pro-thrombogenic surface.
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TNF and IL-1 have been shown to down-regulate thrombomodulin and induce expression of tissue
factor on endothelial cells (Lijnen and Collen 1997), whilst endotoxin, TNF, and IL-1 increase the
expression of the plasminogen activator inhibitor-1, impairing fibrinolysis (Maiser and Bulger 1996).
Matrix Constituent Comment
Collagens Family of proteins with type 1, 11, and IV supporting adhesion, spreading
and secretion
von Willebrand factor Multimeric protein critical for the hemostatic function of platelets
Fibronectin Dimeric or multimeric protein which supports attachment and spreading
of platelets
Thrombospondins Trimeric proteins exhibiting adhesive and antiadhesive properties
Laminins Proteins supporting platelet attachment
Microfibrils A fibular bundle of protein constituents found in some matrices
Table 1.2: Subendothelial matrix components supporting platelet adhesion
However, a subset of platelet responses and an alteration of their attachment to the matrix
constituents, listed in Table 1.2, occurs due to several compounding factors: Under some conditions
platelets attach to, but do not spread on laminin (111 et al 1984), whilst von Willebrand factor (vWF)
and fibronectin support attachment and spreading (Sakariassen et al 1979). Collagen on the other
hand not only supports attachment and spreading, but also mediates a secretory response (Brass et al
1974). A growing body of evidence has led to the suggestion that a phenotypic difference in
endothelial cells of different blood vessels may alter the composition of the subendothelium, hence
eliciting a different response (Ruf and Morgenstern 1995). Indeed one can envisage a tiny capillary
may only warrant a "small layer" of platelets, and hence attachment and spreading are enough, whilst
a major vessel would require the secondary secretory activities to amass a greater platelet plug.
Vessel shear stress also substantially alters platelet adhesion, particular in reference to vWFs
contribution. In vitro experiments have demonstrated a role for vWF-mediated attachment at high
shear but not at low shear (Weiss et al 1978). Intriguingly, the major physiological stimulus for the
continuous production of NO in vivo is shear stress, and hence areas of high shear, and hence high risk
of platelet activation, bear a nonthrombogenic microenvironment (Schini-Kerth 1999). Fibronectin,
however, supports attachment at high and low shear (Houdijk et al 1985). In addition, matrix proteins
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can interact with one another. Thrombospondin, fibronectin, and vWF all bind to collagen, which
may serve to bridge the platelet to the matrix protein (Santoro and Cowan 1982; Engvall et al 1978;
Mumby et al 1984). Most matrix proteins are open to degradation by a range of proteolytic enzymes,
which has been shown to alter the adhesive properties. In fact "cryptic adhesion sequences" have
been elucidated, which on degradation and subsequent exposure mediate interaction with additional
sets of platelet adhesion receptor (Pfaff et al 1993).
1.7.2 Platelet adhesion receptors and integrins
The individual matrix proteins discussed above interact with the platelet by acting as ligands
for a panel of surface proteins, collectively termed adhesion receptors (Table 1.3). Multiple
designations exist for each, with cluster of differentiation (CD) terminology, integrin family
designations, and the original glycoprotein (Gp) nomenclature all regularly used. The oldest Gp term,
and most favoured among platelet biologists, arose from the relative electrophoretic mobility of the
proteins, whereby the slowest moving, and hence biggest molecular weight, was given the designation
Gpl, and so on. However, as electrophoresis became more advanced several proteins were found in
the same positions and hence Gpla, Gplb, etc, were designated (Phillips and Agin 1977). In addition,
several Gp members exist on the platelet membrane as non-covalent complexes, for example, GpIIb-
Illa, Gplc-lla, and GpIb-lX, and as such are generally regarded as a single membrane protein.
Although confusing in complexity, the inescapable fact is the redundancy that exists in the system,
enabling a single matrix component to enact several distinct responses by interaction with different
receptors.
As mentioned previously, many adhesive receptors are integrins. Integrins represent
heterodimeric cell surface molecules that share structural, immunochemical, and functional homology
(Hynes 1987). The a subunits, of which fourteen are known, are similar to one another, but the p
subunits, of which eight are known, share a high degree of sequence homology of around 35-45% at
the amino acid level. Each p subunit combines noncovalently with an a subunit to form an adhesive
protein receptor. Platelets express two major p subunits, Pi and p3, and five a subunits, a2 a5 av anb a6
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Table 1.3: Platelet receptors for adhesion proteins.
(Kishimoto et al 1998). The integrin GpIIalllb (aubPm) is one of the most narrowly distributed of
blood cell integrins, appearing exclusively on platelets and MKs, and thus serving as a lineage marker.
Integrins play an important role in platelet biology, and in particular during aggregation, due to an
interesting transduction property termed "outside in" and "inside out" signalling.
1.8 Platelet secretory mechanisms
As mentioned in the preface to this section, once platelets have attached to exposed matrix
they typically release a variety of substances capable of stimulating or inhibiting platelets and other
blood cells, covalently modifying the thrombus to affect its mechanical properties, modulating the
growth of cells within the vessel wall, and regulating coagulation. Platelets in effect can directly
orchestrate the response at the site of injury, and mediate the longer term repair responses, much more
than simply acting as a physical plug.
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1.8.1 Mechanisms ofsecretion
The majority of platelet-derived substances are actively released from preformed storage
granules, degranulation, or are directly synthesised at the membrane by modification to membrane
phospholipids. Some factors also reside in the cytosol and are thought to be released through some
degree of platelet lysis. Secretion by platelets is triggered by a variety of strong agonists, such as
thrombin, binding and spreading on collagen, and only by weaker agonists such as ADP, in the
presence of thromboxane A2, when cells are brought into close proximity as during aggregation
(Charo et al 1977). Incorporation ofmembrane markers into the alpha granules established exocytosis
as the principal method of granule content release (Stenberg et al 1985; Wencel-Drake et al 1986;
Berman et al 1986). However, different routes are taken by the alpha and dense granules, probably
accounting for the relative difference in rate of release between the two. On stimulation dense
granules appear to individually fuse with the plasma membrane (Morgenstern et al 1985), whilst alpha
granules are seen to move toward the centre of the platelet, clearly not an ideal position to fuse with
the plasma membrane (Ginsberg et al 1980; Stenberg et al 1984; Morgenstern et al 1987). One
hypothesis proposes that the granules individually fuse with the deep invaginations of the plasma
membrane running through the platelet, termed the open canalicular system (OCS), from where the
secretory products are moved to the outside of the cell (White et al 1970). The other suggests that ci-
granules fuse with each other at the cell centre, forming a "compound granule". This compound
granule then moves to the cell surface and fuses with the plasma membrane (Ginsberg et al 1980;
Morgenstern et al 1987; Painter and Ginsberg 1984). However, there is also substantial evidence to
support a great deal of inward membrane traffic, thought to act in clearing adhesive and procoagulant
proteins from the cell surface (Wencel-Drake et al 1996), hence limiting thrombogenic events. In
particular, internalisation of the GpIIbllla receptor complexed with fibrinogen occurs, and there
appears to be a cycling intracellular receptor pool of GpIIbllla and Gplb (Wencel-Drake et al 1986;
1990; 1993).
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1.8.2 Platelet granule contents andfunctions
The major platelet factors and their subcellular location are outlined in Table 1.4. The
platelet membranes and the dense bodies produce a variety of short-lived mediators, either due to
degradation or diffusion, and are the most rapidly secreted (Ginsberg et al 1980). Their contents have
rapid effects on the cells of the local vessel wall and the behaviour of other platelets, in particular with
regard to vessel tone. ADP acts as a potent agonist which recruits other platelets to the forming
thrombus, whilst released ATP effects other blood cells, in particular causing Ca2+ fluxes in MO that
inhibit phagocytosis (Sung et al 1985; Greenberg et al 1988). Platelets also represent the major blood
source of the psychoactive serotonin, which again can alter vascular tone. The role of the divalent
cations released is unclear, but is assumed to provide local excess for some of the calcium-dependent
enzymes involved in coagulation and cross-linking of the thrombus. Thromboxane A2, an
arachidonate-derived mediator generated by hydrolysis of membrane phospholipids (Kroll and
Schafer 1989), acts as a potent chemotractant to recruit other platelets, and has vasoconstrictive
properties, thus reducing blood flow through the damaged vessel.
A wide variety of peptides able to modulate the gene expression and growth of the vessel
wall cells are contained within the a-granules. The first to be investigated was the platelet-derived
growth factor (PDGF)(Ross 1989), which occurs as three isoforms and has two known receptors
occurring mainly on smooth muscle cells and fibroblasts (Heldin and Westeremark 1989). In normal
physiology PDGF is thought to play a role in promoting wound healing after platelet interaction with
a damaged vessel wall. However, it has also been strongly implicated in the overt proliferation of the
intimal smooth muscle cells after interaction with atherosclerotic plaques (Ross 1979). Transforming
growth factor-P (TGF-P) was first isolated from platelets, which represent an abundant source of this
cytokine. Along with having inhibitory effects on macrophage activation, TGF-P has complex effects
on cell proliferation, inhibiting in some systems whilst promoting in others. Again platelets represent
the major blood source of Thrombospondin, a large ~450kDa protein that is known to play a role in
platelet aggregation, angiogenesis (Dawson et al 1997), phagocytosis (Savill et al 1992), and in the
activation of TGF-P (Majack et al 1988).
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Table 1.4: Substances released from platelets and their intracellular location.
PDECGF, platelet-derived endothelial cell growth factor. VWF, von Willebrand Factor. PDGF,
platelet-derived growth factor. CTAP III, connective-tissue-activating peptide III. TGF-P,
transforming growth factor p. HMWK, high molecular weight kininogen. CI INH, CI-esterase
inhibitor. PAI-1, plasminogen activator inhibitor-1.
Many of the platelet a-granule contents are proteins found within the plasma, however
whether platelets directly scavenge these or if MKs biosynthesise, for example fibrinogen, remains
controversial. Although present within the blood a wide variety of coagulation factors reside within
platelets. Platelets contain large amounts of factor-V, which plays a role in the assembly of
prothrombinase, one of the final steps of coagulation (Mann et al 1981). The plasminogen activator
inhibitor-1 (PAI-1), an inhibitor of urokinase and tissue plasminogen activators, is also released in
high concentrations from the a-granules (Erickson et al 1984). It is tempting to speculate that to
complement the blood derived factors, platelets hold a cache of important "rate limiting" factors of
direct benefit in thrombus formation at higher microenvironment concentrations, factor-V catalysing
thrombin generation, and PAI-1 in preventing immediate fibrinolytic activities in the vicinity of the
newly formed thrombi (Braaten et al 1993; Fay et al 1994). The a-granule protein P-selectin (CD62P,
PADGEM, GpIIa, GMP140) represents an unusual case. It resides on the membrane of the a-granules
but on activation is rapidly expressed on the cell surface, occurring even before degranulation is
apparent (Sternberg et al 1985). As mentioned previously a-granules centralise and coalesce before
release, and the OCS does not become incorporated into the plasma membrane, as in other specialised
secretory cells such as basophils and mast cells (Zucker-Franklin 1989). Explanations have suggested
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that P-selectin is translocated by lateral flow within the plane of the membrane (White and Escolar
1990), but given that P-selectin can be detected within seconds of activation these seem unlikely.
1.9 Molecular basis of platelet aggregation
To summarise, platelets maintain haemostasis in three main ways: by sticking to collagen and
then to one another (aggregation) at sites of vascular injury they form part of the physical plug that
prevents blood loss; by accelerating the rate at which coagulation proteins are activated, and hence the
rate of fibrin deposition to strengthen the clot; and by secreting granule contents to cause local
vasoconstriction, recruit more platelets, and promote eventual wound healing. The central caveat of
this process is how a free circulating platelet changes into a sticky interacting platelet. Broadly
Agonist Comment
ADP Acts synergistically with many other agonists
Thrombin Formed by activation of the coagulation system
Collagen Constituent of subendothelial matrix
Epinephrine May allow hormonal control of haemostasis
Calcium ionophore Synthetic drug; mobilises calcium within platelets
Arachidonate metabolites Formed and released from plasma membrane of activated platelets
Serotonin May act primarily to sensitise platelets to other agonists
Platelet-activating factor Lipid mediator produced by, and able to activate other cells and platelets
Table 1.5: Common platelet activating agents
speaking platelets need a stimulus to initiate this range of responses, of which the key factors are listed
/
in Table 1.5. Of particular physiological significance are the platelet derived agonists ADP, serotonin,
and the arachidonate metabolites, as mentioned previously, all of importance in recruiting and
activating other platelets. The key protease thrombin, which is the most powerful platelet agonist in
vivo, connects the blood coagulation system with thrombus formation, cleaving the soluble fibrinogen
into the insoluble fibrin.
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1.9.1 Molecular requirements for platelet aggregation
Platelet aggregation is evidently different from agglutination, induced by ristocetin or certain
platelet antibodies, by its energy requirement. In addition, three main factors are required for true
aggregation: platelet agonist, divalent cations, and fibrinogen. With, for example, ADP treatment
only, platelets undergo a shape change from a discoid to a more spherical form bearing pseudopodia,
reflecting rearrangement of the underlying actin cytoskeleton, but aggregation will not occur until
fibrinogen and Ca2+ is added. The requirement for agonist, fibrinogen, and Ca2+ together is easily
understandable once the mechanism of the platelets interaction with fibrinogens is described. Resting
platelets bind little fibrinogen, however on stimulation and in the presence of Ca2+ around 50,000
molecules of fibrinogen are seen to interact with the cell (Bennett and Vilaire 1979; Marguerie et al
1979; Mustard et al 1979), an amount comparable to the number of Gpllbllla receptors on the platelet
surface. As fibrinogen is a symmetric molecule it is able to bind two Gpllbllla receptors and hence
two platelets. Thus, when repeated 50,000 times a very tight union between a mass of platelets is
formed - the aggregate. The competence to bind fibrinogen occurs within seconds of platelet
stimulation, indicating a receptor conformational change and not the presentation of a new receptor on
the surface. The key event is the Ca2+-dependent conversion of the Gpllbllla receptor from a low
affinity to a high affinity state able to bind fibrinogen. The reversible phase of fibrinogen binding
occurs with a Kd of around 0.3pm (Bennett and Vilaire 1979; Marguerie et al 1979; Marguerie and
Plow 1981) that may appear low, but given the plasma concentration of fibrinogen (10pm)(Kumar and
Clark 1998) it represents a thirty fold molar excess. During this reversible phase chelation of divalent
cations causes dissociation of fibrinogen from Gpllbllla, and hence dissolution of the aggregate.
However, by an unknown mechanism a time-dependent stabilisation occurs leading to irreversible
fibrinogen binding, correlating to irreversible platelet aggregation, and removal of divalent cations is
no longer effective (Marguerie and Plow 1981; Muller et al 1993). The stability given by irreversible
binding may help maintain the thrombus in a microenvironment that progresses to conditions that
limit platelet activation and thrombus growth.
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1.9.2 The fibrinogen receptor - GpIIbllla, integrin aufh
The key to platelet aggregation and pharmacological intervention for therapeutic benefit is
the mechanism underlying the conformational change from fibrinogen binding incompetent to
competent. Occurring as the most abundant cell surface protein on platelets and representing around
15% of surface protein, GpIIbllla is also contained within a-granules, with platelet activation able to
double the copy number (Gerrard et al 1980). GpIIb, the anb subunit, is synthesised in the MK as a
single polypeptide chain, but is proteolytically cleaved to a heavy and light chain held by a disulphide
bond (Duperray et al 1989), whilst the GpIIIa is the p3 subunit and is known to complex with the av
subunit to form the vitronectin receptor on platelets and other cells (Ginsberg et al 1987). The two
subunits interact non-covalently in a 1:1 ratio soon after biosynthesis, and interaction is required for
efficient surface expression (Jennings and Phillips 1982; O'Toole et al 1989; Duperray et al 1989).
Stabilisation of the complex requires pM concentrations ofCa2+(Kunicki et al 1985; Brass et al 1985;
Steiner et al 1991), whereas conformational change to fibrinogen binding requires a mM
concentration.
The process whereby agonist stimulated platelets internally transmit signals to change the
GPlIbllla conformation has been referred to as "inside-out" signalling (Shattil et al 1994; Clark and
Brugge 1995). Many aspects of this activation mechanism have been extensively studied, but the
biochemical basis for the final transition is still not known. Many classes of signal response elements
become activated following agonist stimulation, and mutation studies have definitively shown the
GpIIbllla cytoplasmic tail to modulate affinity states (Shattil et al 1994; Shattil and Ginsberg 1997).
Proteins found to interact with the cytoplasmic tails include the cytoskeletal components a-actinin,
paxillin, talin, and filamin (Schaller et al 1995; Horwitz et al 1986), focal adhesion kinase (Schaller et
al 1995), integrin-linked kinase-1 (Hannigan et al 1996), and the potential regulatory proteins beta3-
endonexin, cytohesin-1, integrin cytoplasmic domain associated protein-1, and calreticulin (Shattil et
al 1995; Kolanus et al 1996; Chang et al 1997; Coppolino et al 1995). Binding of ligand (fibrinogen)
to the active integrin induces a further conformational change in GpIIbllla, exposing regions termed
ligand-induced binding sites (LIBS) (Frelinger et al 1988; 1991). This secondary conformational
39
change results in a series of intracellular changes including activation of serine/threonine kinases and
phosphatases, a process conversely called "outside-in" signalling (Schwartz et al 1995; Shattil et al
1994). Whether this secondary change alters, or is required for aggregation processes is not known,
but some evidence has shown instances of fibrinogen bound to active GpIIbllla without induction of
aggregation (Schwartz et al 1995).
1.10 Platelet clearance and cell death
1.10.1 Platelet cell death
All cells must die. Therefore even the anucleate platelet, with a defined half-life in vivo, will
at some stage lose function and need to be "marked" to allow removal from the circulation. For the
majority of mammalian cells, initiation of the apoptotic cell death program results in rapid
morphological and biochemical changes that ultimately result in cell surface changes able to mediate
their swift recognition and engulfment by phagocytes. However, relatively little data can be found on
any form of cell death program within the platelet, with most investigations having looked at the
parallels between platelet activation and apoptosis, such as PS externalisation, spectrin cleavage, and
fragmentation into membrane bound vesicles. An early study by Vanags et al (1997) examined
changes in members of the Bcl-2 family following ionomycin stimulation. By RT PCR platelets were
confirmed to contain mRNA for both Bax and Bcl-2, which shifted to a more proapoptotic ratio on
ionomycin stimulation, demonstrating platelets to be capable of altering the balance of these important
mediators of cell death. In addition, agonist induced PS exposure by platelets was found to be
independent of caspases or calpains, whilst caspase-3 activity remained at basal level following
stimulation (Vanags et al 1997). Conversely, a second study identified caspase-3 as a key participant
in platelet activation, being found processed to its active form, and responsible for PS exposure,
microvesicle release, and cleavage of moesin (Shcherbina and Remold-O'Donnell 1999). However,
the study was badly controlled, used inappropriate protease inhibitor concentrations, and inferred
active caspase-3 from loss of proform alone. The caspase-independent nature of apoptosis-like PS
exposure was strengthened by a third study in which calpain was demonstrated to be responsible for
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PS exposure, microvesiculation, and gelsolin cleavage in activated platelets, and the processing to
inactive forms of recombinant caspase-3 and -9 (Wolf et al 1999).
Two in vivo studies from the same group suggest older populations of platelets within dogs
express PS on their surface, and undergo mitochondrial alterations. Using an estradiol-mediated
model of thrombopoiesis suppression, it was found that during platelet decline, and hence increasing
mean age of those remaining in the circulation, the percentage of PS positive platelets significantly
increased (Pereira et al 1999). Using an identical model in the second study, changes in platelet A\|/M
were studied using potential sensitive dyes. Again as older platelets appeared a loss of A\|/M was
apparent, concordant with PS exposure (Pereira et al 2002), however no study of caspase activity was
undertaken (perhaps their third paper!). From all this we can see that no real study of any constitutive
and potentially age-induced death program within platelets has ever been made.
1.10.2 Platelet clearance
Considering around 200 billion platelets are removed and destroyed ever day, surprisingly
little work has been conducted on the molecular mechanisms mediating this. Hundreds of radioactive
tracer experiments have proposed the spleen and liver to be the primary and secondary site of platelet
removal, respectively, as evidenced by the large numbers localising to these sites (Kaplan and Saba
1978). However, given the known sequestration of platelets and other blood cells by these two
organs, whether this truly reflects clearance remains unknown. In fact the central dogma of most
platelet clearance experiments to date has been the assumption that if they are no longer circulating
then they must have been cleared. Given that many of the experiments have involved protease or
chemical treatments to alter surface molecules (Greenberg et al 1975; 1979), it is quite possible that
the adhesive properties of platelets have been increased, given the appearance of them having been
cleared. To our knowledge no TEM has ever been published of a platelet that has been internalised or
phagocytosed in an in vitro or a physiological in vivo context.
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Much early work focussed on the role of platelet sialic acid on the platelet surface, and
demonstrated that its removal with the sialidase neuraminidase caused an apparent clearance of these
platelets by the liver within an hour of reinfusion (Greenberg et al 1975; 1979). Given the more
recent understanding that sialic acid removal exposes previously hidden "siglec" binding sites, able to
mediate cell-cell interactions (Munday et al 1999), these findings may be somewhat misguided.
Platelet aggregates or thrombi are phagocytosed in part by monocytes and neutrophils (Zucker-
Franklin 1989), therefore many groups have investigated the role of platelet activation markers in
mediating clearance, and in particular P-selectin. Fluorescent-labelled thrombin activated platelets
exposing P-selectin that are reinfused back into baboons are found to lose P-selectin surface
expression, are not cleared from the circulation when compared to untreated controls, and do not lose
haemostatic functions (Michelson et al 1996). In support of this, comparison of platelets from wild
type and P-selectin deficient mice show an identical half-life of 4.7 days, and again activation of these
platelets did not alter life span (Berger et al 1998). The aetiology of idiopathic thrombocytopenia
purpura, an autoimmune disease causing low circulating platelet numbers, is thought to occur through
immune complex mediated platelet clearance (Goad et al 1994; Cordiano 1996). Human platelets
express FcyRIIA as their sole Fc receptor (Karas et al 1982; Cassel et al 1993). As mice lack the
genetic equivalent for FcyRIIA, transgenic mice were generated to express FcyRIIA on both platelets
and macrophages. Treatment of the mice with anti-mouse platelet antibody resulted in severe
thrombocytopenia compared to control littermates due to immune mediated clearance, occurring even
in the absence of the FcR y-chain subunit (McKenzie et al 1999). However, the half-life remained the
same between control and transgenic mice, suggesting FcyRIIA does not mediate clearance of aged
platelets (McKenzie et al 1999).
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Megakaryocyte structure and function
Not only is the megakaryocyte (MK) the most conspicuous and largest cell within
mammalian bone marrow, it is arguably the most fascinating and unique. With the relatively recent
cloning and subsequent commercial availability of the MK differentiation and growth factor
thrombopoietin (TPO), researchers finally have the ability to expand MKs in vitro, and these elusive
cells are slowly beginning to give up their secrets. It is a polyploid cell (not to be confused with
polynucleated), which refers to the multiple duplications of the chromosomes from the usual 2N up to
64N, all contained within the same nuclear envelope. Multiple rounds of abortive mitosis, which has
been termed endonritosis, result in a large multilobed nucleus and a cell body up to 60pm in size. The
multiple endonritotic events almost certainly serve to increase the volume of the cell, akin to normal
mitosis but without the cell division, enabling MKs to undergo their prime function, the production of
large numbers of platelets. Following final maturation and biosynthesis of platelet specific organelles
the MK extends long processes containing platelet-sized nodes, termed proplatelets, from the tips of
which individual platelets are released. Each mature MK is capable of releasing hundreds of platelets,
with daily production balancing destruction at around 2 x 10" platelets (Harker and Finch 1969).
1.11 Megakaryocyte development
1.11.1 Megakaryocytopoiesis
MK development proceeds within the bone marrow from the pluripotent myeloid stem cell,
and is more easily understood when divided into three general stages: progenitor cells, immature MKs
or promegakaryoblasts (PMkB), and mature MKs. As in erythropoiesis, progenitor cells are
responsible for expansion of committed MK numbers, and can be induced to proliferate in response to
a number of general mitotic growth factors such as stem cell factor and IL-3, and by the lineage
specific factor thrombopoietin (TPO). PMkBs are transitional, spanning the mitotic progenitors to the
mature post-mitotic MKs. The mature MKs do not proliferate, but do continue DNA synthesis
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through endomitosis. In vitro studies have revealed the earliest detectable progenitor committed to the
lineage to be the MK high-proliferative-potential colony-forming cell (MK-HPP-CFC), whose prolific
abilities lead to macroscopically visible colonies of a few thousand MKs (Long et al 1988; 1989;
Lowry et al 1995). The burst-forming unit MK (BFU-MK) is more mature and thought to be the
direct progeny of the MK-FIPP-CFC (Long et al 1989), but still leads to the classical "bursts" of
individual colonies of around 100-500 MKs (Long et al 1985). The CFU-MK is the most
differentiated of the progenitors with a limited proliferation potential of 2-32 MKs, and with a very
particular cytokine requirement. Such is the requirement that the first CFU-MK colony was not
reported until 13 years after Donald Metcalfs (1966) original bone marrow cultures (Fauser and
Messner 1979; Vainchenker et al 1979).
The PMkB are transitional cells and are not readily recognisable by morphology, however
the expression of MK/platelet specific markers such as Gpllbllla, and vWF begins to occur (Rabellino
et al 1979; 1981). They lack proliferative ability, but continue DNA synthesis by endomitosis. In
vitro they respond to a wide variety of haemopoietic growth factors, such as IL-3, c-kit ligand, IL-6,
and TPO, maturing into single large MKs (Vainchenker et al 1982; Long et al 1982). PMkB are
highly sensitive to TPO, and as such are the first observable cells to increase in number after induction
of thrombocytopenia, and to decrease under conditions of thrombocytosis (Jackson 1973; Long et al
1979). The mature MKs are the first morphologically recognisable, and have been divided into three
stages reflecting this: stage I typically bears a high nucleus to cytoplasm ratio; stage II tend to show
great increases in total cell volume and granule content; whilst stage III/IV "granular MKs" are the
most mature platelet producing cells. In general the lineage-specific antigen expression, granule
content, and DNA content increases with this maturation.
1.11.2 Cytokine regulation ofmegakaryocytopoiesis
The regulation ofMK numbers can be divided into three areas: the expansion of progenitor
cells, the regulation of the maturation of these progenitors, and the control of terminal maturation and
platelet formation. Extensive work has revealed a number of cytokines able to modulate the first two,
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however to date, with the exception of extreme pharmacological intervention, little conclusive
evidence has been described on the physiological regulation of platelet shedding. However, evidence
suggests the role of the ECM components and stromal cells surrounding MKs in vivo may
significantly contribute to the effect of the cytokine milieu. Although the MK growth and
differentiation factor TPO has been confirmed to have powerful proliferative and maturational effects
through all stages of development (Zeigler et al 1994; Young et al 1996; Sitnicka et al 1996), optimal
in vitro expansion has shown to require factors such as stem cell factor (SCF), IL-3, IL-6, and IL-11
(Broudy et al 1995; Ku et al 1996). However, much of the work remains controversial with widely
differing results between rodents and humans, between in vitro and in vivo, and a belief that many of
the pleiotropic cytokines such as IL-6 may be regulators under stress conditions such as inflammation
(Norol et al 1998). In addition, the cytokine driven proliferation of contaminating non-MK cells may
have profound inhibitory effects on MK maturation (in particular IL-3 mediated myeloid lineage
growth) (Lazzari et al 2000). The preferred consensus appears to be that TPO induces the
differentiation of MK-committed haemopoietic progenitor cells, whereas IL-3, SCF, IL-6, and IL-11
trigger extensive growth of progenitors, which are then "channelled" by TPO into MK differentiation
pathways (Laluppa et al 1997; Lazzari et al 2000). Whatever the true nature of the complex cytokine
interactions, TPO is very much established and accepted as the definitive megakaryocytopoiesis
factor, able alone to drive MKs into full terminal differentiation and platelet production.
1.11.3 Thrombopoietin
TPO had been postulated to exist over forty years ago, and had been proved in principle as an
activity within the plasma of thrombocytopenic animals (low platelet counts) that could stimulate
platelet production on transfer to a second recipient (Odell et al 1961; Spector 1961; Schulman et al
1965). The search for TPO continued unsuccessfully for many decades, but in the early nineties
Vignon et al (1992; 1993) cloned murine and human homologues of the v-mpl oncogene that is
transduced by the myeloproliferative leukaemia virus. The c-mpl gene encoded a protein with strong
homology to the haemopoietin receptor superfamily, and was found expressed on cells of
haemopoietic origin. Further RT-PCR studies demonstrated c-mpl to be present on platelets MKs,
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and CD34+ cells, and that specific antisense oligonucleotides inhibited MK colony formation in vitro
(Methia et al 1993). The data established this receptor as important in megakaryocytopoiesis, and a
role for the still unidentified c-mpl ligand. As always in research, the definitive cloning of TPO along
with associated work to demonstrate its effects in vivo occurred shortly afterwards by no less than five
independent groups (Lok et al; de Sauvage et al; Kaushansky et al; Wendling et al; Bartley et al, all
1994). The TPO gene encodes a protein with an expected size of 36kDa,which is heavily glycosylated
to around 65-85kDa (Gumey et al 1995). Containing two domains, TPO has an amino terminal
bearing strong homology to the erythrocyte differentiation factor erythropoietin, whilst the COOH-
terminal contains serine and proline rich stretches (Lok et al 1994). Promoter regions of the gene
show binding sites for transcriptional activators including GATA-1, NF-E2, and Ets family members
(Deveaux et al 1996).
The system regulating circulating TPO levels, and hence MK numbers, is so elegantly simple
and effective it reassures one's belief in evolution and its ability to develop the simplest answers to
complex problems. Countless studies over the last 30 years have shown an inverse relationship
between circulating platelet mass and TPO (or TPO-like activity pre-1994). The data fitted the idea
that the main feedback mechanisms regulating circulating TPO levels was its binding to c-mpl
positive cells, i.e. platelets, MKs and CD34+ cells. Under most conditions the production of TPO by
the liver or kidney occurs constitutively and at a static basal rate, with mRNA levels not altered on
changes in platelet numbers (Fielder et al 1997; Cohen-Solal et al 1996). Therefore, during periods of
thrombostasis platelet mass remains constant and TPO remains at a basal level. However, during
thrombocytopenia platelet mass has dropped and hence less TPO is "mopped up" resulting in a higher
TPO concentration and the ensuing MK proliferation. Conversely, during thrombocytosis or primary
thrombocythaemia (high platelet counts), platelet mass has increased resulting in lower circulating
TPO and the concomitant reduction in MK proliferation and maturation. (Fielder et al 1996; Kuter
and Rosenberg 1995).
Many of the signal transduction pathways activated by the binding of TPO to its receptor c-
mpl have been elucidated. Intracellular domains of c-mpl closest to the transmembrane region are
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required to induce the proliferative response, and have been shown to activate the Janus kinases /
signal transducers and activators of transcription (JAK / STAT) signal transduction pathway (Gurney
et al 1995; Morella et al 1995). TPO binding activates JAK2, which phosphorylates the transcription
factors STAT 1, 3, and 5, with STAT 5 thought to be the major component (Drachman and
Kaushansky 1995; Sattler et al 1995). In addition, ligand binding results in phosphorylation of the
receptor itself (Sattler et al 1995), along with activation of PI-3 kinase, and phospholipase-Cy
(Drachman and Kaushansky 1997).
1.12 Platelet formation by megakaryocytes
1.12.1 Mechanics ofplateletformation
The fact that platelets originate from MKs following terminal maturation is universally
accepted (Wright 1906; 1910; Thiery and Bessis 1956a; 1956b), however the process by which this
shedding occurs has remained elusive and dogged by controversy. Elucidation of the process has been
hampered by the relatively low abundance of MKs within the bone marrow, ~0.05% of cells, and by
the lack of reliable culture systems resulting in terminal maturation. These constraints resulted in
most original work being conducted by TEM examination of fixed MKs, and as such forced the
development of the original "demarcation model" of platelet shedding (Yamada 1957; Zucker-
Franklin and Petursson 1984). Mature MKs are replete with platelet-specific granules, and contain
unique internal membrane structures termed demarcation membranes (DMs). The essence of the
model is that these DMs outline (demarcate!) future platelet territories, and hence platelets exist as
nascent preformed entities with all specific organelles present within the mature MKs. It is then
proposed MKs leave the bone marrow intact and under go circulation shear-induced fragmentation at
the first capillary bed they encounter, usually the lungs (Trowbridge et al 1982). Examination ofMKs
by TEM certainly reveals platelet-sized fields between DMs, and since granules are plentiful within
the MKs cytoplasm these fields appear as "platelets". However, this model oversimplifies platelets,
tending to view their genesis as a problem of packaging granules into membrane-bound "bags", and
thus overlooking their rich and unique cytoskeletal architecture. To this extent, immunofluorescence
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microscopy, immunogold TEM, and SEM analysis of mature MKs have all failed to detect the
characteristic microtubule coil or platelet-specific antigens within or along the DM platelet fields
(Choi et al 1995; Italiano et al 1999)
The second model proposes that mature MKs extend long filamentous extensions, termed
proplatelets, containing many platelet-sized nodes along their length, much like the appearance of a
pearl necklace (Becker and DeBruyn 1976; Radley and Scurfield 1980). This model is not mutually
exclusive of the previous as it makes two major reinterpretations: platelets are assembled de novo
within the extended proplatelets; and that the DMs are not a partition, but serve as a reservoir for the
vast quantity of plasma membrane required to package platelets (Radley and Haller 1982). Although
numerous groups have contributed to the overwhelming evidence for the proplatelet model, by far the
most convincing is the time-lapse phase microscopy by Italiano et al (1999) of a mature MK
extending proplatelets and eventually releasing mature platelets (Figure 1.6). In combination with
immunofluorescence microscopy and analysis by SEM of isolated cytoskeletons, they were able to
correlate proplatelet morphogenesis with distinct ultrastructural changes to the cytoskeleton. Initial
extensions of large pseudopodia were shown to contain unique parallel bundles of microtubules that
elongated to form thin proplatelets with bulbous ends. These ends were shown to contain a peripheral
bundle ofmicrotubules that appeared to loop back onto itself to form a teardrop shaped structure. The
importance of microtubules in driving the formation was revealed by the use of nocodazole, which
blocked proplatelet extension, and taxol, which resulted in the formation of one or two very large
abnormal processes. The timelapse also revealed proplatelets to be dynamic structures, undergoing
multiple bending and bifurcation events to amplify greatly the number of tips from a single extension.
Interestingly, treatment with cytochalasin B resulted in multiple long processes, devoid of bends or
bifurcations implicating an actin-dependency. Use of an anti-tubulin Ab revealed microtubule coils to
exist only at the very distal tips of the processes, and not within the platelet-sized nodes. This
suggests that final formation and release of "mature" platelets only occurs at these tips, explaining the
need for the multiple bifurcations of proplatelets as a means of amplifying platelet release. This
model is somewhat validated in vivo by mice lacking the transcription factor NF-E2. MKs derived
from these mice undergo a late arrest in maturation, resulting in a severe thrombocytopenia.
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Figure 1.6: A mature megakaryocyte forming platelets. Phase time-lapse video microscopy of a
mature murine MK extending proplatelets and eventually shedding functional blood platelets. Time
points shown are 0 h, 2h, 3h, 4h. Pictures adapted from Italiano et al (1999).
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In contrast to normal murine MKs that develop many proplatelets, MKs derived from the NF-E2
mice never produce proplatelets (Lecine et al 1998), underscoring the model as the physiological
mechanism of platelet release.
1.12.2 Control ofplateletformation
Although the basic mechanics of platelet production are becoming clearer, details of how the
event is initiated and controlled remains vague and contradictory. Culture of whole human bone
marrow cultures with serum results in little proplatelet formation, whilst serum-free conditions result
in many proplatelets (Norol et al 1998). This data lead to the conclusion that serum must be
inhibitory, ignoring the plethora of papers detailing that other bone marrow cells, kept proliferating by
the serum, inhibit MK maturation. TPO has been reported to both promote (Nagahisa et al 1996) and
inhibit (Choi et al 1996) proplatelet formation, and its ability to increase platelet numbers in vivo is
almost certainly indirect via increases in MK mass. In contrast, plasma has been reported to promote
proplatelet formation (Choi et al 1995; Leven and Yee 1987), as has coating culture vessels with
extracellular matrix. Interestingly, matrix components reported to promote proplatelet formation
include vitronectin (Leven and Tablin 1992; Leven 1995) and glycosaminoglycan-serglycin (Hunt et
al 1993), both of which are found in the perivascular area of the bone marrow, exactly where platelet
formation has been proposed to occur (Becker and DeBruyn 1976; Scurfield and Radley 1981). A
pharmacological inhibitor based strategy investigated the effect of various cell signalling pathways.
Proplatelet formation was found to be unaffected by inhibitors of PI-3 kinase, ERK, p38 MAP kinase,
and protein kinase-A signalling pathways. However, blockade of protein kinase-C (PKC) with bis-
indolylmalemide I, or down regulation by prolonged exposure to phorbol myristate acetate resulted in
a significant inhibition of proplatelet formation. Use of a PKC class specific ribozyme strategy
revealed the alpha isoform to specifically be involved (Rojnuckarin and Kaushansky 2001), whilst
novel PKCa antisense oligonucleotides under clinical trials for the treatment of cancer has revealed
the major in vivo side effect to be thrombocytopenia (Nemunaitis et al 1999; Yuen et al 1999).
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Using a seven-step protein purification strategy a Japanese group claim to have found a
putative proplatelet formation factor, isolated from normal human plasma (Ishida et al 2001). Based
on its amino acid sequence the protein was identified as the protease inhibitor antithrombin III (AT
III), known to be involved in the coagulation cascade. Interestingly the factor was found within the
HDL fraction of plasma, which was shown to be required for its activity. Addition of thrombin to the
AT III and HDL fraction to form the thrombin / antithrombin III complex (TAT) resulted in a two fold
increase in the factor's efficacy, producing more than a ten fold increase in proplatelet extension
above control. Intriguingly, the TAT complex is formed to prevent thrombin from acting during the
"resolution phase" of coagulation. Therefore, its postulated that following acute platelet loss through
bleeding and platelet consumption the activated coagulation cascade will result in the production of
TAT, allowing a rapid stimulation of platelet release (Ishida et al 2001). Although the report is yet to
be validated, reproduced, or extended by any other group, the ideas presented are of great interest.
1.12.3 Megakaryocytes and apoptosis
The concept that MKs can undergo apoptosis is well established with multiple reports of
MKs with apoptotic morphology to be found within bone marrow. The MKs appear as condensed
nuclei with a small veil of cytoplasm surrounding, indicative of having undergone platelet shedding,
and have been described as denuded MKs (DMKs) (Radley and Haller 1983). In addition MO have
often been sighted in the vicinity of these DMKs with processes extended to partially or completely
engulf the dying cell (Radley and Haller 1983). An in vitro study demonstrated MKs grown out in
culture for over 18 days underwent apoptosis constitutively to become TUNEL positive, propidium
iodide positive, and to display nuclear fragmentation and a highly granulated cytoplasm. Although
the study had evidence of some apoptotic cells they clearly had a very high amount of necrotic cells,
"masquerading" within their quantifications as apoptotic (Zauli et al 1997). An interesting two part
study by Battinelli et al (2000; 2001) studied the effect of nitric oxide (NO) on the induction of
apoptosis in the MEG-01 cell line, concluding that NO exerted a powerful pro-apoptotic stimulus.
Interestingly, they demonstrated that TPO was able to suppress this NO-mediated death. This effect
of TPO to be able to suppress apoptosis of MKs had in fact previously been suggested to be a
mechanism allowing them to continue endomitosis and increase cell volume (Borge et al 1997). The
very recent second part of the study proposed NO-induced apoptosis could induce MEG-01 cells to
produce platelets (Batinelli et al 2001). Unfortunately their assay for platelet numbers was based on
size of GPIIbllla positive particles as assayed by forward scatter (FSC) by flow cytometry, and made
no real functional or morphological study of the particles produced. In addition, proplatelet bearing
MK morphology was not alluded to or shown, and SEM micrographs revealed a MK morphology, that
they proposed to be responsible for their platelet formation, indistinguishable to that reported for
ROCK I mediated apoptotic membrane blebbing (Coleman et al 2001; Sebbagh et al 2001). Despite
the many weaknesses of these studies they have set precedence for the possibility that MK apoptosis
is associated with platelet formation, but do not conclusively show whether it is a cause or an effect.
1.13 Aims
The initial aims of this study were to try and elucidate whether human blood platelets
undergo a form of constitutive cellular death, and subsequently whether this program could account
for their safe clearance by phagocytes.
Preliminary studies investigated changes platelets had undergone during extended culture,
including alterations in members of the Bcl-2 family, assessment of function, examination of
subcellular changes by electron microscopy, and cell surface changes. In addition, aged platelets were
assayed for their specific recognition and clearance by phagocytes. Subsequent experiments tried to
elucidate molecular mechanisms responsible for the apparent "intrinsic death" of platelets.
Involvement of the ubiquitous mediators of cell death, the caspases, were investigated. Furthermore,
upstream mitochondrial changes, release of cytochrome-C, and apoptosome formation was assessed.
Finally, work was undertaken to establish whether caspases were involved in initiating or
driving the birth of platelets from their progenitor cell, the megakaryocyte, and established whether a
classical Fas death could induce platelet formation. In addition, the mechanistic contradiction of "life
from death" was considered, investigating how a caspase death could be "compartmentalised" to
allow formation of viable platelets capable of oxidative metabolism throughout their own lifespan.
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Chapter 2 - Materials and Methods
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2.1 Materials
All chemicals were of analytical reagent grade and purchased from Sigma Chemical Co (Poole, UK),
and all tissue culture media and supplements were obtained from Gibco Life Technologies (Paisley,
UK) unless stated otherwise. Animals were obtained from the Department of Biomedical Resources,
University of Edinburgh. Further materials were purchased from the following companies:
Adobe Systems Incorporate, San Jose, CA, USA: Photoshop 6.0
Alexis Corporation UK Ltd, Nottingham, UK: Fas ligand and enhancer
Amersham Pharmacia Biotech UK Ltd, Buckinghamshire, UK: Hybond-P polyvinylidene
fluoride (PVDF) membrane, ECL plus detection reagent, Dextran T500, Percoll. 2D-E equipment;
MultiPhor II 2D-E unit, Immobiline DryStrip IPG gels, IPG buffer, IPG cover fluid.
Ancell Corporation, Bayport, MN, USA: CD62P blocking mAb clone Gl/Gl-4
Anthos Labtec Instruments, Salzburg, Germany: Automatic plate reader
ATCC, Manassas, VN, USA: MEG-01 megakaryoblastic cell line
Bachem AG UK Ltd, St. Helens, UK: zVAD-fmk, zDEVD-fmk, zLEHD-fmk
Baxter Healthcare Ltd, Glasgow, UK: Diff Quick stain, saline solution 0.9% (sterile)
Becton Dickinson, Cowley, UK: FACScalibre flow cytometer
Biodata Corporation, Horsham, PA, USA: PAP4 aggregometer
BioSource International, Camarillo, CA, USA: Anti-human Bid pAb
Boehringer Mannheim, Mannheim, Germany: Annexin-V-FLUOS
Calbiochem-Novabiochem UK, Nottingham, UK: Caspase-3 substrate (DEVD-AMC), ALLN
Caltag Laboratories UK Ltd, Towcester, UK: CD61-FITC pAb
Carl Zeiss Ltd, Welwyn Garden City, UK: Axiovert SI00 inverted microscope
Cecil Instruments, Cambridge, UK: Spectrophotometer CE2021
Chemicon International UK Ltd, Southampton, UK: Human recombinant caspase-9
CoolSnap, Leiden, The Netherlands: Air cooled CCD camera
Costar UK Ltd, High Wycombe, UK: Tissue culture plates, flasks, pipettes
Dako UK Ltd, Cambridgeshire, UK: Horse radish peroxidase (HRP)-conjugated goat anti-rabbit
secondary pAb
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Falcon, Becton Dickinson, Cowley, UK: Various plastic labwear; centrifuge tubes, pipettes,
multiwell tissue culture plates
Improvision, Coventry, UK: OpenLab 3.0 image acquisition and analysis software
Intergen, Oxford, UK: CaspaTag fluorescent active caspase reagent
Intracel, Royston, UK: Willco glass bottomed microwell dishes
Leica Microsystems AG, Heidelberg, Germany: TCSNT confocal microscope system
Martindale Pharmaceuticals Ltd, Romford, UK: Calcium chloride
Molecular Dynamics, Amersham Pharmacia Biotech UK Ltd, Buckinghamshire, UK: STORM
860 phosphoimager, ImageQuant acquisition and analysis software
Molecular Probes Inc, Leiden, The Netherlands: JC-1 [5,5',6,6'-tetrachloro-l,T,3,3'-
tetraethylbenzimidazocarbocyaniniodide]; FLUO-3, Alexa Fluor 488 goat anti-mouse secondary Ab
Ortho Diagnostics, no longer trading: PermeaFix permeabilisation and fixation reagent
PeproTech EC Ltd, London, UK: Human thrombopoietin (TPO), human IL-ip
Perkin Elmer, EG&G, Wellesley, MA, USA: Spectrofluorimeter LS50B, FL WinLab acquisition
software
Pharmingen, Becton Dickinson, Cowley, UK: Caspase-3 pAb, caspase-9 mAb (clone B40),
caspase-9 pAb, APAF-1 pAb
Philips Electron Optics, Eindhoven, The Netherlands: CM 150 transmission electron microscope
(TEM)
Phoenix Pharmaceuticals Ltd, Gloucestershire, UK: Sodium citrate solution (3.8%)
Pierce Biotechnology Inc, Rockford, IL, USA: BCA protein assay
Polysciences Europe Gmbh, Eppelheim, Germany: 10 pm polystyrene beads
R&D Systems Europe Ltd, Oxon, UK: Human TNFa
Serotec Ltd, Kidlington, UK: CD41-PE pAb
StemCell Technologies, London, UK: StemSpan H2000 serum replacement media
Upstate UK Ltd, Botolph Clayton, UK: Human anti-Fas mAb clone CH-11
Zetos, EOBM, Philipps-University, Marburg, Germany: Zetos bone culture and loading system
The following reagents were kindly donated as gifts: Megakaryoblastic cell line SET-2 was kindly
provided by K.Uozumi, Faculty of Medicine, Kagoshima University, Japan.
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2.2 General Buffers
General cell lysis buffer with protease inhibitors
10 ml Hepes 100 mM pH 7.4
10 ml EDTA lOmM
1 ml Benzamidine lOOmM
138pl Pepstatin A 5mg ml"1
1 ml ct-PA 19.8 mg ml"1 (in MeOH)
86 pi Leupeptin 5 mg ml"1
120pl Antipain 5 mg ml"1
1 ml PMSF 17.4 mg ml"1 (made up fresh in MeOH)
To 100 ml with ddH20
lx Laemmli sample buffer
0.8 ml Tris pH 6.8
1 ml SDS 20%
1 ml Glycerol
0.53 ml (3-Mercaptoethanol
~5 mg Bromophenol blue
To 10 ml with ddH20
3x Laemmli sample buffer
2.4 ml Tris 1 M pH 6.8
3 ml SDS 20%
3 ml Glycerol
1.6 ml P-Mercaptoethanol
~5 mg Bromophenol blue
To 10 ml with ddH20
Sealing gel solution
0.5 ml 30% Acrylamide
2 ml ddH20
20 pi APS (lOOmg ml"1)
10 pi TEMED
Separating gel solutions
6% 9% 12% 15%
30% Acrylamide 2 ml 3 ml 4 ml 5 ml
Tris 2 M pH 8.8 2 ml 2 ml 2 ml 2 ml
ddH20 6 ml 5 ml 4 ml 3 ml
10% SDS 100 pi 100 pi 100 pi 100 pi
APS (lOOmg ml"1) 50 pi 50 pi 50 pi 50 pi
TEMED 25 pi 25 pi 25 pi 25 pi
Stacking gel solution
3.6 ml ddH20
0.7 ml 30% Acrylamide solution
0.6 ml Tris 0.5 M pH 6.8
50 pi 10% SDS
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25 fj.1 APS (lOOmg ml"1)
5pl TEMED

















5 g non-fat dried milk powder
100 ml PBS




± 100 pi TWEEN-20
Wash buffer
500 ml PBS







10 ml Tris lOOmM pH 8.0
20 ml NaCl 2M
20 ml EDTA lOmM
To 100 ml ddH20
pH to 8.0
2.3 Cell culture
2.3.1 Maintenance ofcell lines
Human megakaryoblastic cell line MEG-01 (Ogura et al 1985) (ATCC) and Jurkat T cells
(Jurkats) were routinely maintained in RPMI 1640 supplemented with 10% FCS, L-glutamine (2
mM), and penicillin/streptomycin (0.1 mg ml"1). Human megakaryoblastic cell line SET-2 (Uozumi et
al 2000) was maintained in DMEM supplemented with 10% FCS, L-glutamine (2 mM),
penicillin/streptomycin (0.1 mg ml"1), 2-ME (10 pM), and 10% NEAA. Jurkats were cultured in
suspension at a density of between 0.4-1 xlO6 ml"1, splitting every 2-3 days. Megakaryoblastic cell
lines were similarly cultured in suspension, but at a density of between 0.1 - 0.5 xlO6 ml"1, and only
required splitting every 5 days.
2.3.2 Isolation ofhuman mononuclear cells
Human neutrophils were purified from the peripheral blood of healthy human volunteers by
modification of previously described methods (Haslett et al 1985; Dransfield et al 1994). Neutrophil
isolation was performed at room temperature, under sterile conditions and using endotoxin-free
reagents and plasticware (Falcon). Venous blood was collected into 50 ml polypropylene tubes,
anticoagulated (4 ml 3.8% sodium citrate/36 ml blood) and centrifuged (350g, 20 min., RT), to give
two layers. The upper layer contained plasma and platelets and a lower layer contained a mixture of
erythrocytes and leukocytes. Platelet-rich plasma (PRP) was aspirated and used to prepare autologous
serum in glass tubes by the addition of CaCl2 (220 pi of 1 M CaCl2 added to 10 ml PRP) at 37°C. To
sediment the erythrocytes, 5 ml of 6% dextran (T500; pre-warmed to 37°C) was added to the pelleted
cells and the volume made up to 50 ml with 0.9 % saline (pre-warmed to 37°C). The tubes were
mixed gently and the cells allowed to sediment at RT (~30 min), resulting in formation of two
distinguishable layers; a bottom layer containing mainly sedimented erythrocytes and an upper
leukocyte-rich layer. The leukocyte-rich layer was aspirated, centrifuged (350g, 6 min) and the
supernatant discarded. The resulting leukocyte pellet was resuspended in 2.5ml of 55% isotonic
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Percoll (9:1 v/v Percoll: 10 x PBS) in 1 x PBS w/o. Discontinuous Percoll gradients were prepared by
overlaying 2.5ml of 68% Percoll onto 2.5ml of 79% isotonic Percoll in a 15 ml Falcon tube.
Leukocytes were then resuspended in 55% Percoll and overlayed to form the final layer of the
gradient. The gradients were centrifuged (720g, 20 min) and polymorphonuclear cells harvested from
the 68% / 79% Percoll interface. Mononuclear cells sedimented at the 55% / 68% Percoll interface.
Purified cells were washed sequentially in PBS twice and cell yield assessed using a haemocytometer.
Cell viability was assessed by trypan blue exclusion and was routinely >99%. The typical yield for
this isolation method was 100 x 106 polymorphonuclear and 50 x 106 mononuclear cells/40 ml whole
blood.
2.3.3 Generation ofprimary monocyte derived macrophages
Freshly purified human mononuclear cells were plated at 4 xlO6 ml"1 in Iscove's Dulbecco's
modified Eagles medium and allowed to settle and attach (~1 h). Non-adherent cells were washed off
with two washes of HBSS w/o, followed by the addition of Iscove's containing 10% autologous
serum (PRPDS), and incubated at 37°C for 6-7 days. Detached lymphocytes were removed by
washing on day 2, and 5, replacing media with fresh Iscoves's 10% autologous serum.
2.3.4 Generation ofprimary MKs
Generation of primary murine megakaryocytes is described in detail elsewhere 1617
(Drachman et al 1997; Rojnuckarin and Kaushansky 2001). Briefly, bone marrow was flushed from
femurs of 6-8 week old male BALB/c mice and a single cell suspension obtained by gentle pipetting.
Cells were incubated overnight in StemSpan H2000 (StemCell Technologies) with human
recombinant TPO (40 ng ml"1; PeproTech) and all non-adherent cells transferred to fresh wells and
incubated for a further 72 h. Enrichment of mature megakaryocytes was by velocity sedimentation
through a discontinuous 1.5%, 3.0% BSA gradient, retaining those cells reaching the bottom within 30
min. Purified primary MKs were replated and cultured with TPO (30 ng ml"1) and 10% normal human
plasma. Staining of purified MKs for CD41 (1:1000; Serotec) and CD61 (1:1000; Caltag
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Laboratories) followed by FACS analysis revealed >95% to be highly positive for both markers,
indicative ofmature MKs.
2.3.5 Treatment ofprimary MKs andMK cell lines
Primary or cell line MKs were treated with reagents as indicated as follows; zVAD-fmk (100
pM; Bachem), zDEVD-fmk (10 pM; Bachem), zLEHD-fmk (10 pM; Bachem), Calpeptin (lOOpM;
Calbiochem), anti-Fas agonistic antibody CH. 11 (50 ng ml"1; Upstate), anti-Fas antagonistic antibody
ZB4 (1 pg ml"1; Upstate), soluble Fas ligand and enhancer (5 ng ml"'; Alexis), TNF-a (25 ng ml"1;
R&D Systems), IL-ip (25 ng ml"1, Peprotech), and JO-2 (250 ng ml'1; Pharmingen).
2.3.6 Platelet isolation and culture
Freshly drawn venous blood was obtained from aspirin-free healthy donors, citrated (0.33 %;
Pharma Flameln), and PRP prepared by centrifugation (350 g, 20 min). PPP was prepared from PRP
by further centrifugation (1200g for 15 min). Washed platelets were prepared by diluting PRP with 5
volumes of F1BSS w/o, pH 6.4, containing EDTA (4 mM final) into a round-bottom capped
polystyrene centrifuge tube before centrifugation (280 g, 20 min). After washing platelets were
resuspended in HBSS w/o, pH 6.4, or media as indicated, and maintained at 37 °C in a closed round
bottom polystyrene tube at 3 x 108 ml"1. Platelet samples for SDS-PAGE were purified free of the
majority of contaminating leukocytes by three successive centrifugations of the PRP / HBSS / EDTA
(220 g, 5 min), retaining the supernatant each time, before finally pelleting the platelets by
centrifugation (280 g, 20 min). Platelet preparations were routinely checked by microscopy for the
presence of leukocytes or aggregates which if found resulted in the experiment being discarded.
60
2.3.7 Platelet activation
For analysis of activated platelets by TEM, fresh washed platelets resuspended in HBSS w/o,
pH 6.4, were treated with ADP (10 pm) or Thrombin (3 U ml"1) at 37°C (1 min) before fixation with
2.5% glutaraldehyde as detailed below. For positive controls of CD62P or PS exposure, 5 pi of fresh
PRP was added to 500 pi of PBS and activated as above before staining and sampling by flow
cytometry.
2.3.8 Phagocytic recognition ofaged platelets
For experiments involving phagocytic recognition of aged platelets, following isolation
platelets were first incubated in HBSS w/o Ca2+ at 5 xlO9 ml"' (10 min) with Cell Tracker Orange (1.8
pM; Molecular Probes). Unincorporated dye was removed with two washes of HBSS w/o, pFI 6.4,
before resuspending at 3 xlO8 ml"1 in HBSS w/o, pH 6.4, and aging in culture. Platelets labelled with
Cell Tracker Orange were washed free of conditioned media and resuspended in HBSS w/o before
addition to a prewashed monolayer of adherent phagocytes cultured in 24-well plates. Typically 5 x
107 platelets were incubated with 1 x 105 phagocytes at 37°C for 10 min for platelets aged in the
absence of plasma and 30 min for platelets aged in citrated plasma. Following the incubation period,
the phagocyte monolayer was washed free of non-interacting platelets and any adherent platelets
removed by treatment with trypsin at 37°C (5 min), followed by 5 mM EDTA at 4°C (20 min), to
recover the human M<j>, and trypsin/EDTA treatment alone at 37°C (5 min) for all other cell lines
tested, before flow cytometric, confocal, and epifluorescence microscopic analysis. For phagocyte
inhibition experiments MDM monolayers were preincubated at 37°C (10 min) with a panel of
inhibitors diluted in Iscoves w/o serum at concentrations as indicated. Monolayers were then
rewashed and the target platelets added to the wells along with inhibitors.
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2.3.9 Treatment ofplatelets with proteases and a sialidase
Aged washed platelets in HBSS w/o (1 ml) were incubated at 37°C (30 min) with the
proteases Elastase, Protease 9, Protease 14, Chymotrypsin, or Papain (all 10 pg ml"1), or the sialidase
Neuraminidase (0.01 U ml"1). Following incubation platelets were washed free of proteases by
centrifugation (280g, 5 min), resuspended in HBSS w/o to the original concentration, and transferred
to a prewashed phagocyte monolayer, before incubation and analysis of phagocytosis as detailed
above.
2.4 Ex-vivo bone culture
Trabecular bone from femoral heads was isolated from a 58-year old male patient undergoing
hip surgery, machined with high precision to cylindrical cores under sterile conditions, and inserted
into a Zetos™ bone perfusion and loading chambers (Smith and Jones 2001). Each core was
individually perfused with 5 ml DMEM under recirculation at a rate of 5 ml h"1, maintained at 37°C /
5% C02, and subjected to a daily 5 Hz loading cycle which was found necessary to ensure viability.
A brief schematic of the system is outlined in Figure 2.1. On day 5, anti-Fas antibody CH. 11 (50 ng
ml"1) and/or zVAD-fmk (100 pM) were added directly to reservoirs containing fresh media that was
perfused to the bone cores. Perfused media was collected over an 18 h period, after which the flow
rate was increased to 15 ml h"1 for 2 h, with a final flush of the core with 5 ml of PBS. Large cellular
material was removed by centrifugation (200 g, 5 min) and remaining supernatant components
concentrated by further centrifugation (1500 g, 15 min). Resuspended pellets were stained for Gpllb-
PE (1:1000; Serotec) and GpIIIa-FITC (1:1000; Caltag), and analysed on a FACScan (Becton




Figure 2.1: Schematic of the Zetos™ ex-vivo bone core culture system: Human trabecular bone,
typically obtained during hip surgery, is high precision-machined under sterile conditions to multiple
cylindrical cores and inserted into flow chambers. Up to 24 flow chambers and cores are connected to
a looped media perfusion system driven by a multi-channel peristaltic pump. Each core has an
individual media reservoir that is pre-gassed with 5% C02. All components of the system are
maintained at 37°C in a thermostatically controlled enclosure.
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2.5 Platelet functional studies
2.5.1 Platelet aggregation
Platelet aggregation studies were performed in a PAP4 aggregometer (Bio-Data Corporation)
in which 0.5 ml aliquots of platelets were incubated (2 min) with stirring at 37°C before the direct
addition of agonist. Changes in transmittance were compared to autologous PPP as the control. Prior
to aggregation experiments, washed platelets were harvested by centrifugation (280g, 20 min) and
resuspended in autologous PPP. Agonists used were ADP (10 pM), thrombin (10 units ml"1), and
U46619 (10 pM). In reconstitution experiments freshly washed platelets in HBSS w/o, had TPO (5 ng
ml"1; Peprotech), PDGF (10 ng ml"'; Peprotech), IGF-1 (100 ng ml"1; Peprotech), or BSA (4 mg ml"1)
directly added to final concentrations, followed by incubation at 37°C (2 h).
2.5.2 Platelet adhesion and cell spreading on collagen
Glass microscope slides were coated with either collagen I or IV solutions (100 mg ml"1) in
PBS. After 30 min the slides were washed with PBS before applying a volume of suspended platelets
in cultured media. Following incubation (20 min), the slides were flicked free of media and non¬
adherent cells and snap-frozen with ice-cold methanol and acetone (1:1). The slides were then air-
dried before staining with phalloidin-TRITC in PBS (2 pg ml"1) and anti-CD41-FITC (1:1000,
Serotec). Slides were examined by epifluorescent microscopy (Zeiss).
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2.6 Immunolabelling and flow cytometric analysis
2.6.1 Analysis ofplatelet cell surface proteins
Immunofluorescent labelling of intact platelets for surface expression of CD41 (clone
PM6/248; Serotec), CD42a (clone GRP-P; Serotec), CD61 (clone BL-E6; Caltag Laboratories), or
CD62P (clone CRC81; Caltag Laboratories) was typically performed by resuspending 5 pi of cultured
platelets with 40 pi of the appropriate fluorophore-conjugated Ab diluted 1:1000 with 10% NBCS in
PBS (10 min), before adding 400 pi of FACS sheath fluid and sampling by flow cytometry using a
FACScaliber and CellQuest software (Becton Dickinson). Phosphatidylserine (PS) exposure by intact
platelets was determined by resuspending 5 pi of cultured platelets in 400 pi of HBSS containing 2
mM Ca2+ and FITC-conjugated annexin-V (0.3 pi ml"1; Boeringer). All labelling steps were
maintained at 4°C.
2.6.2 Analysis ofplatelet intracellular proteins
Intracellular immunolabelling of the Bcl-2 family of proteins was performed following
fixation and permeabilization of the platelets with PermeaFix (Ortho Diagnostics), typically using 1
ml per 3 x 108 platelets on ice (30 min). Excess fixative was then removed with two washes of HBSS
w/o (280g, 5 min) before resuspending with 10% NBCS in PBS at 3 x 10s ml"1. 5 x 106 platelets were
then incubated overnight with neat antibodies to Bak (1 pi), Bax (1 pi), Bcl-2 (1 pi), Bcl-x (1 pi), and
Mcl-1 (1 pi) (all Pharmingen) or their appropriate negative controls. All primary Abs were detected
with FITC-conjugated F(ab')2 fragments of sheep anti-rabbit pAbs or goat anti-mouse pAbs.
2.6.3 Analysis ofplatelet mitochondrial transmembrane potential
Immunofluorescent labelling of intact platelets for inner-mitochondria] membrane potential
(Avj/M) was performed by adding 5 pi of platelets to 400pl of PBS w/o Ca2+ containing JC-1 (10 pg
ml"'; Molecular Probes), followed by incubation at 37°C (20 min), before sampling by flow cytometry.
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Deliberate uncoupling of the respiratory chain with subsequent loss of platelet Atj/M was achieved by
direct addition of the protonophore mCCCP (10 pg ml"1).
2.6.4 Enumeration andfunctional evaluation ofculture derivedplatelets
Culture supernatants containing platelets were separated by centrifugation (300 g, 2 min) and
platelets enumerated by reference to a fixed count of 10 pm polystyrene beads (Polysciences).
Functional platelets were distinguished from cellular debris by the characteristic increase in side
scatter on shape change following thrombin (1 U ml"1) or ADP (3 pM) treatment, and an absence of
annexin-V binding (0.3 pi ml"; Boeringer) to the shape changed population. All conditions contained
propidium iodide (10 pg ml"1), with events staining positive excluded from subsequent analysis.
Transient calcium flux was detected using FLUO-3-AM (10 pm; Molecular Probes). Culture derived
platelets were separated as above, incubated at 37°C with FLUO-3-AM (20 min), and stimulated with
agonists as above before sampling by flow cytometry.
2.7 SDS-PAGE and protein blotting
2.7.1 General considerations
For analysis of protein changes on induction of cell death, protein was analysed on the basis
of equal numbers of extracted cells, rather than on the amount of protein loaded. Using a ratio of 100
platelets to 1 Jurkat cell resulted in lysates of comparable protein content as assayed by the BCA
protein assay (Pierce). The assay is based on the ability of protein to quantitatively cause a reduction
of Cu2+ to Cu+, and bicinchoninic acid (BCA) to chelate Cu+ forming a purple compound, which can
be measured by spectrophotometry (562 nm). Samples were diluted 1 in 10 in dH20 and 10 pi
incubated with 200 pi of test solution (30 min, 37°C) prior to analysis using an automated plate reader
(Anthos). Samples were assayed in triplicate and standard curves formed using pre-made BSA
standards. For comparison of relative protein levels between cells under constitutive conditions
extracts were analysed on an equal protein loading basis. This distinction was made so that any
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"global" loss of cellular protein witnessed on induction of cell death would not result in the apparent
"false amplification" of other proteins when adjusting cell lysates for equal protein loading. Lysates
were prepared by resuspending pelleted cells into ice-cold general cell lysis buffer with protease
inhibitors (PMSF added fresh just before use) and incubated on ice (10 min). Cells were disrupted by
passing through a 25 G needle ten times, followed by centrifugation (10,000g, 10 min, 4°C) retaining
the supernatant. Lysates were added directly to four times laemlli buffer and boiled (97°C, 3 min)
before long-term storage at -20°C. Molecular weight markers used were Rainbow Markers, SDS-7B,
or BenchMark (Gibco Life Technologies).
2.7.2 Detection ofcytochrome-C
For cytochrome-C detection, washed platelets were resuspended in ice-cold 10 mM Flepes
buffer, pH 8.0 (containing ImM EDTA, 1 mM 1,10-phenanthroline, ImM
phenylmethylsulphonylfluoride, 1 mM benzamidine, 10 pM pepstatin, 10 pM leupeptin, 10 pM
antipain,), and lysed following two rounds of freeze-thaw. The lysed platelets were then centrifuged
at 10,000g to yield a cytosolic supernatant (S10) and the pellet resuspended in lysis buffer before
centrifuging again and dissolving the pellet in 1% TX-100 and re-centrifuging at 10,000g to yield
soluble protein from intact mitochondria (T10). The S10 and T10 fractions were then pre-cleared with
a control IgG and Protein-G agarose before immunoprecipitating cytochrome-C with clone 6H2.B4
(Pharmingen) and boiling in SDS sample buffer (Laemmli). Cycloheximide (20pg ml"1; Calbiochem)
treated Jurkats were used as a positive control and prepared identically. Cytochrome-C was detected
using clone 7H8.2C12 (Pharmingen)
2.7.3 Cellfree caspase-3 activation
For detection of caspase-3, Jurkats and fresh platelets were resuspended in ice-cold 20 mM
Hepes buffer, pH 7.5 (containing 1.5 mM MgCl, ImM EDTA, 1 mM EGTA, 1 mM DTT, 100 pm
PMSF, 10 pg ml"' leupeptin, 2 pg ml"1 aprotinin), and incubated on ice (10 min). In addition platelets
were subjected to three cycles of freeze-thaw, before disruption of both cells by passing through a 25
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G needle ten times. Cell free apoptosis was initiated by addition of cytochrome-C (10 pg ml"1) and
dATP (1 mM) to lysates, followed by incubation at 37 °C. In reconstitution experiments, human
recombinant caspase-9 (0.1 U ml"1; Chemicon) was directly added to lysates. Control sample lysates
had buffer alone added. At indicated time points aliquots were removed and directly added to
eppendorfs containing 4 times Laemmli buffer, and immediately boiled (3 min).
2.7.4 Two-dimensional electrophoresis
Two-dimensional electrophoresis (2D-E) was conducted using the Multiphor II
electrophoresis unit, Immobiline DryStrip IPG gel kit, and additional ancillary reagents and
equipment (all Amersham Pharmacia Biotech). 2D-E and the use of the Multiphor system is
described in extensive detail and at great length elsewhere (Berkelman and Stenstedt 1998), and is
unnecessary for this thesis. Briefly, 50 pg of cell derived protein prepared in 2D lysis solution was
mixed with IPG rehydration buffer to a final volume of 200 pi. An 11 cm pH 3-11 IPG strip was
placed into an Immobiline DryStrip reswelling tray, the sample and rehydration solution applied,
everything overlayed with IPG cover fluid, and allowed to rehydrate overnight. The rehydrated IPG
strip was transferred to a pre-cooled Multiphor flatbed electrophoresis unit, aligning the acidic end
towards the anode, electrodes applied, and everything overlayed with IPG cover fluid. Isoelectric
focusing is conducted at very high voltages (-3500 V), and very low currents (<lmA) due to the low
ionic strength within the IPG strip. Voltage was stepped from 300 V (2 h), through 800 V (2 h), 1500
V (4 h), to a final voltage of 3500 V, which was maintained overnight (~16h). Focused IPG strips
were equilibrated with an SDS buffer system to allow second dimension separation. Equilibrated
strips were applied to the stacking gel of a typical vertical gel system, overlayed with 1% agarose, and
electrophoresed and immunoblotted in a conventional manner.
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2.7.5 Immunoblotting and detection
Electrophoresed proteins were transferred to PVDF membranes using a cooled "wet" transfer
tank system. Typically transfers were conducted at 2 mA per cm"1, whereby proteins less than 80 kDa
fully transferred after 1.5 h. Larger proteins, such as APAF-1, usually required 2.5 h. Membranes
were blocked with either 2% casein or 5% non-fat dried milk powder (Marvel) for 1 h, before
incubation at 4°C in a rolling tube with primary Ab overnight. Primary antibodies were typically used
at a dilution of 1:1000 in blocking buffer, but were titrated where necessary. Again were necessary
due to high levels of non-specific antibody binding Tween-20 was added at a concentration of
between 0.05-0.1%. Membranes were thoroughly washed with PBS or PBS/Tween, before incubation
with an FIRP-conjugated secondary antibody in blocking buffer for lh. For development by the 4-
chloro-l-napthol method, secondary antibodies were used at 1:1000, whilst for development by ECL
plus a dilution of 1:5000 was more typical, but again titration of optimum levels was conducted when
necessary.
For development by the 4-chloro-l-napthol method, lOmg of 4-chloro-l-napthol was
dissolved in a minimal volume of ethanol and diluted to 50ml with development buffer. Washed
stained membranes were incubated in this solution with agitation and the development reaction
initiated with the addition of 50pl of FL02 (30% v/v). Development was stopped by washing the
membrane free of developer solution with PBS. ECL plus (Amersham Pharmacia Biotech) was
conducted as per the manufacturers instructions. ECL signals were detected using either a
phosphoinrager (Molecular Dynamics) equipped with image analysis software (Molecular Dynamics),
or following exposure to autoradiographic film (Amersham Pharmacia Biotech). Primary Abs used
were caspase-3 pAb, caspase-9 pAb, caspase-9 mAb (clone B40), APAF-1 pAb (all Pharmingen), Bid
pAb (BioSource International), and (3-actin mAb (clone AC-15).
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2.8 Analysis of platelet plasma membrane integrity
2.8.1 Flow cytometric analysis usingphalloidin-FITC as a vital dye
Due to platelets anucleate nature more typical DNA binding vital dyes were unsuitable.
Phalloidin is a natural filamentous-actin binding toxin extracted from the mushroom amanita
phalloides, is extremely hazardous, and should be used with great caution. Fresh or washed aged
platelets, 5pl, were added to 500pl of PBS containing phalloidin-FITC (2 pg ml"1) and incubated at
RT (10 min). Platelets were washed once by centrifugation (280g, 5 min), and resuspended in PBS
before analysis by flow cytometry. As a positive control for saturated actin phalloidin binding,
platelets were permeabilised on ice (30 min) using PermeaFix (Ortho Diagnostics) before staining.
2.8.2 Spectrophotometry assayfor Lactate Dehydrogenase
Fresh washed platelets were incubated overnight and pelleted by centrifugation (280g, 20
min). The supernatant was removed and the pellet resuspended to the same volume in HBSS and
sonicated. Stock solutions ofNADH (0.2 mM) and sodium pyruvate (1.6mM) were freshly prepared
in a Tris (81.3 mM)/NaCl (203.3mM) buffer, pH 7.2. The assay was initiated by the addition of
platelet supernatant or sonicate (40 pi) to a quartz silica cuvette maintained at 37°C and containing
420 pi of NADF1 and 80 pi pyruvate. LDH activity was measured as the time-dependent and
pyruvate-dependent decrease in the absorbance of NADF1 at 339nm using a spectrophotometer
(Cecil). LDH activity was expressed as pmoles of NADH consumed per min per ml of platelet
supernatant or sonicate.
2.9 Extraction of genomic DNA for analysis of fragmentation
During the extraction of genomic DNA the mixture must never be vortexed, vigorously
shaken, or pipetted thorough fine tips due to the shearing that will occur, with the result that the
genomic DNA will run on the gel as a continuous smear. Approximately 2 x 106 cells were collected
70
by centrifugation (220g, 5 min) and resuspended in 1 ml of nuclear lysis buffer. Proteinase K was
added (30 pi of 10 mg ml"1 stock) and the solution gently mixed, followed by the addition of 20 pi of
SDS (10%), gentle mixing, and incubation at 55°C for at least 3 h, or alternatively overnight. This
solution was gentle mixed with 1 volume of 1:1 phenokchloroform and centrifuged (10,000g, 1 min),
to form two layers. The top layer was gently removed ensuring the interface, consisting of denatured
protein, was not disturbed. DNA was precipitated by addition of 1 volume of ice-cold isopropanol
and several inversions of the tube. DNA was pelleted by centrifugation (10,000g, 15 min), the
supernatant aspirated, the pellet gently washed with 70% ethanol, and the tube allowed to air dry.
Genomic DNA was redissolved in 50 pi of TE at 37°C for several hours. DNA concentration and
purity was determined using a spectrophotometer (Cecil) at 260 nm and 260/280 nm respectively.
Typically, 1 pg of genomic DNA was loaded onto a 1.2% agarose minigel and electrophoresed at 140
mA for 45 min. DNA was visualised under UV light with ethidium bromide staining.
2.10 Microscopy
2.10.1 Phase and epi-fluorescence microscopy
Images were captured on an inverted microscope (Zeiss) equipped with an air cooled CCD
camera (CoolSnap) and OpenLab 3.0 image acquisition software (ImproVision). Final overlayed
image were produced using PhotoShop 6.0 (Adobe). Live cell suspensions were incubated in situ in
Willco micro dishes (Intracel) and directly imaged through the 0.17 cover glass bottoms. Active
caspases were detected using CaspaTag as instructed (Intergen). Briefly, cultured control or treated
MKs were gently and slowly transferred to an eppendorf using a wide bore pipette and incubated at
37°C (30 min) with CaspaTag diluted to a final lx solution. Following this incubation period all MKs
were found to have pelleted, thus enabling supernatant to be aspirated and the MKs to be gently
resuspended into CaspaTag wash buffer. MKs were again allowed to pellet, supernatant removed and
cells resuspended before analysis. Although slow this method allowed a greater recovery of intact
proplatelet bearing MKs.
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Mitochondrial membrane potential was qualitatively determined using JC-1 (Molecular
Probes) at a final concentration of 5 pg ml"1, following incubation at 37°C (20 min). Nuclear
morphology was detected by the direct addition of Hoechst 33342 (2pg ml"1) to culture medium.
Confocal images were captured on a Leica TCSNT microscope and software system. Assessment of
proplatelet A\|/M by confocal microscopy was with a limited number of Z-axis scans due to cell and
proplatelet motility. MKs were stained for cell surface Fas using a murine anti-Fas IgM mAb (clone
CH.l 1). Cells were fixed with formaldehyde (2%) on ice (30 min), before washing away fixative by
centrifugation (180g, 5 min), followed by staining with CH.ll (50 ng ml"1) on ice (1 h). Primary
antibody was washed away and detected using an AlexaFluor (Molecular Probes) anti-murine
secondary antibody (1:1000), following incubation on ice (1 h).
2.10.2 Transmission electron microscopy
Cells or culture supematants were directly fixed with 2.5% glutaraldehyde (EM grade I) in
0.1 M sodium cacodylate buffer for at least 1 h at RT. Fixative was removed with one wash of 0.1 M
sodium cacodylate buffer, cells pelleted, and overlayed with a minimal volume of fresh PPP for at
least 1 h at RT. A fibrin plug was formed around the pellet by overlaying the PPP with a minimal
volume of fixative, resulting in pseudo coagulation. Plugs were subsequently treated as normal
resected tissue and processed with osmium tetroxide, lead citrate, araldite embedding and ultra thin
sectioning (60nm). Samples were analysed on a Philips CM 150 TEM.
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Chapter 3 - Platelet Cell Death
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Introduction
Close to 2 x 1012 platelets circulate in the average adult human, and around a tenth of these
are efficiently and safely cleared from the circulation every day. Representing an anucleate cell with a
defined in vivo lifespan (Stuart et al 1975), platelets are of critical importance for the maintenance of
normal haemostasis, but disorders of platelet number and function are common giving rise to a range
of bleeding or thrombotic disorders, including stroke and myocardial infarction. Given this central
role in normal mammalian physiology and disease, it is remarkable that there has been very little
study of any potential constitutive death program that could account for platelet deletion in vivo.
Many older studies have proposed platelets to passively lose surface markers of self through attrition
within the circulation, leading to clearance mediated by the spleen (Greenberg et al 1975; 1979).
Interestingly, platelets activated and reinfused into the circulation show an identical lifespan to control
platelets, suggesting activation related platelet changes are dissociated from biochemical alterations
leading to their clearance (Berger et al 1998; Michelson et al 1996). An important preliminary study
(Vanags et al 1997) suggested that platelets may undergo an apoptotic program since increases in the
expression of proapoptotic members of the Bcl-2 family of death regulating proteins were observed
following treatment with ionomycin, a calcium ionophore which induces apoptosis in a range of cell
types, most notably lymphocytic cells (Wyllie et al 1984; Squier and Cohen 1997). Interestingly, this
study showed that ionomycin induced an increase in Bax and Bak, as well as the cell surface
expression of PS, both representative of key features of apoptotic cell death.
Apoptosis represents a designation of a particular form of cell death defined by classical
morphological and biochemical changes, and has attracted intense scrutiny as a self-contained and
physiological program for deletion of unwanted cells (Kerr et al 1972; Wyllie et al 1980), eventually
resulting in plasma membrane changes which lead to the key physiological outcome of apoptosis - the
non-phlogistic recognition and uptake of the intact dying cells by phagocytes (Martin et al 1996).
However, the study of apoptosis has been dominated by experiments which have frequently relied on
artificially induced death in transformed cells and which have rarely paid attention to their recognition
and clearance by phagocytes. Nevertheless, these criticisms have been addressed in studies of primary
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blood cells freshly isolated from healthy human donors (Ren and Savill 1998). For example,
neutrophil granulocytes purified by methods designed to minimize artefactual activation (Haslett et al
1985) undergo constitutive apoptosis that clearly directs specific recognition by phagocytes (Savill et
al 1989; 1993). Nevertheless, many other forms of cell death that do not meet the typical biochemical
and morphological criteria of apoptosis have now been reported (Lavoie et al 1998; Mathiasen et al
1999; Foghsgaard et al 2001). These newly described programs of cell death highlight the various
adaptations to the basic program nature has produced for utilisation in different cell types, tissue
locations, death stimuli, and of course underscores the strong redundancy in a cells ability to die
safely.
To investigate whether platelets could undergo a constitutive apoptotic-like death program,
freshly isolated platelets were cultured for up to 24 h at 37°C. In the presence of autologous plasma
we observed an increase in the levels of proapoptotic Bax and Bak, in keeping with an earlier report
(Vanags et al 1997), and consistent with the idea that platelets might engage a constitutive death
program on aging ex vivo. In support of this, we also observed a constitutive loss of key platelet
functional responses, including agonist-induced aggregation and spreading on collagen. By washing
platelets free of their native plasma, a putative source of survival factors, not only was loss of function
accelerated but there was also revelation of a cell death program characterized by cytoplasmic
condensation as revealed by TEM, display at the cell surface of phosphatidylserine and P-selectin, but
with retention of plasma membrane integrity, and specific recognition and clearance by phagocyte
scavenger receptors.
75
3.1 Cultured platelets exhibit increased levels of pro-apoptotic Bcl-2 family members
An important determinant of whether a cell will undergo apoptosis is its intracellular balance
between anti-apoptotic members of the Bcl-2 protein family such as Bcl-2 and Mcl-1, and
proapoptotic members such as Bax and Bak (White 1996; Reed 1998). The possibility that platelets
might be able to undergo an apoptosis-like death was first raised by Vanags et al (1997) who reported
that ionomycin, a calcium ionophore which triggers apoptosis in many cell types (Wyllie et al 1984;
Squier and Cohen 1997; Gwag et al 1999), caused an increase in the expression of proapoptotic Bax
and Bak, but not Bcl-2. In order to extend the findings ofVanags et al we decided to study a different
model system in which apoptosis-like death might occur. Granulocytes "aged" in culture undergo
constitutive death that is accelerated in the absence of survival factors (Mangan et al 1991; Lee et al
1993; Dibbert et al 1998) and is correlated both with increased levels of Bax (Manfredini et al 1998;
Weinmann et al 1999), but not Bak (Bazzoni et al 1999), and decreased levels of Mcl-1 (Moulding et
al 1998). We therefore tested the hypothesis that, as with granulocytes, prolonged culture of platelets
might also lead to an increase in the expression of pro-apoptotic Bcl-2 family members and a
susceptibility to apoptosis-like death.
3.1.1 Platelets aged in plasma show increased expression ofBax and Bak
Following intracellular staining and assessment by flow cytometry we confirmed that freshly
isolated platelets expressed Bax, Bak, and Mcl-1, but intriguingly not Bcl-2 (Figure 3.1). The ability
of each antibody to recognise its antigen by flow cytometry was verified with appropriate control cell
lines (Magowan 2001). Interestingly, the levels of immunodetectable Bak and Bax increased by 3.4
and 2.4-fold respectively as platelets were aged for 18 h in citrated plasma, while no significant
changes in Mcl-1 were apparent (Figure 3.2). In keeping with studies of ionomycin stimulation of
platelets (Vanags et al 1997), these data suggest that platelets cultured for 18 h can adopt a more
proapoptotic balance and further suggest that aging in culture, as originally reported for neutrophils




Figure 3.1: The proapoptotic balance of Bel homologues is accentuated in aged platelets. (A)
Typical immunofluorecence flow cytometry histograms of PermeaFixed cells which demonstrate that
freshly isolated platelets express the proapoptotic Bcl-2 homologues Bak and Bax, but not the anti-
apoptotic Bcl-2. The negative controls for mouse (Bcl-2) and rabbit (Bak, Bax) Abs were
superimposable and no different from autofluorescent controls, confirming an absence of non-specific
binding. (B) Overlays of representative histograms showing the shift in fluorescence for Bak and Bax
expression between freshly isolated and aged platelets. Autofluorescence and control irrelevant

















Figure 3.2: The proapoptotic balance of Bel homologues is accentuated in aged platelets. The
mean peak fluorescence for various members of the Bcl-2 family are presented as the arithmetic mean
± 95% confidence interval for n = 4 separate experiments (4 different donors). Each experiment was
performed in duplicate on PermeaFixed samples with fresh citrated platelets (open columns), platelets
cultured in the presence of citrated plasma for 18h (A) (solid columns), or platelets washed and
cultured without plasma for 6 h (B) (solid columns). ** denotes p < 0.02 as determined by ANOVA.
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3.1.2 Washingplateletsfree ofplasma factors accelerates the increase in Bax or Bak
Since plasma represents a potential source of exogenous survival factors we went on to seek
evidence that plasma deprivation might accelerate and therefore reveal other biochemical changes
indicative of a constitutive death program, previously overlooked in short-term culture experiments on
platelets. Using a washing protocol based on diluting the plasma 1:5 with HBSS w/o Ca2+, in the
presence of 4mM EDTA, the majority of platelets (74 ± 3 %) could be pelleted and subsequently
resuspended in HBSS w/o followed by incubation at 37 °C. Platelets aged under these conditions
exhibited increased levels of Bax and Bak comparable to those observed for platelets aged in the
presence of plasma, however the change occurred much more rapidly, seen within 6 h of culture
(Figure 3.2).
3.2 Aged platelets exhibit impaired function
Platelets possess many of the functional responses exhibited by other inflammatory blood
cells and a key feature of apoptotic leukocytes cultured overnight in the presence of serum is loss of
the ability to respond to external stimuli and subsequently mount pro-inflammatory responses (Whyte
et al 1993). A range of easily detectable platelet functional responses exist including aggregation,
shape-change, fdopodia extension on collagen, intracellular calcium flux and serotonin reuptake, a
subset ofwhich we used to assess whether platelets lost functionality on aging.
3.2.1 Fresh platelets undergo normal aggregatory responses when stimulated by agonists
With the use of an aggregometer, which measures the light transmittance of a stirred platelet
suspension, we confirmed that treatment of freshly isolated (viable) platelets with 10 pM ADP
resulted in an immediate shape change, observed as a slight decrease in light transmittance (upward
deflection in Figure 3.3; arrow), followed by an irreversible decrease in light transmittance that was
indicative of a full aggregation response. By reducing the concentration of ADP to 3 pM, and in
accordance with the biphasic nature of platelet aggregation (MacMillan 1966), we observed a reversal
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TIME
Figure 3.3: Agonist-induced aggregation is down regulated in aged platelets. Freshly isolated
platelets (A) or platelets aged in citrated plasma for 24 h (B), were monitored for changes in light
transmittance over a 10 min period following activation with ADP to a final concentration of 10 pM
(i), 3 pM (ii), and 1 pM (iii). The upward deflection in the traces (arrow) following the addition of
ADP is indicative of shape change, while increases in transmittance are indicative of reversible (ii) or
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Figure 3.4: Time course for loss of agonist induced aggregation. PRP, washed platelets, or
washed platelets resuspended into PPP were incubated at 37°C and assayed for the level of
aggregation at the times indicated. Platelets were stimulated with U46619 (10 pM) or ADP (10 pM)
as indicated. Data is reported as % aggregation relative to control levels (typically 70% maximum).
Data represents mean ± one S.D. of n = 3.
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of the initial wave of aggregation due to the absence of endogenous agonists such as ADP being
secreted by the weakly activated platelets (Figure 3.3). In the presence of 1 pM ADP there was no
evidence of aggregation although shape change, which is arguably the most sensitive response of
platelets, persisted (Figure 3.3).
3.2.2 Platelets aged in the presence or absence ofserum lose aggregatory responses
In contrast, we were able to confirm that platelets aged over a 24 h period in plasma lost the
ability to aggregate (t|/2= 12 ± 2h), but not to undergo a shape change in response to ADP (Figure 3.3).
The loss of response by aged platelets was also observed with the endoperoxide analogue and
powerful platelet agonist U46619 (Main and Pearce 1978), although aggregation was still detected
following 24 h of culture (tI/2=24 ± 3h)(Figure 3.4). In keeping with the hypothesis that plasma might
contain exogenous survival factors that normally retard constitutive platelet death, we found that the
loss in aggregatory response to ADP was markedly accelerated when platelets were washed and
cultured in the absence of plasma (t|/2 = 55 mins ± 15 mins)(Figure 3.5). Similarly, the loss of
response to U46619 was accelerated under these conditions (t|/2 = 4 ± 0.7 h)(Figure 3.4). This rapid
loss in ADP-induced aggregation by washed platelets was prevented and returned to rates comparable
to those of unwashed platelets maintained in plasma by reconstituting the washed platelets with
platelet-poor plasma (PPP) (f/2 =12 ± 2h) (Figure 3.4). This indicated that the loss in platelet response
was not dependent on the washing procedure per se but rather on the absence of factors within plasma
that normally suppress the observed loss of responsiveness.
3.2.3 Known survival factors for other cell systems fail to reverse loss offunction
To extend these findings we assessed whether known survival factors from other cell
systems, such as PDGF (Harrington et al 1994), and IGF-1 (Rodriguez-Tarduchy et al 1992), or the
megakaryocyte differentiation factor thrombopoietin (Lok et al 1994; deSauvage et al 1994), could
attenuate the loss of the ADP aggregatory response that occurred after 2 h with washed platelets.
Freshly washed platelets were cultured in the presence or absence of these factors at concentrations
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Time / hours
Figure 3.5: Time course for loss of agonist induced aggregation. PRP or washed platelets were
incubated at 37°C and assayed for the level of aggregation at the times indicated. Platelets were
stimulated with ADP (10 pM). Data is reported as % aggregation relative to control levels (typically
70% maximum). Data represents mean ± one S.D. of n = 3.
Figure 3.6: A panel of growth and survival cytokines fail to prevent the loss of aggregatory
response. Freshly isolated platelets were maintained for 2 h at 37°C in either citrated plasma (i) or,
after being washed free of plasma, in HBSS (ii) containing either thrombopoietin (5 ng/ml)(iv), PDGF
(10 ng/ml)(v), IGF-1 (100 ng/ml)(vi) or BSA (4 mg/ml)(vii). Alternatively, washed platelets were
returned to PPP (iii). ADP was added to 10 pM and change in light transmittance recorded for 10
min. Error bars represent the 95% confidence interval for n = 5 separate experiments.
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typically seen to modulate death in other systems, and platelets assessed for their aggregatory
capabilities after 2 h of culture. Figure 3.6 clearly shows no affect on the loss of the ADP response
with these factors, and as stated previously returning washed platelets to their native PPP abrogated
loss of function. As a control for oncotic effects we tested BSA at 4 mg ml"1 and found no protective
effect. Initial investigations to characterize the putative soluble plasma survival factor(s) by dialysis
have revealed the activity to be of 50 kDa or greater in molecular size and stable to long term storage
at 4°C and -20°C.
3.2.4 Agedplateletsfail to spread on collagen coated glass slides
Constitutive loss of platelet function on incubation at 37°C was further confirmed by
assessing the ability of aged platelets to adhere and spread on collagen coated surfaces. In the context
of haemostasis of the vasculature, platelets encountering collagen represents a powerful activation
stimulus, usually indicative of exposure of the underlying basement membranes through damage to
endothelial cells (Brass et al 1974). Direct contact of platelets to collagen surfaces results in the
formation of lammelipodia and filopodia mediating a firm adhesion and providing a surface on which
to recruit further platelets. Using the filamentous actin binding toxin phalloidin-FITC, microscopic
examination of stained preparations revealed that freshly isolated platelets readily adhered and spread
on both collagen I & IV coated glass slides, whereas aged platelets, whether cultured in the presence
or absence of plasma protein, did not (Figure 3.7).
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Fresh Aged
Figure 3.7: Aged platelets fail to adhere and spread on collagen. Fresh or aged platelets were
incubated on collagen coated glass slides at 37°C to assess their ability to spread. Slides were fixed
and stained with actin binding phalloidan-TRITC (orange), and the platelet specific CD61-FITC
(green). The majority of fresh platelets can be seen to adhere and spread (arrow), whilst aged platelets
rarely bind or spread. Scale bar represents 5 pm.
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3.3 Aged platelets maintain plasma membrane integrity
Although down-regulation of cell function is a feature of cell death in other blood cells
(Whyte et al 1993; Dransfield et al 1994; Dransfield et al 1995) it might also have reflected necrosis.
Assessing necrosis is not straightforward in platelets as their small size precluded the use of vital dyes
such as Trypan Blue, since admission of dye could not be confidently assessed by light microscopy.
Similarly, the absence of a nucleus precluded the use of DNA staining vital dyes such as Hoechst
33342 and propidium iodide. Nevertheless, flow cytometry revealed that the forward and side scatter
properties of fresh and aged platelets, whether cultured in HBSS or native plasma, were
superimposable. This contrasted with the deliberate impairment of plasma membrane integrity by
hypotonic lysis, thermal treatment, or mild acid treatment, which invariably resulted in appearance of
debris and loss of platelets as assessed by forward and side scatter.
3.3.1 The filamentous actin binding phalloidin-FlTC can be used as a vital dye
Evidence against necrosis being a confounding factor in the constitutive loss of platelet
function was the use of phalloidin-FITC as an actin binding "vital dye". Using this reagent greater
than 99% of both fresh and aged platelets excluded the dye when assessed by flow cytometry (Figure
3.8). As a positive control to reveal the potential saturation level of intracellular staining, aged
platelets were permeabilised with the formaldehyde/saponin based fixative PermeaFix prior to
staining with phalloidin-FITC. Following permeabilisation greater than 90% of aged platelets
displayed a clear log order shift in fluorescence levels. Use of Epi-fluorescence microscopy
confirmed that phalloidin-FITC appeared to stain the intracellular space of permeabilised platelets,
supporting the use of this reagent as a novel vital dye. These data were a strong indication that aged
platelets were capable of maintaining plasma integrity under the aging conditions employed in this
study.
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Figure 3.8 Aged platelets maintain plasma membrane integrity. (A) Flow cytometric analysis of
platelet membrane integrity using actin-binding phalloidin-FITC as a vital dye. Platelets aged in the
presence (aged PRP) or absence of plasma (aged washed) were incubated with phalloidin-FITC before
flow analysis. The FL1 channel was set to the autofluorescence of unlabelled freshly isolated washed
platelets. As a positive control for phalloidin-FITC staining, aged platelets cultured in the absence of
serum were permeabilised with Permeafix. (B) Freshly isolated platelets were resuspended in FIBSS
and cultured in the absence of plasma for either 1 h or 18 h before separating cells from conditioned
supernatants and resuspending the cells in an equivalent volume of fresh HBSS and sonicating.
Clarified supernatants of fresh (i) and aged (ii) washed platelets, or lysates of fresh (iv) or aged (iii)
were monitored for LDH activity. Lysates from fresh platelets were also incubated for 18 h in HBSS
either on their own (v) or in the presence of erythrocytes (vi). The level of LDH in PPP is shown for
comparison (vii). Error bars represent the 95% confidence interval of n = 4 separate experiments each
done in duplicate.
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3.3.2 LDH activity within culture supernatants confirms maintenance ofmembrane integrity
As extended confirmation of platelet integrity we assessed the level of lactate dehydrogenase
(LDH) activity, an abundant cytoplasmic enzyme of platelets, within supernatants of cultured platelets
(Figure 3.8). Reassuringly, less than 4% of total LDH activity was found in the supernatant of
platelets aged for 18 h in HBSS in the absence of serum. However, the possibility that these low
levels within supernatants were the result of enzymatic instability during prolonged culture, or cell
surface endopeptidase mediated degradation of LDH was investigated. Therefore, soluble LDH
within fresh platelet lysates was maintained under comparable conditions either on its own or with
erythrocytes. These experiments revealed that soluble LDH was stable in culture over a 24 h period in
both instances (Figure 3.8). The 75% loss in LDH activity in the cytoplasm of intact aged platelets
appeared likely to reflect intracellular catabolism of retained LDH, or its inactivation by, for example,
transglutaminases as opposed to leakage. Unfortunately, and given the high levels of LDH in plasma,
we were unable to reliably assess the release of LDH from platelets aged in plasma. Taken together
with the phalloidin data, these results provide strong evidence against the possibility that aged
platelets may have undergone necrosis, but rather may have undergone a form of programmed cell
death.
3.4 Transmission electron microscopy of aged platelets is suggestive of a cell death
program
To further eliminate the possibility of necrosis or an activation phenomenon, we prepared
samples for ultrastructural analysis by transmission electron microscopy (TEM). For cells in
suspension there are two main preparation methods, pre- and post- fixation cell pelleting. The former
will bind pelleted cells together by fixation of the plasma membranes within the pellet, whilst the
latter requires formation of a fibrin clot around the pellet after fixation. Given the potential for
artefactual platelet activation on manipulation we deemed it better to fix platelets in suspension,
before pelleting and encapsulation within a fibrin plug. In addition this method essentially provides a
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protein rich support-matrix allowing the pellet to be treated as resected tissue, producing excellent
results.
3.4.1 Washing does not induce obvious evidence ofplatelet activation
Washed or untreated freshly isolated platelets exhibited characteristic discoid-like features of
non-activated platelets (Figure 3.9). This was confirmed and easily contrasted to the presence of
elongated filopodia, enlarged canalicular system and coalescence of granules, surrounded by a
circumferential band of a constricting microtubular network, seen within deliberately activated
platelets. A cross-section through both platelets revealed the typical distribution of dense bodies, a-
granules, mitochondria, and glycogen particles, as indicated.
3.4.2 Aged platelets exhibit cytoplasmic condensation
Platelets aged in culture under conditions leading to loss of function exhibited dramatic
morphological changes. Control platelets maintained in citrated plasma for 24 h exhibited few
changes from the freshly isolated state, except that the majority of cells assumed a more spherical
rather than a discoid shape (Figure 3.10). However, when aged for 12 h in HBSS in the absence of
serum, when loss of function was complete, there was remarkable condensation of cytoplasm and
granules with sub-membrane vacuolisation, with these features more pronounced at 24 h of culture
(Figure 3.10). Interestingly, cultured platelets did not exhibit plasma membrane blebbing, a common
feature of many cell types undergoing apoptosis, but not of granulocytes (Savill et al 1989).
Furthermore, and in keeping with granule fusion with the plasma membrane as aged neutrophils
progress to an intact late apoptotic state prior to secondary necrosis (Gilligan et al 1996), platelets
aged for 24 h contained evidence for fusion of granules with the plasma membrane (Figure 3.10;
arrows).
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Figure 3.9: Washing of platelets does not induce activation. Transmission electron micrographs
(TEMs) of (A) freshly isolated washed platelets displaying a smooth unactivated morphology, with an
even distribution of alpha and dense granules. (B) Freshly isolated ADP activated platelets bearing
filopodia extensions (arrows) and evidence of granule coalescence (open arrow) indicative of
activation. Scale is as indicated by white bars.
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Figure 3.10: Aged platelets exhibit cytoplasmic condensation. Transmission electron micrographs
of platelet preparations. Washed platelets fixed immediately following isolation (A); aged platelets
maintained in citrated plasma for 24 h (B); and washed platelets maintained in HBSS for 12 h (C) and
24 h (D). Note evidence of granule fusion with the plasma membrane (arrows). The white bar scale
represents 500nm.
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3.5 Aged platelets exhibit cell surface changes of apoptosis
In view of the morphological changes suggestive of an apoptosis-like program of platelet
death, bearing similarities to those observed in granulocytes, we went on to seek comparable plasma
membrane changes. Although Ca2+ dependent exposure of phosphatidylserine (PS) in the outer
membrane of platelets was originally demonstrated to be a marker of platelet activation with
procoagulant properties (Bevers et al 1983), PS exposure is also recognised as a reliable marker of
cells undergoing caspase-dependent cell death (Vanags et al 1996; Martin et al 1995; Koopman et al
1994). In granulocytes, PS exposure and caspase activation are tightly linked to nuclear changes
typical of apoptosis (Fadeel et al 1998; Zhuang et al 1998; Knepper-Nicolai et al 1998). In addition,
we sought to confirm the morphological evidence of granule fusion with the plasma membrane during
platelet death.
3.5.1 Aging platelets progressively expose phosphatidylserine at their cell surface
By flow cytometry we determined the level of PS exposure using FITC-conjugated annexin-
V, a high affinity probe for PS (Koopman et al 1994). Flow cytometric analysis of control platelets
aged for 24 h in citrated plasma and labelled with annexin-V-FITC revealed a bimodal distribution
with typically no more than 9 ± 1% found positive (Figure 3.11). Although a background level of 0.2-
0.5% of fresh platelets bound annexin-V, any increases were not apparent until at least 8 h of culture
where annexin-V binding increased steadily to around 9% by 24h, with minimal increases seen
thereafter (Figure 3.12). In contrast, washed platelets aged in the absence of plasma, which again
contained few annexin-V binding cells in the first 6 h of culture, rapidly switched after 8 h to be >80%
positive by 15 ± 2 h (Figure 3.11 & 3.12). To address the confounding possibility that PS-exposure
was simply a result of the cell having insufficient energy to maintain the "flippase" activity
responsible for keeping membrane asymmetry, washed platelets were aged in the presence of varying
concentrations of glucose (1 mg ml"1 to 10 mg ml"1). Following assessment of the level of PS-
exposure by annexin-V binding and flow cytometry, no significant differences were seen (Figure
3.13). In concordance with this we are not aware of any significant variation between the typical
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Figure 3.11: Aged platelets express phosphatidylserine at their surface. Fresh washed platelets,
or washed platelets aged in HBSS in the absence of serum protein (aged washed), and platelets aged in
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Figure 3.12: Platelets slowly and progressively expose PS and CD62P at their cell surface.
Platelets were monitored by flow cytometry every hour for cell surface changes, as previously
described. Open points represent washed platelets, whilst closed points represent platelets aged in



















Figure 3.13: Glucose concentration has no effect on the level of PS-exposure. Fresh washed
platelets were aged in the presence of varying levels of d-glucose, and the percentage of cells
exposing PS quantified by flow cytometry as described previously. The data represents mean ± one








Figure 3.14: Aged platelets express P-selectin at their surface. Fresh washed platelets, or platelets
aged in HBSS in the absence of serum protein (aged washed), and platelets aged in citrated plasma
(aged PRP), 24 h, were assessed by flow cytometry for granule cell fusion with the plasma membrane
by monitoring for cell surface P-selectin expression using a FITC-conjugated anti-P-selectin mAb.
The FL1-H channel was set to the autofluorescence of unlabelled platelets and confirmed that non¬
specific binding of control antibodies was minimal.
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glucose concentrations in HBSS of 1 mg ml"1 to normal clinical biochemistry values for plasma
glucose of 0.7-1.2 mg ml"1 (Kumar and Clark 1998).
3.5.2 Agingplatelets progressively expose CD62P at their cell surface
To confirm the possibility of granule fusion with the cell membrane we probed for the
intracellular alpha granule marker P-selectin (Israels et al 1992)(Figure 3.14). Reassuringly we found
that platelets maintained in citrated plasma did not express any cell surface P-selectin in the first 8 h of
culture (Figure 3.12), again evidence against platelet activation due to the washing procedure. Indeed,
after aging for 24 h in the presence of plasma we found that only a small proportion (~ 10%) of
platelets expressed P-selectin. However, washed platelets cultured in HBSS in the absence of serum
rapidly mobilised intracellular stores of P-selectin following 6 h of in vitro culture, so that all cells
were positive by 7-10 h (Figure 3.12). Given the slow progression of both the PS and CD62P
exposure, and the time period between platelet preparation and onset of the changes, especially in
light of the TEM, we are confident that this profile does not match the acute response typical of
activated platelets.
3.5.3 Platelets aged in the presence ofcalcium expose PS, but undergo microvesiculation
Initial experiments to age platelets had been within their native citrated PRP, and therefore
contained very little calcium (~40pM) (Bell et al 1990). Due to the clotting factors present, re-
addition of calcium to physiological levels results in initiation of the coagulation cascade with clot
formation and retraction, a technique routinely used to produce autologous serum (Haslett et al 1985).
Hence, parallel experiments on aging washed platelets had been conducted in HBSS without calcium.
To investigate effects of calcium, platelets were aged following washing and resuspension in either
HBSS w/ Ca2+, HBSS w/o Ca2+, platelet poor plasma derived serum (PPPDS), re-citrated PPPDS, or
left untouched to age in PRP. A comparable percentage of platelets exposed PS within HBSS w/ or
HBSS w/o or PPPDS, with few platelets in PRP becoming PS positive (Figure 3.15). However, flow
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Figure 3.15: Aging platelets with calcium either in the presence or absence of clotting proteins
results in microvesiculation and PS-exposure. Fresh platelets were left untreated, or washed and
resuspended into HBSS with Ca2+, HBSS without Ca2+, PPPDS, or re-citrated PPPDS and incubated at
37°C for 16 h. The level of PS exposure and microvesiculation was assayed by flow cytometry. Data
represent mean ± one S.D. of n = 3.
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HBSS w/ or PPPDS, had undergone microvesiculation, with evidence of platelet loss when compared
to conditions without calcium present (Figure 3.15). Comparison between both HBSS conditions
indicated a small but significant (p<0.05) increase in the level of PS exposure from 50 ± 5 % to 63 ± 8
% in the presence of calcium. Given the microvesiculation that occurred with calcium present, a
marker indicative of platelet activation, this increase in PS exposure may reflect an activation-induced
phenomenon. Likewise, platelets aged in PPPDS, and therefore with calcium present but with most
clotting factors removed, showed similar level of PS exposure and microvesiculation (Figure 3.15).
Intriguingly, platelets that had been aged in cit.PPPDS (PPPDS that has been re-citrated, and therefore
is without calcium and clotting factors) had not microvesiculated, but did show a significant increase
(p<0.001) in PS exposure when compared to PRP, 30 ± 5 % and 10 ± 2 % respectively. As the only
major difference between platelets aged in PRP, or washed and aged in cit.PPPDS is the removal of
clotting factors, the data indicates that a putative plasma derived survival factor was being removed
during the coagulation process.
The inability of aged platelets to maintain an asymmetric distribution of PS under Ca2+ free
conditions was strong evidence of an apoptotic-like constitutive cell death program and not an
activation induced phenomenon for two reasons: firstly, activated platelets are well characterised to
express a PS translocase that re-establishes an asymmetric distribution, unless platelets have
undergone secondary events of aggregation (Bevers et al 1989; Bondanza et al 2000); secondly, PS
exposure on platelets aged in PRP or aged in HBSS w/ o following washing occurs in a calcium free
medium, whilst activation-induced PS exposure is well characterised to be a highly calcium dependent
event (Comfurius et al 1990). Accordingly this suggests that the molecular basis of PS exposure by
activated cells differs from that underlying PS exposure by dying cells.
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3.6 Aged platelets are selectively cleared by professional and semi-professional
phagocytes
In vivo, the most important feature of a cell death program is that intact effete cells are
recognised and rapidly ingested by professional and semi-professional phagocytes (Savill et al 1989;
Savill and Fadok 2000). In keeping with this, we found that fluorescent-labelled platelets cultured for
18 h in the absence of plasma appeared to readily associate with human M(j), as evidenced by epi-
fluorescence microscopy. However due to the small size of platelets, whether this represented binding
or internalisation could not reliably be determined.
3.6.1 Confocal microscopy and TEM confirms phagocyte ingestion ofagedplatelets
Aged platelets were incubated with 6-day old human M(j> (30 min) to allow phagocytosis, and
cell samples prepared for TEM. As can be seen in the representative electronmicrograph, the M<j>
displays clear evidence of having ingested two aged platelets, both within the cell membrane (Figure
3.16). In addition Bowes melanoma cells were also able to phagocytose aged platelets, again
evidenced by TEM (Figure 3.16). Secondary conformation of ingestion, and not surface binding, was
obtained with the use of confocal microscopy. Progressive Z-axis scans confirmed that fluorescent-
labelled aged platelets were dispersed throughout the cell within phagolysosomal vacuoles, strongly
arguing against the possibility of platelets being lodged between the many surface protrusions and
invaginations present on the macrophage surface (Figure 3.17).
3.6.2 A novelflow cytometric based method allows quantification ofplatelet phagocytosis
In order to quantify platelet ingestion by a range of phagocytes we developed a novel flow
cytometric method that was dependent on incubating the phagocytes with platelets that had been pre-
labelled with an orange fluorescing dye (CM-Orange) (Figure 3.18). Phagocytes were then analysed
by flow cytometry where they were readily resolved from platelets by forward and side scatter, and
therefore any shift in orange fluorescence of the phagocyte population could be attributed to
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Figure 3.16: Phagocytes readily ingest aged platelets. Representative TEMs showing cytoplasmic
regions just beneath the plasma membrane of a human monocyte derived macrophage (A) and a
Bowes melanoma cell (B), both containing distinct evidence of having ingested aged platelets (solid




Figure 3.17: Aged platelets are ingested by phagocytes. Scanning confocal microscopic images of
human MOs having ingested fluorescent labelled aged platelets. (A) Progressive Z-axis scans
through the cell revealed platelets to be dispersed throughout the inside of the M<l>s and to not be
surface bound, thus supporting internalisation. (B) Reconstruction of the focal planes reveal many
aged platelets (>20) to have been ingested by each macrophage. The white scale bar represents 10pm.
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interacting platelets (Figure 3.18). To discriminate between adherence and ingestion we labelled the
phagocytes prior to flow cytometry with an anti-CD61-FITC mAb. Also known as glycoprotein Ilia
(GpIIIa), CD61 is a platelet specific cell surface marker, whose expression was not found to alter as
platelets were aged in culture, in comparison to freshly isolated platelets (Figure 3.18). Results could
also be reproduced with other platelet specific markers such as CD42a or CD41. Reassuringly, we
observed that anti-CD61 mAb routinely failed to label our phagocyte populations suggesting that
platelets were ingested, in keeping with TEM, and that any adherent platelets were removed prior to
flow cytometry during trypsin/EDTA treatment to lift the adherent macrophages. Assessment of
cytospin preparations by confocal microscopy in parallel to cytometry confirmed that the two methods
closely correlated, proving the efficacy of the system. In contrast, and as a control comparison, we
confirmed that freshly isolated labelled platelets adhered to the surface of freshly isolated monocytes
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Figure 3.18: Ingestion of aged platelets is readily quantified with a flow cytometric method. (A)
Human platelets, pre-labelled with CM-Orange (i) and aged in HBSS in the absence of plasma, were
confirmed to express the platelet specific marker CD61 with an FITC-conjugated mAb (ii), whose
expression remained unaltered relative to freshly isolated CM-Orange unlabelled platelets (iii). (B)
CM-Orange labelled platelets (i) incubated with human macrophages (ii) or with Bowes melanoma
cells (iii) for times indicated elsewhere, were readily resolved from the phagocytes according to their
forward and side scatter properties. (C) CM-Orange-labelled platelets that associated with the
phagocyte population are seen as a distinct subpopulation that is shifted in orange fluorescence. These
platelets were predominantly ingested given that they failed to dual label with the CD61 mAb.
Similar results were found with mAbs to other platelet markers such as CD41 or CD42a. (D) In
contrast, freshly isolated monocytes readily bind, but do not ingest, freshly isolated CM-Orange
labelled platelets, evidenced by a shift in both channels.
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3.6.3 Aged platelets are phagocytosed by a range ofcell lines tested
Although fresh and activated platelets on microscopic examination were observed to adhere
to all phagocytic cell lines tested, only aged platelets were found to be ingested following flow
cytometric analysis (Table 3.1). We also observed that the degree of phagocytosis was always greater
for platelets aged in the absence of plasma survival factors than those aged in citrated plasma.
Typically, after a 30 min interaction, greater than 85 ± 11% of human M(|> and around 65 ± 7% of
Bowes melanoma cells ingested platelets aged in the absence of plasma (Table 3.1), compared to only
30 ± 12% and 20 ± 6% respectively when aged in the presence of citrated plasma. Moreover, time-
course experiments repeatedly showed that in a fixed-time phagocytosis assay the maximal level of
ingestion by human M<j> and Bowes melanoma cells was achieved with platelets aged for 12 h in the
absence of plasma or 24 h for those cultured in citrated plasma.
Phagocyte
MDMs BOWES TEPM HUVEC
Fresh platelets 3 ± 2 2 ± 1 1 ± 1 2 ± 1
Aged washed platelets 85 ± 11 65 ±7 40 ±8 47 ±5
Activated platelets 3 ± 1 2 ± 1 3 ± 2 1 ±2
Table 3.1: Aged platelets are phagocytosed. Fresh, aged washed, and activated platelets
were incubated with a panel of phagocytic cells; human MDMs, human Bowes melanoma cells
(BOWES), murine thioglycollate-elicited peritoneal macrophages (TEPM), and human umbilical vein
endothelial cells (HUVEC). Phagocytosis was assayed by flow cytometry as described previously.
Data represent mean ± S.D. from a minimum of at least four experiments
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3.6.4 Ingestion ofagedplatelets by phagocytes occurs specifically via scavenger receptors
The degree to which cell lines ingested aged platelets, whether cultured in the presence or
absence of plasma, was found to be unaffected by various well-characterised inhibitors of recognition.
(Table 3.2) (Hart et al 1997). These included the integrin inhibitor RGDS, the PS receptor-competitor
phospho-L-serine, the cationic sugars glucosamine and galactosamine, the anti-CD36 mAb SM(|>, and
the anti-CD 14 mAb 61D3 (Table 3.2). However, greater than 82 ± 10% inhibition was observed with
fucoidan, a recognised inhibitor of the scavenger receptor pathway, in contrast to the lack of inhibition
by dextran at the same concentration, which served as control. Polyinositol, another inhibitor of the
scavenger receptor pathway, but not its standard control polycytidine, also inhibited recognition by 38
± 4%, although not as effectively as fucoidan (Table 3.2). Nevertheless, further confirmation of a
major role for the scavenger receptor was obtained with the anti-murine scavenger receptor mAb 2F8,
which inhibited mouse peritoneal macrophage uptake of aged platelets by 76 ± 13%.
Since our studies had also shown that aged platelets expressed P-selectin (Figure 3.14),
which is known to mediate adhesion of activated platelets to monocytes (de Bruijine-Admiral et al
1992), and given that fucoidan is known to bind the lectin domain of P-selectin, we explored the role
of P-selectin in platelet recognition. By using a function-blocking mAb to P-selectin, clone Gl/Gl-4,
which recognises the lectin domain, we found that the recognition of aged platelets by human M<j> and
Bowes melanoma cells was only weakly affected (14 ± 3 %), and no synergy with polyinositol was
observed (12 ± 4%) (Table 3.2). This suggests that although P-selectin had a minor role in the
phagocytosis of aged platelets, potentially mediating an initial tethering, it was not primarily
responsible for mediating phagocytic recognition and clearance, a conclusion in agreement with others





























































































































































































































































3.6.5 A chymotrypsin sensitive protein on the aged platelet is requiredfor phagocytosis
Previous work on the in vivo clearance of platelets has proposed few potential molecules and
mechanisms involved, with reoccurring data spanning over three decades. These include the loss of
sialic acid residues (Greenberg et al 1975; 1979), and the involvement of the Fc receptor FcRIIA
(McKenzie et al 1999), all leading to a 'recognition competent' platelet and its clearance. However,
the majority of studies, with the exception of the Fc data, promote the idea that platelets are passive in
the process and do not direct these changes, and that they occur to them through 'attrition' over their
lifespan. As a brief investigation into the potential platelet molecule mediating clearance in our
system, aged washed platelets were treated with a panel of proteases, and a sialidase at low
concentrations (10 pg ml"1), before washing, incubation with MDMs, and assessment of phagocytosis
by flow cytometry. These included the serine proteases chymotrypsin and elastase, protease nine and
fourteen, and the thiol protease papain. In addition the sialidase neuraminidase, which is able to
specifically cleave sialic acid residues from glycoprotein conjugates, was also tested. Under the
enzyme concentrations stated in materials and methods chymotrypsin and papain significantly
inhibited phagocytosis by 65 ± 8 % and 23 ± 5 % respectively (Figure 3.19). In addition, data against
general background surface protein cleavage, due to high protease concentrations, was evidenced by
doubling the enzyme amount. At this higher concentration only chymotrypsin gave a significant
increase in the level of inhibition of phagocytosis, 81 ± 4 % (p < 0.05), suggesting that at both of these
relatively low protease concentrations the target protein removed must contain an exposed highly
chymotrypsin sensitive residue. Chymotrypsin has been shown to require aromatic or non-bulky polar
side chains on the amino side of the scissile bond (Stryer 1998). Although the data is insufficient to
identify a specific molecule it does suggest that a platelet surface protein, which may bear modified
sugars such as sialic acid, is required for clearance.
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Control Elastase Protease 9 Protease 14 Chymotrypsin Papain Neuraminidase
Figure 3.19: Pre-treatment of aged washed platelets with the serine protease chymotrypsin
inhibits phagocytosis. Aged platelets were pre-treated with a panel of proteases and a sialidase,
washed, and then incubated with human MDMs. Phagocytosis was quantified by flow cytometry as
previously described. The grey bars represent a doubling of the enzyme concentration used in the
experiments represented by the black bars. A significant reduction in the level of phagocytosis
compared to control occurred on platelet treatment with chymotrypsin (p < 0.001,**), and to a lesser
extent with papain (p < 0.02, ***). Interestingly, only chymotrypsin treatment inhibited phagocytosis
to a greater extent on increasing concentration (p < 0.05, *). Data represent ± one S.D. of n = 3
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Discussion
Platelets play a crucial role in haemostasis and thrombosis, with the consequence that they
are of central importance in common disorders such as myocardial infarction and stroke. However,
little has been known of any candidate mechanisms for safe clearance of these anucleated blood cells
every day. Prompted by earlier work on constitutive apoptosis in other key blood cells, granulocytes,
we sought evidence for any constitutive death program within platelets. Key findings of this study
include the discovery that platelets expressed members of the Bcl-2 family of cell death-regulating
proteins, in keeping with earlier work (Vanags et al 1997), and that there was an apparent pro-
apoptotic shift observed in platelets aged for 18 h in citrated plasma. We also observed that aged
platelets lost the ability to aggregate in response to agonists such as ADP, and failed to adhere and
spread on the key subendothelial matrix component collagen. Given that serum is a rich source of
survival factors for granulocytes, we reasoned that the physiological milieu of platelets, plasma, was
likely to also contain factors capable of retarding their cell death. We therefore sought evidence of
accelerated cell death when platelets were cultured in the absence of plasma, finding that they not only
exhibited an accelerated loss of function but also displayed many features in common with
programmed death of granulocytes. Such changes included morphological evidence of cytoplasmic
condensation and cell surface expression of the "eat me" signal phosphatidylserine (Fadok et al 1992),
and granule components such as P-selectin. Importantly, however, there was strong evidence that
such aged platelets retained plasma membrane integrity since there was no detectable release of the
cytoplasmic marker enzyme lactate dehydrogenase, and nor did the aged cells admit actin-binding
phalloidin-FITC, used as a novel "vital" dye. Furthermore, aged platelets were recognised and
ingested by all professional and semi-professional phagocytes tested, and by a mechanism in which
scavenger receptors predominated.
The abrogation of platelet function witnessed on aging represents a strong parallel to
granulocyte apoptosis. Both cell types can mediate responses potentially deleterious to a metazoan,
with granulocytes (and platelets to a lesser extent) able to secrete a plethora of pro-inflammatory
mediators, and platelets able to form thrombi. Thus, down regulation of these functions at the onset of
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cell death acts to safeguard against any uncontrolled and adverse consequences (Whyte et al 1993).
What actually mediates loss of the platelets ability to aggregate has not been elucidated. However,
although the level of CD41 or CD61 does not alter on platelet aging, the possibility exists that the
complex dissociates, or inside-out integrin signalling is blocked, hence resulting in effective loss of
the fibrinogen receptor and an inability of platelets to aggregate. This dissociation would be an
elegant way of effectively "switching off' any potential for unwanted thrombi formation, and the
molecular mechanisms responsible for such an event would be an excellent target for future
antithrombotic drug design.
The PS exposure witnessed on aging is unusual in platelets for two reasons. Firstly, PS
exposure is a classical marker of platelet activation that helps to provide a procoagulant surface that
accelerates thrombin generation. This exposure is well characterised to be a highly Ca2+ dependent
process, but in our system platelets are aged in either ~45pm Ca2+ in the PRP, or no Ca2+ when aged in
the HBSS. Both result in PS exposure, with Ca2+ free conditions producing a greater level of PS
exposure. These differences between the levels of PS exposure are not thought to reflect the level of
Ca2+, but rather the presence of the native plasma and hence putative survival factors. In addition, this
change occurs slowly and progressively over an 8 h timecourse, which is at odds with a more typical
acute exposure of PS seen upon platelet activation. Secondly, and in contrast, aging platelets in levels
of physiological Ca2+ (~lmM) results in high levels of PS exposure whether plasma factors are present
or not, and a large amount of microvesiculation occurs that is not present without Ca2+. This form of
PS exposure appears to be quite distinct from that occurring without Ca2+ and is more indicative of an
activation-dependent event. In this respect it is also quite clear from our work, and that borne out by
many others, that activated platelets are not cleared from the circulation or phagocytosed in vitro or in
vivo (Michelson et al 1996; Berger et al 1998), in contrast to the senescent platelets which in our
system are readily phagocytosed.
The exposure of PS by an aged platelet may seem a little counter intuitive given its powerful
procoagulant properties. However, a low level of PS exposure alone is relatively benign given that its
main role is in accelerating the generation of thrombin and hence requires tissue factor, exposed on
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subendothelial matrices after endothelial damage, to effect a response. In this respect an aged platelet
encountering such a site would simply be "pre-primed" to aid in aggregation. Nevertheless, PS
redistribution during cell death is a highly conserved and ubiquitous event, and has been strongly
implicated in phagocytic mechanisms (Fadok et al 1992). Although we have implicated a scavenger
receptor mechanism in the clearance of aged platelets, our lack of effect when using the reagent
phospho-L-serine does not rule out the involvement of PS in phagocytosis. Firstly, phospho-L-serine
is not a particularly good competitive inhibitor of PS. Secondly, given the short size of PS within the
relative "forest" of the plasma membrane glycocalyx of platelets, we believe PS is more likely to
function as an ancillary molecule to an initial scavenger receptor interaction, acting like "Velcro" to
mediate a tight interaction. The evolutionary origin of PS exposure by a dying cell represents an
elegant and simple "external tag of death". As living functional cells posses an active translocase to
maintain PS on the inner side of the membrane, any form of death stimulus or cell death occurrence
could be argued to eventually result in loss of PS asymmetry due to the intrinsic membrane flip-flop
of phospholipids. In this respect "inert" microvesicles containing a PS component have been
demonstrated to be phagocytosed by macrophages (Rimle et al 1984).
It will also be important to define in more detail the molecular mechanisms by which
phagocyte class-A scavenger receptors mediate recognition and ingestion of aged platelets, as clearly
indicated by the inhibitor studies presented. Although the role of the scavenger receptor has already
been implicated in the clearance of apoptotic thymocytes by mouse macrophages (Piatt et al 1996),
the ligands displayed by dying cells that lead to their recognition by scavenger receptors are currently
less well known. Furthermore, the novel finding that cells of endothelial origin can phagocytose
platelets opens a new insight into potential sites of platelet removal. As discussed in the introduction
most work has emphasised the spleen and liver as the primary sites of platelet removal, as implicated
by radioactive tracer studies. However, if endothelial cells lining the vasculature in vivo are capable
of recognising and clearing effete platelets this would not have been detected by the tracer
experiments, as there would have been no "concentrated" site of radiation. The phagocytosis of aged
platelets also has implications for the maintenance of normal levels of circulating platelets -
thrombostasis. Although of limited in vivo relevance, this data suggests the potential that diseases of
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circulating platelet numbers may reflect abnormalities or defects in the cell death program leading to
recognition, or alternatively in the phagocytosis step itself, resulting in either increased or decreased
platelet removal from the circulation. Given the implication of the scavenger receptor in mediating
aged platelet uptake, and its known function as a receptor for acetylated lipoproteins (Traber et al
1993), it may be interesting to examine whether familial hypercholesterolemics, or similar conditions
resulting in raised serum lipoproteins, effectively "self-inhibit" uptake of effete platelets.
Since constitutive death in plasma-deprived platelets cannot be assessed for typical nuclear
changes, since these cells have no nucleus, we feel it is not appropriate to label this form of cell death
as apoptosis, which by semantic definition requires nuclear condensation and oligonucleosomal DNA
cleavage. However, we believe that the data indicates that platelets can undergo a form of cell death
that can be regulated by exogenous influences, in particular plasma-derived survival factors. In
keeping with this, we observed that the return of plasma-deprived platelets to plasma slowed the
phenomena of cell death, most notably returning the rate of loss of aggregation and levels of PS
exposure to that observed for platelets cultured in plasma. Ongoing work is directed at the
biochemical characterisation of the survival activity present in plasma since a range of candidate
cytokine survival factors could not substitute for plasma. Nevertheless it should be emphasised that
plasma deprivation appeared merely to accelerate a constitutive death program that was already active
in platelets at 37°C and evident after 18-24 h of culture in native plasma. However, study of
constitutive death in plasma-replete platelets will be difficult as our preliminary work demonstrated
progressive loss of platelets from populations cultured for >24 h, presumably reflecting relatively
rapid secondary necrosis of that proportion of cultured platelets undergoing cell death each day.
In conclusion, we have provided in vitro evidence that human platelets can undergo a
constitutive program of cell death that resulted in the specific recognition of effete cells by phagocytes
employing the scavenger receptor as a recognition mechanism. While these findings have potentially
important implications for understanding platelet kinetics and the related pathogenesis of thrombotic
and bleeding disorders, no firm conclusions on in vivo relevance can be drawn from the current data.
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Nevertheless, these data raise the exciting prospect that platelet lifespan and clearance is amenable to
exogenous regulation for therapeutic purposes.
Ill
Chapter 4 - Caspase-Independent Platelet Death
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Introduction
Caspases have been the subject of intense investigation since their discovery and the
elucidation of their role as the central effectors of the apoptotic cell death program (Thornberry et al
1992). Existing as latent proforms within the cytoplasm of most cells, their activation occurs in a
hierarchical cascade by cleavage of downstream "effector" caspases by "initiator" caspases, activated
in response to a number of initiating stimuli and factors, often promoting oligomerisation (Thornberry
and Lazebnik 1998). Having an extremely specific substrate cleavage preference, which also occurs
within the proform as the cleavage site for activation, their structure enables them to lie dormant
during normal cellular physiology, but to activate with great speed and to large effect when required.
One such caspase cascade occurs in response to the so-called "intrinsic" death pathway, named to
reflect an internal origin of the decision by the cell to die. Although the initiating biochemical events
are yet to be fully understood, the pathway typically proceeds through an increase in the proapoptotic
mitochondrial interacting Bcl-2 family members, which mediate mitochondrial perturbations resulting
in a loss of the transmembrane potential and an associated release of cytochrome-C (Martinou and
Green 2001; Zamzami and Kroemer 2001). The presence of this normally mitochondria exclusive
protein in the cytoplasm initiates an irreversible chain of events, ultimately resulting in the cells
demise. The initiator caspase-9 forms a cytochrome-C dependent complex with APAF-1, named the
apoptosome, and with dATP as a cofactor results in the self-processing of caspase-9 to its active form
(Liu et al 1996). This in turn activates the effector caspase-3, itself able to activate more caspase-9
resulting in amplification of the cascade, and the caspase-3 mediated cleavage of distinct cellular
substrates. These specific directed cleavages, for example nuclear lamins, inactivation ofDNA repair
enzymes, cytoskeletal proteins, and the direction of cell surface changes, lead to many of the classical
changes witnessed during apoptotic cell death, such as nuclear condensation, cell shrinkage, and the
specific recognition and clearance by phagocytes.
Given that platelets undergo a constitutive death program without any apparent external
stimuli required to initiate it, it could be proposed to be an intrinsic type cell death. Indeed, many of
the changes witnessed bear similarities to intrinsic granulocyte apoptosis, including up regulation of
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proapoptotic Bcl-2 family members, surface PS exposure, granule fusion with the cell membrane, and
clearance. Given the central role of caspases in granulocyte apoptosis, and the mitochondrial /
apoptosome pathway in initiating the activation, we investigated what role caspases might play in
directing the platelet changes reported in the previous chapter.
Using the poly-caspase inhibitor zVAD-fmk we were unable to alter or attenuate the changes
witnessed on platelet death, such as PS exposure, loss of aggregatory response, or the "edibility" of
the platelets to phagocytes. In addition, despite containing amounts of caspase-3 comparable to Jurkat
cells, we could find no evidence of enzyme activation within the aged platelets by Western-blot
analysis or fluorescent substrate cleavage. Interestingly, a more detailed examination of the intrinsic
pathway revealed that upon aging platelets underwent mitochondrial permeability transition and
released mitochondrial cytochrome-C into the cytoplasm, but unlike apoptotic Jurkats that proceeded
to activate caspase-3 as expected, platelets did not. This observation was recapitulated in a cell free
system by adding exogenous cytochrome-C and dATP to Jurkat and platelet lysates, whereby Jurkat
lysates processed caspase-3 to its active form implying formation of an active apoptosome, whilst
platelet lysates did not. Western-blot analysis for the apoptosome components revealed APAF-1 to be
present within platelets, but analysis for caspase-9 did not detect this key enzyme.
Despite a previous report claiming caspase-9 to be present within platelets, an extended
analysis with both polyclonal and monoclonal antibodies failed to detect the enzyme. However,
analysis under less stringent blotting conditions revealed a protein band around the weight of caspase-
9, which by two-dimensional electrophoresis was shown to possess a pi inconsistent with it being
caspase-9. Direct addition of human recombinant caspase-9 into platelet lysates enabled the
cytochrome-C dependent activation of caspase-3 to occur, thus definitively demonstrating the absence
of caspase-9 from platelets to prevent cytochrome-C mediated activation of caspase-3, either in a cell
free system or within platelets during aging. Intriguingly, the progenitors of platelets, the MKs,
contained quantities of caspase-9 comparable to Jurkats, suggesting sequestration, detainment or
consumption of the enzyme during platelet formation.
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4.1 Platelet death is caspase and calpain independent
Activation of caspases and calpains is reported to be upstream of plasma membrane changes
associated with apoptosis, including PS exposure (Martin et al 1996; Zhuang et al 1998; Knepper-
Nicolai et al 1998; Vanags et al 1996; Naito et al 1997), and has been shown to be the most
ubiquitous of all apoptotic machinery. Caspase-3 represents a major effector of cellular death
programs in the majority of cell systems, responsible for mediating the typical morphological changes
witnessed on death (Thornberry and Lazebnik 1998). Activation due to proteolysis by upstream
initiator caspases result in the formation of a 17/12 kDa caspase-3 heterodimer, which further
dimerises to form an active tetramer with a preferred substrate cleavage consensus DEVD. The
stringent requirement of the caspases catalytic specificity is for aspartic acid in the Pi subsite, with
variation within the P4 site shown to be an important determinant of specificity between caspase
family members, which enabled the development of a panel of novel inhibitors (Thornberry et al
1997).
4.1.1 PS-exposure by aged platelets is caspase and calpain independent
Using the caspase-3 inhibitor zDEVD-fmk, the poly-caspase inhibitor zVAD-fmk, and in
addition the calpain inhibitors ALLN and calpeptin, we looked to see if the level of PS exposure by
aged platelets could be modulated. Washed platelets were cultured for 18 h in the presence of the
inhibitors, followed by analysis of PS-exposure by flow cytometry using annexin-V-FITC. None of
the inhibitors produced any significant effect suggesting no apparent role for caspases or calpains in
mediating the aged-induced PS-exposure (Table 4.1). Additionally, and to confirm the role of these
proteases in mediating earlier occurring physiological changes we had identified, we also found that
the inhibitors had no effect on the refractiveness of aged platelets to the early loss of ADP-induced
aggregation (Table 4.2), whether cultured either in the presence or absence of plasma.
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Condition /Inhibitor Concentration PS-positive washed platelets
(after 18 h)
pm %
Aged Washed 71.2 ± 6.3 7
DMSO Control [0.1%] 70.6 ±3.8 7
ZVAD-fmk 100 84.2 ± 8.0 5
zDEVD-fmk 10 76.0 ±3.5 5
ALLN 100 71.8 ±5.9 7
Calpeptin 100 77.3 ± 9.9 5
Table 4.1: Caspase or calpain inhibitors do not modulate PS exposure by washed
platelets. Washed platelets were aged for 18 h and analysed for the level of PS exposure by
flow cytometry. Data represent mean ± one S.D. n = number of separate determinations, as
indicated.
~ .... ,, Maximum level of aggregation (%)Condition / Inhibitor aa a v '
Presence of plasma (24h) Absence of plasma (2h)
Control 51 ± 9 6 ± 1
zVAD-fmk 57 ±13 5 + 2
Calpeptin 48 ±11 2±1
Table 4.2: Caspase and calpain inhibitors do not modulate the loss of aggregatory
response to ADP. Fresh or washed platelets were incubated for times as indicated, and
analysed for the level of aggregation following ADP stimulation. Data represent mean ± one
S.D. n = 4.
4.1.2 Caspases do not direct surface changes leading to recognition and clearance
Since PS-exposure did not appear to play a role as a primary recognition molecule during
phagocytic clearance of senescent platelets, as discussed earlier in chapter 3, we pursued the
possibility that caspases might be responsible for directing other surface changes mediating clearance.
Therefore, washed platelets were aged in the presence of caspase inhibitors, washed, and incubated
with macrophages before analysis of phagocytosis by flow cytometry (Table 4.3). Similarly,
phagocyte recognition of washed platelets aged in the presence of caspase inhibitors was no different
from control washed platelets, confirming the unusual caspase-independent nature of the surface
changes by effete platelets that lead to phagocytic recognition and clearance.
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^ -j-,- /, u-u-i ^ » »■ Recognition of aged washedCondition / Inhibitor Concentration . , .a. a
nm %
Aged Washed / 100 4
DMSO Control [0.1%] 99.2 + 4.7 4
zVAD-fmk 100 117.4 + 17.0 4
zDEVD-fmk 10 99.5 + 7.9 4
Table 4.3: Platelets aged in the presence of caspase inhibitors are phagocytosed at
comparable levels to control platelets. Data represent normalised mean ± one S.D.
4.1.3 Aged platelets do not process caspase-3 to an active form by Western-blot analysis
Western-blot analysis confirmed that caspase-3 was present as the 32kDa parent species in
platelets at protein levels comparable to Jurkats, as evaluated by equal protein loading. However, and
in contrast to apoptotic Jurkats, aged platelets had failed to process caspase-3 to its active fragments
(Figure 4.1), but did reveal the presence of several proteolysed species of decreasing molecular
weight, just less than the p32 proform band. Interestingly, recent reports have documented a similar
caspase-3 degradation pattern, which was shown to be calpain-mediated processing to a non-active
species (Wolf et al 1999; Chua et al 2000; Lankiewicz et al 2000). In support of this, platelets aged in
the presence of the specific calpain inhibitor calpeptin prevented this proteolytic "nibbling". As
discussed earlier neither caspase or calpain inhibitors had any effect on the rate of aging or clearance,
therefore it appears this calpain mediated proteolysis is coincidental, is unlikely to be a deliberate step
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Figure 4.1: Caspase-3 is not activated as platelets age in culture. Cytosolic extracts taken from
fresh platelets (iii), platelets aged in the absence of serum (iv), or platelets aged without serum but
with calpeptin (v) were probed for caspase-3 by Western-blot with a pAb that recognised both the 32
kDa (p32) precursor and the 17 kDa (pi7) subunit of the activated enzyme - note lack of the latter.
As positive controls, cell lysates were prepared from untreated Jurkat T-cells (ii) which exhibited low
levels (10%) of constitutive apoptosis as judged by Giemsa stained cytospins, and those induced to
undergo apoptosis (i) following a 5 h treatment with staurosporine (2pM) (approx. 65% apoptosis).
Positions for the 30, 23, and 16.5 kDa mass markers were determined with the use of Rainbow
Markers.
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4.1.4 Caspase-3 activity is not detected in agedplatelets with a fluorogenic substrate
Modifying the small peptide caspase inhibitors to contain a quenched fluorophore instead of
the inhibitory -fmk domain allows the analysis of caspase activity within cell lysates by fluorimetry.
Caspase cleavage of the peptide on the carboxy side of the aspartic acid releases the fluorophore,
which is then free to fluoresce. Use of the DEVD-amino-fluoromethyl-coumarin (DEVD-AFC)
substrate provides the preferred cleavage consensus for caspase-3. Preparation of the cell lysates for
analysis necessitates a modified lysis buffer devoid of cysteine protease inhibitors, thus allowing
caspase enzymatic activity. Treating Jurkats with cycloheximide (20pg/ml) overnight to induce
apoptosis provided active apoptotic cytosols for positive controls. Typically 40 % Jurkat apoptosis
was witnessed, by Giemsa stained cytospins, from which lysates were prepared and frozen until
needed. As can be seen in Figure 4.2, specific caspase activity directed against DEVD can be detected
in the Jurkat lysates, revealed by the inhibition on addition of the caspase inhibitors DEVD-fmk and
zVAD-fmk, which gave a synergistic reduction of activity. However the combination of both
inhibitors failed to completely inhibit all aspartase activity, suggesting non-specific substrate cleavage
still occurred. Using the non-specific protease mixture Pronase, fluorescence counts are similarly
detected indicating cleavage of the caspase substrate, and thus suggests apparent caspase activity can
be mimicked by non-specific protease mediated cleavage. Fresh platelet lysates contained only non¬
specific activity, evidenced by the lack of any significant inhibition on using the caspase inhibitors
(p=0.56). In fact, taking into account the equal protein loading, the magnitude of this non-specific
activity within fresh platelet lysates equates to the 'remaining' activity within Jurkat lysates on using
both zDEVD-fmk and zVAD-fmk. Importantly though, aged platelet lysates displayed little activity
at all. Given the loss of protein per platelet on aging by general cellular degradation, and hence the
increased numbers of cells required to compensate and produce an equal protein concentration within
a lysate, this activity certainly represents an over estimate. Combined, these results confirm that
caspases do not have a major role in the constitutive cell death of platelets, and hence complement
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Figure 4.2: Fresh or aged platelet lysates do not contain active caspase-3. Fresh and aged
platelets, or apoptotic Jurkats were lysed, incubated with caspase inhibitors as indicated, followed by
incubation at 37°C with fluorescent caspase substrate. Reactions were stopped by placing all tubes on
ice, before analysis of caspase activity in a fluorimeter using quartz cuvettes. Non-specific substrate
cleavage activity was revealed by the lack of effect of caspase inhibitors. As a control for non¬
specific substrate cleavage, the protease mixture pronase was also tested. Data represent mean ± one
S.D. of n = 3.
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4.2 Aging platelets undergo biochemical changes indicative of an intrinsic death
pathway
As platelets spontaneously undergo a constitutive death without any obvious external stimuli
required, it could be argued that cell death was intrinsically controlled. Although the primary
biochemical event initiating intrinsic cell death has yet to be fully elucidated, the downstream events
have been extensively studied in many cell types. Given the absence of caspase-3 activation in aged
platelets and the perceived relatively late ordering of caspase activation within a classical intrinsic
death pathway hierarchy, we looked at events upstream with intent to find a possible block or
divergence between platelet cell death and more classical forms. Intrinsic death normally proceeds
through an increase in pro-apoptotic Bcl-2 family members, subsequently mediating mitochondrial
dysfunction (Martinou and Green 2001). We have already demonstrated upregulation of pro-
apoptotic Bax and Bak within aged platelets in the previous chapter, and hence investigated potential
mitochondrial changes during platelet death.
4.2.1 Aged platelets progressively lose their inner mitochondrial membrane potential on
aging
The opening of the permeability transition pore along with a loss of the inner mitochondrial
membrane potential (AyM) has been proposed by some to precede and cause release of cytochrome-C
(Zamzami et al 1996a; 1996b; Zamzami and Kroemer 2001), and by others to occur as a later event as
a result of cytochrome-C release (Martinou and Green 2001, and references therein). This issue
remains controversial and unresolved, but in either case cytochrome-C release leads to a subsequent
amplification of caspase activation, and as such loss of Av|/M still represents an early step in the
intrinsic death pathway. Using JC-1, an electrochemical gradient-sensitive inner mitochondrial
membrane-specific styryl dye, analysis of the level of mitochondrial transmembrane polarisation is
possible by epi-fluorescent microscopy or FACS (Salvioli et al 1997). The JC-1 dye exists as two
forms. In the presence of a mitochondrial potential it forms J-aggregates emitting principally orange
fluorescence (~590nm). However, upon loss of the A*|/M, through either apoptosis or use of a
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Figure 4.3: Senescent platelets show loss of inner-mitochondria membrane potential. Fresh
PRP, aged PRP, or aged washed platelets were stained with the inner-mitochondrial membrane
potential (A\|/M) sensitive dye JC-1. a, Flow cytometric analysis of fresh platelets display a typical
fluorescent profile of high orange fluorescence, indicative of an intact AyM. b, In contrast, platelets
aged in the presence of plasma show a small (-10%) distinct sub-population with a fluorescent profile
indicative of a collapsed AyM, i.e. loss of orange fluorescence with concomitant increase in green, c,
Aged washed platelets show the entire population to have lost their AvyM. d, As a positive control,
treatment with the protoionophore CCCP chemically collapses the electron gradient, whereby platelets
emit similar fluorescent profiles to the aged cells.
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respiratory chain uncoupler, such as the protonophore mCCCP, the dye disaggregates to monomers
emitting a green fluorescence (~530nm). As can be seen a progressive loss occurs when platelets are
aged either in the presence or absence of plasma, with cells obtaining a fluorescent characteristic
identical to those deliberately uncoupled with mCCCP (Figure 4.3). This characteristic of platelet
senescence appears to be the earliest change detectable within an aging population, preceding the
CD62P and PS-exposure, and occurring before phagocytic clearance, a phenomenon very recently
confirmed by Pereira et al (2002).
4.2.2 Release ofCytochrome-C in aging platelets occurs concordant with a loss ofAi//M
As platelets were able to undergo a mitochondrial permeability transition comparable to
conventional apoptosis, we investigated whether this was associated with a mitochondrial release of
cytochrome-C. The conventional method of detecting release is to compare by Western-blot the
levels of cytochrome-C contained within a mitochondrial pellet and a cytosolic supernatant following
subcellular fractionation. This is usually accomplished by mechanical homogenisation, whereby
selection of pestle size allows a defined clearance between wall and pestle enabling cells to be reliably
"split open" without damage and leakage ofmitochondrial contents. However, given the small size of
platelets this method was unsuitable. By using a gentle hypotonic lysis fresh platelets could be readily
separated into a cytosolic supernatant and a subcellular pellet, from which cytochrome-C could be
immunoprecipitated. These samples showed minimal artefactual release of cytochrome-C from
mitochondria to the cytosolic fraction due to preparation technique. Using this technique aged and
freshly isolated platelets were compared with cycloheximide (20pg ml"1) treated Jurkats, used as an
apoptotic positive control. As can be seen, aged platelets contain mitochondrial-released cytochrome-
C within their cytosol, in contrast to fresh platelets that contained cytochrome-C only within
mitochondrial pellets (Figure 4.4). Equivalent results were seen in Jurkats, although cytochrome-C
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Figure 4.4: Aged platelets release mitochondrial cytochrome-c into the cytoplasm. Fresh (viable)
and aged washed (non-viable) platelets, as indicated, were lysed and cells fractionated by
centrifugation to yield a cytosolic supernatant and a subcellular pellet. Both supernatant and
solubilized pellet were pre-cleared with a control IgG before immunoprecipitating cytochrome-C.
Cytochrome-C was detected by Western-blot analysis, with positive controls provided by treatment of
Jurkats with cycloheximide. As can be seen cytochrome-C is detected within the pellet of viable cells,
in contrast to the supernatant of non-viable cells.
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4.3 Platelets undergo biochemical changes necessary for caspase activation, but do
not activate caspases
As discussed in previous and present chapters, platelets undergo many changes indicative of
cell death. In summary, aged platelets exhibit increased levels of proapoptotic Bak and Bax, undergo
loss of release cytochrome-C, contain caspase-3, undergo plasma membrane changes associated
with cell death, and are selectively cleared by phagocytes. However, the combined data also suggest
that caspases do not play a role in the constitutive cell death of platelets. It has previously been
reported that platelets contain significant levels of caspase-9 that is readily activated by the addition of
exogenous cytochrome-C and dATP to platelet lysates (Wolf et al 1999). It was therefore surprising
in our experiments that caspase-3 was not activated within the aged platelets, especially given release
of mitochondrial cytochrome-C, which represents the key initiator for formation of an active
apoptosome.
4.3.1 Addition ofCytochrome-C and dATP to platelet lysates in a cell free system does not
result in activation ofcaspase-3
In order to investigate the disparity of why caspase-3 was not activated within the aged
platelets, we attempted to activate caspase-9 in fresh platelet lysates by adding exogenous
cytochrome-C and dATP. This should have reconstituted an active cell free apoptosome resulting in
the processing of caspase-3 to its active pi2/17 form (Liu et al 1996). However, pro-caspase-3
remained unprocessed in excess of 3 h, whether looking at untreated control samples or those induced
by cytochrome-C/dATP addition (Figure 4.5). This was in stark contrast to caspase-3 activation in
Jurkat lysates where exposure to cytochrome-C/dATP reveals a clear progressive processing of
caspases-3 pro-form to the pl2/17 active fragments (Figure 4.5). Several reports have shown that
calpain activity is able to cleave and inactivate caspase-9, and hence block caspase-3 processing (Wolf
et al 1999; Lankiewicz et al 2000; Chua et al 2000). However, given the lack of Ca2+, the presence of
ImM EGTA, EDTA, and calpain inhibitors such as leupeptin within the lysis buffer, it appeared
unlikely that the calcium dependent calpains were activated and responsible for the inactivation of
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Figure 4.5: Caspase-3 is not processed to an active form within cytochrome-C/dATP induced
cell free platelet lysates. Jurkat and fresh platelet cytosolic extracts were treated with buffer only
(control), or cytochrome-C (lOpg/ml) and dATP (ImM) and incubated at 37°C. At times indicated
aliquots were removed and prepared for SDS-PAGE, with subsequent western blotting using a
polyclonal anti-caspase-3 antibody. A, Platelet lysates containing equivalent quantities of pro-
caspase-3 as Jurkats fail to process caspase-3 following cytochrome-c/dATP initiation. B, In contrast,
identically prepared Jurkat lysates show progressive processing of the enzyme to the proteolytically
active p 17 and p 12 fragments. The experiment was performed twice
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caspase-9. In addition, the procaspase-3 bands showed no evidence of the 'tell-tale' 28kDa
proteolytic "nibbling" indicative of calpain degradation, shown previously (Figure 4.1) and by others
(Wolf et al 1999; Lankiewicz et al 2000; Chua et al 2000). However the data is still at odds with that
ofWolf et al who showed cytochrome-C / dATP mediated the sequential activation of caspase-9 and
caspase-3 within platelet lysates. Before investigating whether a potentially novel molecular inhibitor
was responsible for blocking the formation of an active apoptosome in aged platelets, and given that
the only other proteins known to be required for cell free caspase-3 processing are caspase-9 and
APAF-1, we took a minimalistic view to see if any of these factors were missing from platelets.
4.4 Platelets contain APAF-1 but not Caspase-9
The previous report that platelets contain both key proteolytic components of apoptosome
APAF-1 and caspase-9 used an in-house polyclonal antibody with Westerns developed by ECL (Wolf
et al 1999). However, given the dubious intensity of the reported bands, absence of molecular
markers, and after consultation with colleagues on the difficulty of blotting for, and low levels of
caspase-9 within many cell types, we investigated the possibility that the data might have been
generated from unchecked non-specific bands.
4.4.1 Freshly isolated platelets contain APAF-1 protein
Using Jurkats as a positive control, fresh blood platelets and megakaryocytes were analysed
by Western-blot using a polyclonal anti-APAF-1 antibody. These blots confirmed that a single band
around the apparent molecular weight of APAF-1 (130kDa) was clearly present within platelets,
although Jurkats and MKs contained multiple bands close to this size that had merged into one on
development, and many other non-specifics of different sizes (Figure 4.6). The blot had been blocked
and washed using a 'standard protocol' of 2 % casein followed by 2 % casein / 0.1 % Tween-20,
which has normally produced very low non-specific background binding. The previous published
data had used 5 % marvel / 0.1 % Tween-20, which did not generally block as well as casein.
However, as with all western blotting each antibody requires individual optimisation of all stages to
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Figure 4.6: Platelets contain APAF-1. Whole cell lysates prepared from fresh platelets (i), Jurkats
(ii), and MEG-01 MK cells (iii) were probed by Western blotting with a polyclonal anti-APAF
antibody. A, Although platelets contained a band around the apparent molecular weight of APAF-1,
130kDa, many non-specifics were obtained within the control samples using 2% 0.1% Tween-20. B,
Developing an identical blot under altered blocking and washing conditions, 5% Marvel 0.1% Tween-
20, resulted in loss of non-specific bands, with only the 130kDa APAF-1 band present in all samples
tested.
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maximise the signal to noise ratio. Reanalysis of identical samples with conditions as before, except
for the replacement of casein with marvel, produced a clean blot with only the pi30 band present in
all lanes (Figure 4.6). Strangely casein is the pure milk derived protein that actually is the blocking
agent in marvel. Nonetheless, all samples contained ample quantities ofAPAF-1, although more was
apparent within Jurkats. However, due to the very high actin content of platelets (>30 % of total
protein) (Fox et al 1984) adjusting samples for loading by total protein content often leads to a
'skewed' lowering of the apparent amount of other proteins when comparing to other cell types.
4.4.2 Freshly isolated platelets do not contain caspase-9 protein
Using Jurkats as a positive control, caspase-9 was reliably observed by Western-blot using a
commercially available polyclonal anti-caspase-9 antibody, and was found to migrate with an
apparent molecular weight around 48kDa. However, we could detect no caspase-9 in fresh platelet
samples, derived from three different donors on separate days, which was again in conflict with Wolf
et al (1999) (Figure 4.7). Interestingly, the platelet sample in lane 4 contained a band just above the
38.5kDa marker, migrating at around 40-4 lkDa. Active caspase-9 is cleaved to an active fragment of
38kDa, but has been demonstrated to run with an apparent molecular weight of around 35kDa on
discontinuous laemlli gels (Srinivasula et al 1998). Taking these sizes and given the clear reduction
in protein from the non-specific band of ~85kDa in the same lane, the band almost certainly
represents a proteolysed fragment, and is highly unlikely to be active caspase-9. Shown for
comparison in the right hand panel are samples from the megakaryocyte cell lines MEG-01 and SET-
2. Intriguingly both cell lines contained quantities of caspase-9 equivalent to Jurkats, thereby possibly
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Figure 4.7: Fresh platelets do not contain caspase-9. Whole cell lysates prepared from Jurkats (i),
fresh platelets (ii - iv), MEG-01 MK (v) and SET-2 MK cells (vi) were probed for caspase-9 by
Western blot with a polyclonal antibody that recognised both pro-form and activated forms. One
major band is detected around the apparent molecular weight of caspase-9, 48kDa, within the Jurkat
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Figure 4.8: Lower stringency blotting reveals non-specific bands at a similar size to caspase-9.
Whole cell lysates were again probed for caspase-9 using the polyclonal antibody, but with altered
blocking and washing conditions. Membranes were blocked in 5 % Marvel and subsequently washed
in 0.05 % Tween-20. Lanes contained Jurkats 1 (i), Jurkats 2 (ii), K-562 (iii), HeLa's (iv) fresh
platelets 1 (v), aged platelets 1 (vi), fresh platelets 2 (vii), and aged platelets 2 (iix). Again only the
cell lines contained the p48 band (a). Interestingly, under these conditions a large diffuse band of ~ 45
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Figure 4.9: Analysis of the relative distance of migration to ascertain protein size. Rf values of
protein standards ran on two 12% gels were measured and plotted. Using this plot, the apparent
molecular weight of a band with a know migration distance, using a polynomial regression line of best
fit, can be calculated. Hence, for the 'a' Jurkat band (Figure 4.8) migrating at an Rf = 21mm:
y = 0.0008(21)2 -0.0552(21)+ 5.4903
y = 0.3528-1.1592 + 5.4903)
y = 0.3528 + 4.3311
y = 4.6839





Jurkat upper 21.5 48300
Jurkat diffuse 23 - 24.5 45900 - 45000
Jurkat lower 26 41200
platelet diffuse 23 - 24.5 45900 - 45000
~78kDa platelet 12.5 88200
Table 4.4: Apparent molecular weights of bands detected by the polyclonal anti-caspase-9
antibody at 'low stringency'. All major bands detected with the polyclonal anti-caspase-9 antibody
under low stringency conditions (Figure 4.8) were assessed for apparent molecular weight from their
Rf values.
y = 0.0008X2 - 0.0552x +5.4903
R2= 0.9848
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4.4.3 Western blotting under different conditions reveals three bands approximating the size
ofcaspase-9
Western blots of the samples from above were probed under the altered blocking and
washing conditions of 5 % marvel, followed by marvel / 0.05% Tween-20. Under these conditions
three protein bands were found to migrate with a molecular weight comparable to that expected for
caspase-9 (a,b,c), as can clearly be seen within the Jurkat positive control (Figure 4.8). However fresh
platelets contained only one of these, the large diffuse central band (b) seen between the two finer
bands (b,c) in the Jurkats. In addition, aged platelets also contained this central band (b).
Speculatively, the diffuseness and intensity of this band seemed in line with the data published by
Wolf et al (1999) for caspase-9 in platelets. To ascertain more accurately the apparent molecular size
for each of these protein bands, relative distance of migration (Rf) was plotted against log of
molecular weight (Figure 4.9). Calculating from two separate blots, it is seen that the large diffuse
central band, appearing in platelets and Jurkats, consistently ran at a size of 45-46kDa, with the thin
upper band at 48.3kDa and the lower thin band around 42kDa (Table 4.4). Given the close proximity
of these three bands insufficient electrophoresis could fail to resolve the individual bands. In addition
overexposure of a blot to photographic film by ECL could potentially "merge" the individual bands,
or conversely a shorter exposure may only reveal the more intense diffuse central band. However,
developing using the 4-chloro-naphol system allows visual monitoring as the blots develop, and hence
allows a better control over the development end-point.
4.4.4 A specific monoclonal antibody confirms the identity and position of the caspase-9
band
In the meantime a more specific monoclonal antibody became commercially available, but
manufacturers recommendations suggested it was only of use in cell lines specifically transfected to
overexpress caspase-9. Nevertheless, given the disparity in the bands witnessed under the two
conditions it was felt necessary to reinforce the data and confirm the upper 48.5kDa band to be the
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Figure 4.10: A specific monoclonal anti-caspase-9 antibody confirms position of the caspase-9
band. Jurkat (i), and fresh platelet lysates (ii-iv) from Figure 4.7, excluding MK cell lines and with
two additional platelet samples (v-vi), were developed with an anti-caspase-9 monoclonal antibody
recognising the pro-form only. Again only Jurkats contained caspase-9, which was found on
calculating RF values to consistently run at 48.5kDa, and therefore in concordance with the 'clean'
polyclonal blot. Platelets did however contain a large non-specific band of ~58kDa, but therefore
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Figure 4.11: The diffuse band seen under low stringency conditions migrates with
characteristics similar to actin. Jurkats (i), fresh platelets (ii), and HeLa's were loaded in duplicate
onto a single acrylamide gel and electrophoresed. Transferred proteins were stained separately for (3-
actin using a mAb, or caspase-9 using the pAb.
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polyclonal blots, along with two other fresh platelet samples, again revealed no caspase-9 bands in
platelet samples (Figure 4.10). In contrast Jurkats contained a band that, on plotting RF values,
consistently ran at 48.6kDa (Table 4.5). The platelet samples did however contain a very broad non¬
specific band with an apparent molecular weight around ~55kDa, although this is clearly too large for
caspase-9. Reassessment of the 'clean' polyclonal blot (Figure 4.7) by calculating RF-values gives
the apparent molecular weight of the single band seen within Jurkat and MK cells to be in line with
that seen using the monoclonal antibody, at an apparent molecular weight of 48.5kDa, and therefore in
concordance of this band being the 'true' caspase-9 band, whilst the diffuse band occurring in platelet
and Jurkats under lower stringency conditions appear to be non-specific.










Table 4.5: Apparent molecular weights of bands detected by the monoclonal anti-
caspase-9 antibody. All major bands detected with the monoclonal anti-caspase-9 antibody
(Figure 4.9) were assessed for apparent molecular weight from their Rf values.
4.4.5 Western blottingfor fi-Actin in parallel with caspase-9
Interestingly the apparent molecular weight of the diffuse band and characteristic intensity
and shape seen under the 'less stringent' conditions equates to that regularly seen by the group when
blotting for p-actin. A single running gel was loaded in duplicate, electrophoresed, and after
transferring to PVDF the membrane was blocked and carefully cut into two. In parallel, each was
stained for either P-actin or caspase-9, and the two membranes were realigned (Figure 4.11). The
large diffuse band occurring in Jurkat and fresh platelet samples on the membrane developed for
caspase-9 ran with an apparent molecular weight, diffuseness, and shape akin to that seen on the
membrane stained directly for P-actin. However, given the greater amount of P-actin detected within
the platelets in comparison to the Jurkats, if the caspase-9 antibody was cross reacting to this, one
would have expected the platelet band in the anti-caspase-9 developed blot to have been more intense.
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Nevertheless, to confirm the band to be a non-specific cross-reactivity to p-actin we attempted to use
immunoprecipitation to selectively clear samples. Unfortunately despite many attempts and
adjustments to specific protease cocktails and more general lysis conditions, the logistics of IP
resulted in loss of all bands. In fact simply slow manipulation of protein samples not kept on ice
resulted in loss of immuno-detectable caspase-9. Assumedly, the epitopes recognised by the antibody
are very sensitive to proteolytic degradation. Taken with the fact that platelets are known to contain
large quantities of elastase, cathepsins, and calpains, and Jurkats to contain high levels of the serine
protease granzyme-B, the proteolysis can only be grossly exaggerated. Speculatively, given the large
amount of p-actin within cells, low amounts of caspase-9, and close apparent molecular weight of the
two, the possibility arises that the published work could represent unchecked non-specific binding to
P-actin.
4.4.6 Two-dimensional electrophoresis confirms non-specificity ofthe platelet band
Two-dimensional electrophoresis (2D-E) is a technique allowing proteins to be separated by
two parameters. Firstly, proteins are prepared to allow separation by isoelectric focussing. Amphoteric
substances, such as proteins or peptides, possess an inherent electrical charge that is either positive or
negative, essentially the sum total of all charges contained within the side chains of its constituent
amino acids. Loading of proteins onto a pH gradient with an applied electric field enables migration of
proteins through the gradient towards either the cathode or the anode until they reach a position within
the pH gradient where their net charge is zero. This pH value is known as the isoelectric point.
Secondly, the separated proteins are equilibrated with SDS to allow the conventional SDS-PAGE
"dimension" to be run, allowing separation by molecular weight. This final gel can then be transferred
to membrane and probed with antibody, essentially allowing 2D-Immunoblotting (2D-IB).
To resolve the disparity between our observations for an absence of caspase-9 with the
previously published data suggesting its presence we employed 2D-IB, developing with the polyclonal
antibody. For Jurkat samples, Westerns were developed under the 'stringent' conditions, as in Figure
4.7, to positively identify caspase-9. Conversely platelet samples were developed under the 'less
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stringent' conditions, as in Figure 4.8, to allow detection of the (non-specific) 45-46kDa band.
Although not specifically published for platelets or available from the SwissProt database, the
isoelectric point of caspase-9 can be calculated empirically to be 5.8. Platelet samples developed by
2D-IB contain three major resolved spots running at around 85, 70, and 45kDa, all of which
correspond to the same sample run in only ID SDS-PAGE on the right hand side (Figure 4.12;
arrows). However, the pi of all three spots was around 7.5, and consequently inconsistent with
caspase-9. In contrast, the Jurkat samples contained one major resolved band with an apparent
molecular weight of 48.5kDa and a pi of around 5.7, both in accordance with it being caspase-9
(Figure 4.12). Although the data does not confirm the identity of the unknown platelet band, it does
support the idea that the band reported by Wolf et al (1999) could have been a non-specific cross-
reaction, highlighting fundamental weaknesses in ID Western blotting, and an absolute need to



































































































































4.5 Direct addition of human recombinant caspase-9 to platelet lysates reconstitutes
an active apoptosome resulting in caspase-3 processing
Having identified caspase-3, cytochrome-C, and APAF-1 in cytosolic fractions of fresh
platelets it remained for us to functionally confirm that the absence of caspase-9 was the sole reason
platelets could not form an apoptosome, and hence activate caspase-3. Human recombinant caspase-9
(0.1 U/mL), cytochrome-C, and dATP were added to the same preparation of fresh platelet lysates as
used in Figure 4.5. This single addition to the lysate resulted in the clear progressive processing of
caspase-3, which must reflect a reconstitution and activation of the apoptosome (Figure 4.13).
Although processing of the caspase-3 proform is not as complete as in the Jurkat cell free lysates
presented previously, this almost certainly reflects the relatively low, and potentially limiting amount
of caspase-9 added. Taken together this set of data definitively identifies caspase-9 as the single
factor missing from platelets, preventing them from activating caspase-3, and hence committing them
to a caspase-independent death program.
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hrCaspase-9 / Cyt-C / dATP
Time (min) 0 15 30 60 120 180
Figure 4.13: Direct addition of human recombinant caspase-9 reconstitutes the apoptosome.
Human recombinant caspase-9 (0.1 U/ml) was added to fresh platelets lysates derived from the
preparation as used in Figure 2, cytochrome-C and dATP added, the sample incubated at 37°C and
aliquots removed at times indicated as previously described. In contrast to before, clear processing of
caspase-3 to its active subunits can now be witnessed within the platelet lysates, indicating a
reconstitution of the apoptosome.
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Discussion
Despite an underlying paradigm against investigating caspase-independent cell death, many
groups have successfully demonstrated cellular systems both in vitro and in vivo that can undergo a
full death program, including clearance, without caspase involvement. This includes, in particular, the
elimination in vivo ofmature dendritic cells and B cells via MHC-II -dependent mechanisms (Drenou
et al 1999), and T cells infected with HIV (Petit et al 2002). Further evidence is afforded from animal
knockout experiments. Although caspase-3 deficient embryos show striking morphological
perturbations of the forebrain, a study of post-mitotic neurons within the spinal cord and brain stem
displayed caspase-independent death, with no effect on their ability to be recognized and cleared
(Oppenheim et al 2001). Similar observations were seen with caspase-9 knockout mice, supporting
the view that requirement for caspases might be dependent on tissue, cell type, age, and species
(Oppenheim et al 2001). However, many of these systems have used synthetic caspase inhibitors or
genetic ablation of caspases to reveal the pathways, and in this respect may reflect redundancy in cells
ability to die, rather than a predetermined choice or requirement to be caspase-independent. Here we
report that the intrinsic constitutive cell death program occurring in platelets on aging does not utilise
caspases due to an absence of caspase-9, a key proteolytic component of the apoptosome.
This simple observation leads to some fascinating possibilities when combined with the fact
that the platelets progenitor, the megakaryocytes (MKs), contain quantities of caspase-9 equivalent to
Jurkats. Why do platelets not have caspase-9 when megakaryocytes do? One possibility is that
caspase-9 is present in freshly formed platelets but is rapidly degraded by calpains, given that platelets
are a rich source of these proteases and that they have previously been demonstrated to inactivate the
precursor (Wolf et al 1999, Lankiewicz et al 2000, Chua et al 2000). Calpains have further been
shown to be activated and function during a number of platelet activation events (Fox et al 1991),
especially given their Ca2+ dependency and the well-characterised Ca2+ flux on platelet activation.
Speculatively, given the multiple reversible activation events and interactions platelets undergo to
maintain haemostasis within the circulation, repeated calpain activation may possibly result in the loss
of caspase-9. However, two major reasons suggest this is not the case. Calpastatin is the
140
physiological antagonist of calpain activity within cells, preventing its activation due to increased Ca2+
alone, and requires cleavage to lose its inhibitory functions (Porn-Ares et al 1998). In addition, as
shown by the caspase-3 blot (Figure 4.1) and work by others (Wolf et al 1999; Lankiewicz et al 2000;
Chua et al 2000), calpain activity can be directed at caspase-3 resulting in a "tell tale" cleavage to
protein bands of a size just less than the p32 proform. As evidenced from the same blot, freshly
isolated platelets clearly do not show these bands indicative of calpain activation, and hence suggest
that calpain mediated consumption of caspase-9 has not occurred.
Another possibility to explain the caspase-9 disparity between platelets and MKs is presented
with understanding that platelet genesis is not a random fragmentation of the MKs cytoplasm, but a
series of elegant active processes. As demonstrated by Italiano et al (1999), and based on much
previous work, MKs actively extend long microtubule supported processes termed proplatelets
(Becker and DeBruyn 1976). Open microtubule loops are thought to translocate through these
processes, delivering platelet specific organelles such as a- and dense-granules to the proplatelet tips,
where the closed microtubule coil forms to produce a mature platelet that is finally shed. The
procedure appears to occur with precise control, given that platelets are rarely seen to contain
endoplasmic reticulum or Golgi apparatus. In addition, further support for molecular
compartmentalisation is provided by a recent report that has demonstrated platelets to contain a
distinct subset of mRNAs derived from the MK (Lindemann et al 2001). From this understanding it
could be proposed that MKs have the "ability" to specifically exclude caspase-9 from platelets during
thrombopoiesis, albeit by an unknown mechanism, and for an unknown reason. This argument could
of course be reversed, accounting for the fact that fresh platelets contain quantities of caspase-3
equivalent to Jurkats on a protein for protein basis, suggesting that the majority of the MKs caspase-3
protein is specifically delivered to the platelet. Separation of caspase-9 and -3 essentially blocks the
intrinsic death program within the platelet, leaving only factors such as the mitochondrial released
AIF or Smac/Diablo to act. If this separation was deliberate it makes sense for the cell to
preferentially retain caspase-9, due to its lower copy number. Given that the cellular target ofAIF has
been shown to be the nucleus (Susin et al 1999), and Smac/Diablos' main target is the antagonism of
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XIAP mediated caspase-9 inhibition (Du et al 2000; Verhagen et al 2000), these appear unlikely to be
able to play a role in platelet cell death.
Therefore, if platelets possess most of the requisite machinery for caspase-dependent death,
which is ubiquitous, what is the evolutionary pressure against platelets acquiring caspase-9 and -3
together? Given the association of caspase activation and PS exposure (Martin et al 1996; Vanags et
al 1996), and the well-known procoagulant properties of PS, could it represent a safeguard against an
accidental breakdown in haemostasis? This may seem odd given that in the previous chapter we
clearly report PS exposure to occur during platelet death. However, senescent platelets are rapidly
cleared, and as indicated in this chapter caspases do not appear to play a role in directing the surface
changes leading to clearance of platelets. In addition, in vivo platelets may display "eat-me" signals
and be phagocytosed before PS exposure occurs, resulting in their safe clearance. Could it be possible
that under certain pathological conditions (blood sepsis?) blood borne toxins or factors could induce
an intrinsic type death in platelets, especially as their anucleate nature limits their potential anti-
apoptotic "counter response", which if caspase-9 was present would result in the mass procoagulant
exposure of PS, certainly resulting in fatality. Similarly, given that procaspase-9 has a detectable
albeit low activity (Thornberry and Lazebnik 1998), could this "smouldering" level ignite a full
cascade, again given platelets limited ability to resynthesise, and hence maintain levels of caspase
antagonists such as XIAP? If this were true caspase-independent death, or rather a blockade in
caspase pathways, would be likely to exist in other anucleate cells, such as the erythrocyte. In fact
caspase-3 activation has been demonstrated to be required, and is hence consumed during transition
from the less mature nucleated polychromatic normoblast to the anucleate erythrocyte (Zermati et al
2001).
Perhaps it is this observation that leads to the third possibility for an absence of caspase-9 in
platelets. Could platelet formation by the MK occur concurrent with, or require a form of altered or
"hijacked" apoptotic program? Thus caspase-9 could be consumed during the generation of platelets.
Examination of the caspase-dependent apoptotic blebbing that occurs in many cell types suggests that
some parallels with platelet formation exist. This caspase-initiated process effects major biochemical
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alterations to the cytoskeleton due to contractile forces generated by the actin-myosin system (Mills et
al 1998), producing many individual membrane bound bodies into which the fragmented nuclear
material has been actively localised (Coleman et al 2001; Sebbagh et al 2001). In addition, it has been
reported that a major phenotype of the Bim k/o mouse, a pro-apoptotic member of the Bcl-2 family, is
a profound thrombocytopenia (Bouillet et al 1999), whilst similarly the high level Bcl-2 expressing
transgenic mouse shows a comparable phenotype (Ogilvy et al 1999). Given this evidence, albeit
circumstantial, a preliminary investigation into a possible role for apoptosis in platelet formation from
the MK was considered worthwhile.
Although confident the data supports an absence of caspase-9 in platelets, it has been
previously reported by Wolf et al (1999) to be present. Our data demonstrate caspase-9 is not present
both by Western-blot analysis, and by a functional reconstruction of the apoptosome. In addition, we
have demonstrated that under altered blotting conditions a non-specific protein band around the
molecular weight of caspase-9 can be detected in platelets, but which was shown by 2D
electrophoresis to be of an incorrect pi. However, the Wolf paper displayed an ability to activate
caspase-9 and subsequently caspase-3 in response to cytochrome-C and dATP. Another possibility to
explain this disparity exists. The platelets used within the Wolf et al study (1999) were obtained from
hospital platelet concentrates, usually destined for platelet transfusion. In the United States platelet
concentrates are separated from whole blood by first preparing PRP, followed by collection of
platelets after a second centrifugation, typically yielding around 5 x 1010 platelets per 50 ml bag
(Vengelen-Tyler 1996). In Europe the buffy coat method is employed, involving centrifugation of
whole blood to form a buffy coat, from which platelets are separated by an additional separation
(Fijnher et al 1990; Murphy et al 1996). Although both methods produce platelet concentrate bags
containing similar numbers of platelets, the difference in leukocyte contamination is large. The
American PRP method yields around 108 leukocytes per bag, whilst the European buffy coat
technique contains only 106 per bag, a hundred-fold variation. This equates to the American
concentrates containing one leukocyte for every five hundred platelets. Given that it typically takes a
hundred times the number of platelets to make a protein lysate of the same concentration as
leukocytes, a sixth of the protein within the Wolf "platelet" lysate would have been derived from
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leukocytes, known to contain caspase-9 (Webb et al 2000; Bantel et al 2001). We have always been
aware of this and thus have ensured that platelets used for making lysates were subjected to multiple
rounds of purification, as described under methods, resulting in around less than one leukocyte per
one hundred and fifty thousand platelets.
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Chapter 5 - Megakaryocyte Cell Death
Introduction
The terminal stage of MK maturation represents a unique and fundamental phenomenon of
cell biology, yet relatively little is known about the process. Following multiple rounds of
endomitosis to increase cell volume, and synthesis of vast amounts of platelet specific material, the
MK breaks up into hundreds of mature blood platelets (Becker and DeBruyn 1976). Flowever, this
procedure is not a simple fragmentation of the MKs cytoplasmic content, but as elegantly shown by
Italiano et al (1999) is an active process occurring with great precision, ensuring that the rich and
unique cytoskeletal architecture of the platelet is properly formed. It is now almost universally
accepted that platelet genesis occurs through intermediate morphological structures known as
proplatelets. Proplatelets appear as long cytoplasmic extensions from the MK along which platelet
sized nodes are observed, and contain multiple branch points to increase the number of tips. Thought
to mainly utilise microtubule and actin components, platelet specific material is actively delivered to
the proplatelet tips where the characteristic microtubule coil is formed and mature blood platelets are
released (Italiano et al 1999). Although the basic "mechanics" of these events have been elucidated,
any details of biochemical mechanisms driving such complex cytoskeletal rearrangements are highly
speculative and based on the use of "blanket" cytoskeletal inhibitors such as taxol and cytochalasin D.
In addition, it is important to realise that at the beginning of this study little was known about the
physiological stimuli capable of driving proplatelet extension and platelet release. Progress in the MK
field in general has been severely held back by the lack of a reproducible culture system that resulted
in terminal maturation and platelet release. However, the relatively recent cloning and subsequent
commercial availability of the lineage specific MK differentiation and maturation factor
thrombopoietin (TPO) has kick-started a renewed interest in these fascinating cells.
Building on the suggestion within the previous chapter that caspase-9 may have been
consumed by a "hijacked" apoptotic program during platelet formation, thus explaining its absence
from platelets, we investigated whether inhibitors of the caspases could modulate platelet formation.
Using a human megakaryocyte cell line and primary murine MKs, we found that platelet formation
was dramatically inhibited by the poly-caspase inhibitor zVAD-fmk. Interestingly, the more caspase-
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3 and -9 specific inhibitors zDEVD-fmk and zLEHD-fmk, respectively, failed to attenuate
thrombopoiesis. Conversely, by treating MKs with Fas death receptor ligating agents, platelet
production was significantly increased, presumably by induction of caspase activation. These
findings were also reproduced in a novel ex vivo human bone core bioreactor culture system,
producing platelets with morphology indistinguishable from blood platelets, and thus suggesting a
strong physiological relevance for the observations. By using a cell permeable active caspase specific
fluorescent dye we were able to identify active caspases within the main cell body of MKs bearing
proplatelet extensions, but not the processes. Furthermore, the nuclear staining vital dye Hoechst
33342 revealed the caspase positive proplatelet bearing MKs to simultaneously display condensed
nuclei typical of apoptosis. These observations were supported by TEM, which further revealed that
MKs showing evidence of very early cytoskeletal and membrane rearrangements displayed nuclear
condensation typical of an early stage of apoptosis, whilst those actively bearing proplatelets
displayed a more marked condensation and fragmentation. In addition, direct enumeration of
proplatelet bearing cells revealed the caspase inhibitor zVAD-fmk to inhibit formation of this
phenotype, suggesting a requirement for caspases in driving, directly or indirectly, proplatelet
extension.
Intriguingly, despite cells containing active caspases and displaying marked nuclear
condensation and chromosomal fragmentation, proplatelet bearing MKs retain a mitochondrial
transmembrane potential, and show evidence of active localisation of mitochondria to platelet sized
nodes along the extensions. Furthermore, mature platelets shed from MKs under constitutive or Fas
induced conditions did not expose PS at the cell surface, underwent typical agonist-induced platelet
responses, and importantly were not phagocytosed by human MO. These data together strongly
suggest that MK apoptosis not only occurs during platelet formation but is required, and may
represent a novel form of "compartmentalised" apoptosis, given the disparity when compared to more
typical apoptotic processes. This presents a fascinating opportunity to not only study two unique and
phylogenetically ancient "co-opted" processes, but also to elucidate potential new therapeutic
strategies for the control of thrombostasis.
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5.1 Production of platelet-like particles strongly correlates with apoptosis
It has been previously suggested that a link exists between remnant denuded megakaryocytes
displaying apoptotic morphology and the number of platelet-like particles (PLPs) found in culture
supernatants (Zauli et al 1997). Although the apoptosis of the MK had been interpreted as being
secondary to platelet formation, we investigated whether the apoptotic machinery was required, and
whether the program of apoptosis itselfwas responsible for driving platelet formation.
5.1.1 Platelet-like particles can be enumerated byflow cytometry
The megakaryoblastic cell line MEG-01 has previously been shown to mature constitutively
and spontaneously produce PLPs in culture (Ogura et al 1985; Takeuchi et al 1998). As the small size
of platelets precludes the reliable use of manual counting methods, a flow cytometric technique was
employed. This was felt to be superior to a Coulter counter, which infers size through the
measurement of impedance changes across a defined opening, and hence can give no indication into
the nature of the counted event. Using MK culture supernatant "spiked" with a known amount of
10pm polystyrene beads, to act as a fixed external control, the bead and PLP populations were easily
divided by their FSC/SSC characteristics, allowing separate counts of each population to be made.
From this ratio, given the fixed quantity of beads added, numbers of PLPs per ml were calculated
(Figure 5.1). On comparing separate wells containing 2 xlO5 MKs each, it can be seen that following
18 h of culture the quantity of PLPs produced was reproducible, at around 1 x 106 ± 5 x 104 (Figure
5.1).
5.1.2 Pro- and anti-apoptotic reagents modulate production ofPLPs
The megakaryoblastic cell line MEG-01 was treated for 18 h with a variety of pro-apoptotic
agents, including staurosporine, etoposide, soluble Fas ligand, CH. 11, lactacystin, ALLN, and anti-
apoptotic agents including zVAD-fmk, zDEVD-fmk, zLEHD-fmk and calpeptin. Following treatment
separated culture supernatants were enumerated for PLPs by flow cytometry, whilst remnant MK cells
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Figure 5.1: The MEG-01 MK cell line constitutively produces platelet-like particles (PLPs) at a
constant rate, a, MEG-01 culture supernatants were enumerated for the number of PLPs produced
by flow cytometry. By reference to a fixed number of beads, easily gated separately from the platelets
(R3), absolute yields of PLPs falling within a typical blood platelet gate (Rl) can be calculated, b,
MEG-01 MKs at 4 x 105 / ml were plated into separate tissue culture wells. Following 16 h of culture
the number of PLPs produced was assayed by flow cytometry. As can be seen, the rate of production
remains relatively constant for a fixed number of MKs seeded. The right hand panel represents the
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Figure 5.2: The number of platelet-like particles produced is strongly correlated to the level of
MK apoptosis. MEG-01 MKs were treated for 16 h with a variety of pro- and anti-apoptotic
reagents, (a) Remnant cells were assayed for the percentage of pyknotic nuclei using Hoechst 33342,
and the number of PLPs produced enumerated by flow cytometry, b, A scatter graph of the level of
apoptosis vs. the yield ofPLPs revealed a tight correlation to exist, with an R2 value of 0.97.
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were counted for pyknotic nuclei, using the DNA binding vital dye Hoechst 33342. A tight
correlation (r = 0.97) was evidenced with a dramatic increase in the number of PLPs produced using
pro-apoptotic agents and a consistent basal level of constitutive platelet production for controls
(Figure 5.2). Likewise, a constant level of approximately 10% apoptosis was present within MKs
maintained under control conditions. Interestingly, treatment with the poly-caspase inhibitor zVAD-
fmk inhibited apoptosis and PLP formation to below this basal level. Given that untreated cultures
spontaneously produced PLPs and spontaneously undergo apoptosis, and given the tight correlation
between the two under "induced" conditions over a relatively short time course, the result suggested a
close association between apoptosis and platelet production, and that a requirement for apoptosis in
PLP production might exist. However, using the current assay it could be argued that any reagent
which induced apoptosis would, depending on cell type, produce blebbed bodies, and given the
absence of phagocytic clearance, cells will undergo secondary necrosis. Therefore, given the
heterogeneous nature of platelet FSC/SSC characteristics, the possibility of necrotic cell debris and
apoptotic bodies colocalising with any culture-derived platelets produced existed. Hence to further
the study a more rigorous method of platelet enumeration was developed, as detailed in section 5.2.1.
5.1.3 Apoptosis is confirmed by DNA laddering
One of the key markers of apoptotic cell death is internucleosomal DNA cleavage, typically
by the endonuclease CAD, and is commonly referred to as a "DNA ladder" because of the evenly
spaced bands which appear when the extracted DNA is electrophoresed (Wyllie et al 1980).
Interestingly, ladders were evident in DNA samples of untreated control MEG-01 MKs, whilst
conditions that had previously increased apoptosis and PLP formation, such as treatment with the
agonistic anti-Fas mAb CH.ll, also increased the intensity of the ladder, given the equal loading
conditions (Figure 5.3). Again the only treatment that reduced the intensity was the poly-caspases
inhibitor zVAD-fmk, in which the ladder appeared fainter and most DNA remained retarded near the
loading well, as indicative of un-cleaved genomic DNA. Intriguingly, the caspase-3 inhibitor







Figure 5.3: MEG-01 MKs undergo oligonucleosomal cleavage to produce a DNA ladder under
constitutive conditions or following treatment with pro-apoptotic reagents. Purified mature
MEG-01 MKs were cultured under control conditions, or with reagents as indicated for 12 h. Cells
were collected and the genomic DNA extracted and electrophoresed on a 1.2% agarose gel, with
bands visualised under UV light following ethidium bromide staining. All lanes contained the
characteristic 200 bp ladder indicative of apoptosis, with increased oligonucleosomal cleavage
witnessed following treatment with the agonistic anti-Fas mAb CH. 11.
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5.2 Culture derived platelets are functional and can be enumerated by several
characteristics using flow cytometry
The positive identification of culture derived platelets is not a simple case of labelling for the
lineage specific marker CD41/61, as material and debris derived from the parent MK inevitably
contained the surface marker whether an actual platelet or not. Hence we developed an enumeration
strategy based on typical functional responses to platelet-specific agonists such as thrombin or ADP.
5.2.1 Agonist-induced shape-change reliably indicates functional platelets
At "threshold" doses of agonist platelets still lose their normal discoid shape, becoming more
spherical and extending membrane filopodia. Known as shape change the response is easily detected
on a flow cytometer as an increase in SSC. Representing a reversible phase of activation at low
agonist doses the platelets do not expose phosphatidylserine (Otterdal et al 2001). Therefore by using
this response combined with propidium iodide and annexin-V staining it is possible to separate
necrotic debris, apoptotic blebs, and dysfunctional PLPs from functional responsive platelets, thus
allowing enumeration. Using freshly isolated blood platelets the cells can be seen to move from the
"resting" gate R1 into the shape changed gate R2 on agonist stimulation (Figure 5.4). As expected, no
binding of annexin-V or PI is witnessed, and as shape change represents a transient response only
80% of fresh platelets are shape changed at any given time. However, when MK culture supernatants
are stimulated the shape-changed population (-60%) remains exclusively PI/AV negative, whilst the
majority of the non-responsive population binds annexin-V (Figure 5.4). By "spiking" with 10pm
beads (gate R3), to ascertain total number of particles (gate Rl), and then undertaking agonist-induced
shape change in the absence of beads (the relatively large size and amount of beads tended to interfere
with the SSC signal from the platelets) it is possible to assay supernatants for total number of
functional platelets per volume. Therefore throughout the chapter, reference to number of functional




Figure 5.4: Functional platelets can be enumerated by a shape change response to platelet
agonists, a, Freshly isolated blood platelets undergo shape change in response to agonist (as
indicated), easily detected as an increase in side scatter (R1 > R2). Absolute counts of platelets were
obtained by 'spiking' with a fixed number of 10 pM beads easily separated from platelets (R3). b,
Freshly isolated blood platelets treated with or without agonist as indicated rarely bind annexin-V
under the conditions employed, c, Culture derived platelets also undergo a shape change when
stimulated, but in contrast contain an annexin-V positive population (d), with only annexin-V negative
cells undergoing thrombin induced shape change. Hence functional platelets were defined as those
able to undergo agonist induced shape, but remaining annexin-V negative. All conditions contained
PI as a dead cell gate, excluded from subsequent analysis.
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5.2.2 Transient calcium fluxes are detected within the shape-changing population only
A well-characterised biochemical change occurring within platelets during the early
reversible phases of activation, and particularly during shape-change, is the classic transient calcium
flux (Robblee et al 1973). Using the visible light excitable Ca2+ sensitive dye FIuo-3, as opposed to
the more commonly used UV excitable Fura-2, allows platelets to be analysed using a standard argon
laser flow cytometer. Following stimulation of MK culture supernatants the shape-changed
population only displays an increased Fluo-3 fluorescence within 30 s (Figure 5.5), indicative of a
calcium flux. As reported in much platelet literature the majority of events return to basal levels
within 90 s (Figure 5.5).
5.2.3 Culture derivedfunctional platelets are not phagocytosed
To confirm the morphological and functional evidence that platelets produced by MEG-01
MKs undergoing apoptosis were viable, we investigated whether monocyte-derived macrophages
(MDMs) would selectively clear non-functional platelets and MK fragments. Incubating MK culture
supernatants with MDMs resulted in the selective clearance of all phosphatidylserine positive bodies,
leaving a population of functional platelets able to demonstrate agonist-induced shape change (Figure
5.6). Interestingly, given the remnant MK cell body is known to be phagocytosed (Radley and Haller
1983), and the initial data that suggests inducing apoptosis increases production of PLPs, there
appears to be a divergence from the more typical apoptotic program, which results in a difference of
"edibility" between MKs and platelets.
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FSC-H ANNEXIN-V
Figure 5.5: A transient calcium flux is detected within the shape changed population of MEG-
01-derived platelets following agonist stimulation. MEG-01 MK culture-derived platelets were
separated, stained with the Ca2+ sensitive dye FLUO-3, and analysed by flow cytometry, a, Without
agonist stimulation platelets remained in a typical blood platelet gate (Rl), whilst a subpopulation
stained positive with annexin-V. b, On agonist stimulation with either thrombin or ADP, platelets
shape changed as evidenced by an increase in SSC-H (events moving from Rl to R2). The majority
of the shape changed population displayed an increase in FLUO-3 fluorescence indicative of an
intracellular calcium flux, c, In line with the transient nature of Ca2+ fluxes, 90 s after stimulation
most FLUO-3 positive events return to basal levels.
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Figure 5.6: Platelets generated by MK are not phagocytosed by macrophages. Culture derived
platelets from purified mature MEG-01 MKs were incubated alone (a), or with human macrophages
(b), and subsequent culture supernatants analysed by flow cytometry, b, Incubation with macrophages
resulted in the clearance of all annexin-V positive debris, with the majority of the remaining
population able to shape change on agonist stimulation.
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5.3 Production of functional platelets by human megakaryocyte cell lines is caspase-
dependent.
In addition to the stringent requirement of all caspases for aspartic acid in the P| position, the
P4 position has been identified as the next most important determinant of the distinct substrate
preference between various caspase family members (Thornberry et al 1997). Using a combinatorial
approach Thornberry and colleagues developed a panel of individual caspase inhibitors with
differential specificity between caspase groups. However, as with all peptide based enzyme inhibitors
one should always hold concern over concentrations applied, with each inhibitor capable of inhibiting
most family members at inappropriate concentrations. In general, a high level of cross-reactivity is
particularly apparent within this family of inhibitors.
5.3.1 The broad spectrum inhibitor zVAD-fmk inhibits constitutiveplatelet production
By using the procedure for counting functional platelets detailed above, the effect of peptidyl
caspase inhibitors on platelet production was investigated. Following 18 h of culture the MEG-01 cell
line significantly produced around 50% less platelets following zVAD-fmk treatment (Figure 5.7).
Interestingly, the caspase-3 inhibitor zDEVD-fmk, and caspase-9 inhibitor zLEHD-fmk had no effect
(Figure 5.7). Given that MKs clearly display nuclear pyknosis and chromosomal fragmentation, as
shown above, and that these two caspases represent the most common pathway by which CAD is
activated (Liu et al 1997; Enari et al 1998), the result is intriguing. However, many studies have
documented compensatory caspase activation enabling PARP cleavage and DNA fragmentation to
occur, in particular by caspase-7 and -6 both able to function as efficient effectors (Kuida et al 1996;
Zheng et al 2000). Culture of the MEG-01 cells with zVAD-fmk over longer time periods appeared
to result in an apparent accumulation of the larger mature MKs, thus possibly implicating a zVAD-
fmk sensitive step between final maturation and the initiation of proplatelet extension that is
presumably caspase-9/3-independent.
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CONTROL zVAD-fmk DEVD-fmk ZVAD/DEVD LEHD-fink CALPEPTIN DMSOO.1% DMSO 0.2%
Figure 5.7: Production of functional platelets is significantly inhibited by the pan-caspase
inhibitor zVAD-fmk. Purified mature MEG-01 MKs were cultured for 18 h with reagents or carrier
DMSO alone as indicated, culture supernatants separated and assayed by flow cytometry for the yield
of functional platelets as detailed in Figure 5.3. As can be seen the pan-caspase inhibitor zVAD-fmk
significantly inhibited platelet production. However, the caspase-3/9 inhibitors DEVD-fmk and
LEHD-fmk, respectively, had no effect and failed to synergise with zVAD-fmk. Data represent mean
± one S.D. of n = 4. ** represents p < 0.02 compared to control.
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5.3.2 Inhibition ofplatelet production by zVAD-fmk is not through inhibition of cytokine
processing, or miscounting due to prevention ofshape-change
The first identified member of the caspase family was the interleukin converting enzyme-1
(ICE-1) (Thornberry et al 1992). Representing the archetypal example of a group-I caspase, the
enzyme is highly sensitive to zVAD-fmk (Garcia-Calvo et al 1998) and is responsible for processing
pro-IL-1 to its active form. To exclude the possibility that platelet production was IL-1 -dependent,
and that zVAD-fmk was mediating inhibition through prevention of pro-interleukin-1 processing,
exogenous IL-1 p (25 ng ml"1) was added to cultures with and without zVAD-fmk. As can be seen, IL-
ip failed to promote platelet production above control levels, and likewise failed to reverse zVAD-
fmk mediated inhibition (Figure 5.8). In addition, as a previous study had suggested a requirement for
caspases for a subset of platelet activation responses (Shcherbina and Remold-O'Donnell 1999), the
possibility existed that zVAD-fmk treated cultures were producing platelets unable to shape change
and therefore were not being counted. Pre-incubation of parallel fresh blood platelet samples with





Control IL-1B zVAD-fmk zVAD-fmk / IL-1B
Figure 5.8: zVAD-fmk inhibition of platelet formation is not mediated through inhibition of
cytokine processing by ICE-1. Purified mature MEG-01 MKs were cultured for 18 h with reagents
as indicated, culture supernatants separated, and functional platelets enumerated by flow cytometry.
Given that IL-1 p failed to reverse zVAD-fmk inhibition or promote platelet formation, it suggests its
action is not mediated through inhibition of IL-1 p processing. Data represent the mean ± one S.D. of n
= 3. ** represent p < 0.02 compared to control.
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Figure 5.9: zVAD-fmk does not inhibit agonist-induced shape change. Fresh blood-derived
platelets were pre-incubated with or without zVAD-fmk as indicated for 20 mins, before analysis of
agonist-induced shape change by flow cytometry. The level of shape change was not significantly
altered by zVAD-fmk treatment, and remained highly reproducible within each donor.
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5.4 Production of functional platelets is induced by particular pro-apoptotic agents
As platelet production appeared to be caspase dependent, shown by the inhibitory effects of
zVAD-fmk, we explored the possibility that deliberately driving a caspase-dependent cell death
pathway could conversely promote platelet formation. However, staurosporine, which we had
previously shown to induce apoptosis, is a poly-kinase inhibitor and thus is known to inhibit PKCa,
recently shown to be required for proplatelet extension (Rojnuckarin and Kaushansky 2001).
Therefore, and given that the Fas death receptor is an important regulator of early haematopoiesis
(Santiago-Schwarz et al 1997; De Maria et al 1999; Josefsen et al 1999; Bryder et al 2001), we sought
to determine if Fas ligand, a recognised initiator of apoptosis, could promote thrombopoiesis.
5.4.1 MEG-01 MKs express Fas on their cell surface as assayed by flow cytometry and epi-
fluorescent microscopy
As a generalisation, most cells of myeloid origin have been demonstrated to express Fas on
their cell surface. However, current literature contains little data about the presence of Fas or Fas
ligand on MKs. Using the anti-Fas IgM antibody clone CH.ll, MKs were labelled on ice, washed,
and stained with an Alexafluor labelled secondary antibody. Using epi-fluorescent microscopy a
subset of cells was seen to have specifically stained with CH.l 1. As can be seen a punctate pattern of
fluorescence is witnessed, with some areas containing large patches of staining indicative of receptor
clustering, and thought to be due to association with lipid rafts, as recently reported (Figure
5.10)(Gajate and Mollinedo 2001). In addition the same samples were assessed by flow cytometry for
a more objective analysis of the number of cells expressing Fas and the relative level of surface
expression. Typically, 42 ± 5% of the population expressed Fas, but a large variation in the level of
expression existed (Figure 5.10).
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Figure 5.10: MEG-01 MKs express Fas on their cell surface, a, MEG-01 MKs where labelled on
ice with the anti-Fas antibody CH.l 1 and stained with an AlexaFluor secondary antibody. Analysis by
epifluorescent microscopy revealed Fas to be expressed on the cell surface (green). Some evidence of
areas of receptor clustering is witnessed (arrow). Scale bar represents 20 pm. Cells stained with
isotype control and secondary Ab (b), or CH. 11 and secondary were also analysed by flow cytometry,
revealing around 40% to stain positive for Fas, but with a large variation in the level of expression.
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5.4.2 Platelet production is significantly increased by soluble Fas ligand, in a caspase-
dependent manner
Given the presence of Fas on the surface of MEG-01 MKs we investigated whether the
physiological agonist, in the form of human recombinant Fas ligand, could induce platelet production
and apoptosis. Using a commercially available Fas ligand and enhancer system, speculatively thought
to optimise receptor clustering using a FLAG- or histidine-tagged Fas ligand and an anti-FLAG/his
antibody, we found platelet production was significantly increased (Figure 5.11). Interestingly, and in
support of the inhibition of constitutive platelet production, this increase was revealed to be caspase-
dependent by the inhibitory effect of zVAD-fmk (Figure 5.11). Furthermore, the ability to promote
platelet production was somewhat restricted to Fas in that ligation of the TNF death receptor with
TNF-a failed to promote platelet production (Figure 5.11).
5.4.3 The Fas agonistic antibody CH.l 1 effectively induces specific Fas ligation andplatelet
production
The archetypal IgM agonistic anti-Fas antibody clone CH. 11 has been extensively studied
and is well known to cause Fas receptor clustering and induction of cell death. MEG-01 cells were
treated with CH.l 1 for 18 h and the functional platelets produced quantified. Platelet production was
significantly increased around eight-fold above control levels at the relatively low CH.ll
concentration of 50 ng ml"1 (Figure 5.12). Using the anti-Fas antagonistic antibody ZB4 we were
reassuringly able to block the agonistic effect of CH.l 1, preventing increased platelet production, and
hence indicating the action of CH.l 1 to be specifically via Fas ligation. Given the high cost of soluble
Fas ligand and the amount required, and taking the data indicating the action of CH.l 1 to be specific,
future studies conducted used CH.ll only. In concurrence with its effect on constitutive platelet
production, zVAD-fmk was able to entirely reverse the induction. In contrast, zDEVD-fmk again was
unable to reverse increased production. The small reduction evidenced using zDEVD-fmk was almost
certainly cross reactivity to other caspase family members, as mentioned previously. If deliberately




Figure 5.11: Production of functional platelets can be significantly augmented by ligation of the
Fas death receptor with soluble Fas ligand. Purified mature MEG-01 MKs were cultured for 18 h
with reagents as indicated, and culture supernatants separated and assayed by flow cytometry for the
yield of functional platelets, as detailed in Figure 5.3. Production of functional platelets was
significantly increased with human recombinant sFas-L, which was revealed to be caspase-dependent
by the inhibitory effect of zVAD-fmk. Interestingly, ligation of the TNF death receptor did not
promote platelet production. Data represent mean ± one S.D. of n = 3. ** represents p < 0.02
compared to control.
CONTROL CH11 CH11 / zVAD-fmk zDEVD-fmk CH11 / ZB4 CH11/ZB4
zVAD-fmk zDB/D-fmk
Figure 5.12: Production of functional platelets can be significantly augmented by ligation of the
Fas death receptor with anti-Fas mAb clone CH.ll. Purified mature MEG-01 MKs were cultured
for 18 h with reagents as indicated, culture supernatants separated and assayed by flow cytometry for
the yield of functional platelets as detailed in Figure 5.3. Production of functional platelets was
significantly increased by the anti-Fas agonistic mAb CH.l 1, again revealed to be caspase dependent
by the inhibitory effect of zVAD-fmk. Again the caspase-3 inhibitor DEVD-fmk had no effect on
constitutive or induced production. Reassuringly, the anti-Fas antagonistic mAb ZB4 was able to
block the effect of CH.ll, indicative of the effect of CH.ll to be specifically ligating Fas. Data
represent mean ± one S.D. of n = 4. ** represents p < 0.01 compared to control.
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conversely inhibition of constitutive production occurs using zVAD-fmk, active caspases must be
strongly implicated to play a pivotal role in platelet formation.
5.5 The physiological relevance of observations in MK cell lines is supported by two
primary systems
The cloning and subsequent availability of the recombinant MK growth and differentiation
factor thrombopoietin (TPO) has presented researchers with the opportunity to expand and culture
primary MKs in vitro, leading to full terminal differentiation and platelet release (deSauvage et al
1994; Lok et al 1994). Using murine femoral bone marrow cells cultured in the presence of human
TPO, mature MKs can be obtained within 5 days. In addition, and in collaboration with Prof. David
Jones, we were able to investigate platelet production within a recently developed novel ex vivo bone
core bioreactor system named the Zetos™.
5.5.1 Primary murine MKs differentiated in culture respond comparable to cell lines
Following five days of ex-vivo expansion and differentiation in the presence of TPO, primary
murine MKs were assayed for the lineage specific fibrinogen receptor (CD41/61) before and after
enrichment through a discontinuous BSA gradient. By flow cytometry the unpurified MK population
exhibits a large heterogeneity in its SSC profile, caused by the increasing granule content as cells
mature. Staining of these cells revealed MKs with a greater SSC profile, and hence greater internal
granule content, expressed higher levels ofCD41/61, and in the expected 1:1 ratio as evidenced by the
fluorescent profile on a dot plot occurring as x = y (Figure 5.13). Likewise, cells with lower SSC
profiles progressively expressed lower levels of CD41/61. Following enrichment, around 98% of
MKs display the higher SSC profile and express high levels of CD41/61, indicative of mature MKs
(Figure 5.13). Reassuringly, the ability of zVAD-fmk to inhibit constitutive platelet production was
also observed for these mature primary murine megakaryocytes, significantly inhibiting around 50%
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zVAD-fmk
Figure 5.13: Caspase-dependent production of platelets by primary murine MKs is augmented
by Fas ligation, a, Primary murine bone marrow cells cultured in the presence of TPO for 5 days
were analysed by flow cytometry for CD41/61 expression. A mixed population of cells is evidenced
with varying levels of CD41/61 expression, b, Following purification through a discontinuous BSA
gradient, all retained cells can be seen to express high levels of CD41/61, indicative of mature MKs.
c, Purified mature primary murine MKs produce functional platelets, inhibitable with zVAD-fmk and
augmented with the anti-murine Fas ligating antibody JO-2. Functional platelets were enumerated by
flow cytometry based on response to thrombin stimulation as detailed previously. Data represent
mean ± one S.D. of n = 4. ** represents p < 0.02.
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equivalent to CH.l 1, we observed that the number of functional platelets produced increased, again
revealed to be caspase-dependent by the inhibitory effects of zVAD-fnrk (Figure 5.13).
5.5.2 An Ex-vivo bone culture system recapitulates data seen in vitro with MK cell lines
Representing a new and novel extension of organ culture systems, the Zetos™ represents a
system in which machined bone cores, obtained typically from femoral heads during hip surgery, can
be kept alive in excess of 48 days within a perfusion system. Originally developed to study the effects
of loading conditions on bone reabsorption and reconstruction, and with particular emphasis on
investigating bone atrophy during spaceflight, in collaboration with the European Space Agency, the
system had not previously been studied for its potential use in haematopoiesis. Human trabecular
bone from femoral heads was found to constitutively produce PLPs that stained positive for the
lineage specific fibrinogen receptor (CD41/CD61) (Figure 5.14). Constitutive PLP production over
an 18 h period was inhibited robustly by the poly-caspase inhibitor zVAD-fmk, and could be
augmented with low levels of the human Fas agonistic antibody CH.l 1, again blockable with zVAD-
fmk (Figure 5.14). Although the number of PLPs generated precluded any functional assessment,
ultrastructural analysis of perfused media components by TEM showed the presence of ~2pm bodies
with a morphology identical to that observed for circulating blood platelets (Figure 5.14). In
particular, TEM demonstrated the presence of an extended and enlarged canalicular system, a typical
distribution of alpha and dense granules, and small pseudopodia extensions (possibly induced by flow
within the system), as indicative of bona fide functional platelets. Although the platelet data only
represents an initial investigation, further work appears to suggest that an intact haemopoietic stem
cell system remains viable over more prolonged culture periods. TEM of culture supernatants
collected following 5 d of bone core culture appear to contain mononuclear leukocyte-like cells,
which could potentially be monocytes, eosinophils or neutrophils (Figure 5.14). Given the relatively
low lifespan of blood leukocytes this may implicate a recent formation, and hence by inference the
presence of myeloid stem cells.
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CONTROL CH11 zVAD-fmk CH11 /
zVAD-fmk
Figure 5.14: Caspase-dependent production of platelets by human bone cores is augmented by
Fas ligation, a, Ex-vivo human bone core ex-plants maintained within a Zetos bone perfusion
chamber were exposed to fresh media containing CH. 11 and/or zVAD-fmk as indicated. Perfused
media 'post bone core' was collected over 18 h, and CD41/61 platelets enumerated by flow cytometry.
Data represent means ± one S.D. In some experiments perfused media components were prepared for
TEM, and showed the presence of platelet-like bodies (b), scale bar represents 1 pm, and leukocyte¬
like nucleated cells (c), scale bar represents 5 pm.
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5.6 A morphological analysis of MKs reveals apoptosis to occur actively during
platelet formation
Although the previous data suggest that MK cell death strongly correlates with functional
platelet formation, it gives no insight into what is actually happening to the cells on a more
"individual" basis. Therefore, to address the nature of the modulation caspase inhibition or induction
appeared to be playing we turned to TEM, phase, and epifluorescent microscopy to further explore
whether apoptosis ofmegakaryocytes was causal and not consequential to platelet production.
5.6.1 MEG-01 MKs mature to large cells containing ultrastructural features identical to
those observedforprimaryMKs
During the terminal stages of maturation MKs undergo rounds of endomitotic
polyploidisation to greatly increase cell volume, whilst synthesis of numerous alpha and dense
granules begins, ready for conferment to the new platelets. In addition, an extensive system of
internal membranes develops, termed demarcation membranes, which were originally believed to
mark out fields or territories of new platelets, but are more likely to serve as reservoirs for the large
amounts of membrane required to "package" platelets. By light microscopy we observed that
untreated primary murine and human megakaryocyte cell lines matured over 5 days from small 10-
20pm cells to larger 40 pm cells with a smooth appearance by phase contrast, and which could be
readily enriched using a discontinuous BSA gradient (Figure 5.15). Reassuringly, TEM analysis of
BSA purified mature MEG-01 MKs revealed the majority of cells to contain numerous alpha and
dense granules (Figure 5.15). Furthermore, these cells containing granules displayed distinct evidence
of an extensive demarcation system (Figure 5.15). Previous reports had claimed the MEG-01 cell line
did not mature to produce granules and was unable to develop demarcation membranes, a conclusion
clearly at odds with our cells under the conditions employed. Also noteworthy is the evenly dispersed
heterochromatin within the polylobed nucleus seen in this section (Figure 5.15). In addition, analysis
of culture supernatants by TEM revealed numerous platelet-sized bodies that contained dense and
alpha granules, in line with that regularly seen for blood platelets (Figure 5.15). Interestingly, a subset
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Figure 5.15: Mature MEG-01 MKs contain ultrastructural features identical to that reported
for primary MKs, and produce platelets with a morphology indistinguishable from blood
platelets, a, MEG-01 MKs typically appear as 20pm cells with a smooth appearance by phase, b, In
culture MKs constitutively mature to larger 40pm cells, which can be enriched for by using a
discontinuous BSA gradient, c, TEM of a purified mature MEG-01 MK, shown at higher
magnification (d), demonstrates a typical distribution of dense and a-granules, displays a
characteristic demarcation membrane system (arrows), and contain nuclei with evenly dispersed
heterochromatin. e, Spontaneously in culture MEG-01 MKs produce functional platelets with a
morphology by TEM indistinguishable from blood platelets, f, In addition, a subset of platelet-sized
bodies exist with a morphology akin to the senescent platelets reported in Chapter 3. Scale bars
represent 20pm, except (e, f) which represent 1 pm.
171
of platelet-sized bodies existed, but at a lower frequency than "normal platelets", with morphology
consistent with that reported in chapter 3 for the senescent platelets. Given the culture period of 18 h
before supernatant collection, platelets formed early in this period may undergo death, especially
given the absence of human plasma-derived survival factors (Figure 5.15).
5.6.2 A subpopulation ofmature megakaryocytes contain cytoplasmically active caspases
In contrast to the normal smooth appearance by phase microscopy of the large mature MKs
displayed above (Figure 5.15), a distinct subpopulation was observed which exhibited a more
contoured appearance (Figure 5.16). Staining of live purified mature MEG-01 MKs with the
fluorescent poly-caspase inhibitor zVAD-FAM (CaspaTag), which binds active caspases, and analysis
by confocal microscopy revealed the contoured subpopulation to display a broad pattern of
cytoplasmic staining. Interestingly, Z-axis scans revealed the nucleus to remain caspase negative
(Figure 5.16; arrow). However, as the CaspaTag reagent is based on the zVAD-fmk peptide, and thus
acts as a competitive inhibitor, the reagent is effectively only of use to display a "snapshot" of the
caspase activity within the cell at the time of staining. Given this, it was impossible to perform a time
course analysis to reveal whether this phenotype progressed to a proplatelet bearing form.
5.6.3 Proplatelet bearing MKs contain active caspases and show evidence of nuclear
condensation
Production ofplatelets has been universally accepted to occur through intermediate structures
termed proplatelets, consisting of thin cytoplasmic processes along which platelet sized nodes form.
Again using the CaspaTag reagent, active caspases were detected within the MKs bearing proplatelet
extensions, in which the fluorescence appeared to remain localised to the main cell body (Figure
5.17). In addition, dual staining with CaspaTag and the nuclear binding Hoechst 33342 revealed that
proplatelet bearing MKs failed to exclude the vital dye, and clearly displayed nuclear condensation
and fragmentation (Figure 5.17). Hoechst staining also revealed the nuclear material to remain
confined within the cell body, in contrast to other cell types, e.g. fibroblasts, which undergo typical
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Phase Caspase Merge
Figure 5.16: A subset of large mature MKs display a contoured morphology and contain
cytoplasmically active caspases. Purified mature MEG-01 MKs were stained with the poly active-
caspase specific substrate CaspaTag. On examination by confocal microscopy a subset of large MKs
can be seen to display a contoured appearance by phase, in contrast to the normal smooth appearance
seen in Figure 5.16. This subset also stained for active caspases within the cytoplasm, but
interestingly the nucleus remained negative (arrow). Scale bars represent 20 pm.
Hoechst
Figure 5.17: Proplatelet extending MKs exhibit nuclear pyknosis and contain active caspases. a,
A mature MEG-01 MK displaying proplatelet extensions stained positive for active caspases (green),
which remained localised within the main cell body. Note that MKs without proplatelet extensions
(left and right) lacked caspase activity, b, Dual staining of nuclear material with Hoechst 33342
(blue), and for active caspases reveals MKs bearing proplatelets to contain pyknotic nuclei, with
nuclear material remaining within the cell body along with active caspases. Scale bars represent 20
pm.
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blebbing morphology and whereby nuclear material localises throughout the apoptotic bodies
(Coleman et al 2001; Sebbagh et al 2001).
5.6.4 TEM ofmatureMKs extends evidence ofapoptosis occurring during plateletformation
In support of proplatelet extension occurring concurrent with nuclear condensation, TEMs of
MKs with a typical demarcation membrane system, apparent throughout the cytoplasm, show evenly
dispersed nuclear material inconsistent with apoptosis (Figure 5.15). In contrast, MKs displaying
extensive "striations" below the cell membrane, indicative of the very earliest stages of cytoplasmic
projection, exhibited the clear nuclear condensation typical of early apoptosis (Figure 5.18). These
features indicate major cytoskeletal and membrane rearrangements within the cell before proplatelet
extension is witnessed, and essentially appear as "unravelled" proplatelets, with size and structure in¬
line with that observed by others (Italiano et al 1999). Whether these internal changes could cause the
visual change from a smooth appearance by phase to the more contoured phenotype described above
is undetermined. In addition, MKs seen to display proplatelet extensions appeared to have proceeded
to more extensive nuclear condensation and fragmentation (Figure 5.18). Although few proplatelet
processes appear in this particular section, the typical 40pm size of mature MKs and 60nm ultrathin
sections cut would require around 700 serial sections to be taken in order to obtain a TEM with more
proplatelets within a section. In retrospect, clear evidence of nuclear condensation has been presented
in many previous ultrastructural studies ofMKs actively producing platelets (Choi et al 1995; Cramer
et al 1997; Zauli et al 1997), but the authors overlooked any relevance to apoptosis.
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Figure 5.18: MKs undergoing proplatelet extension display nuclear condensation and
fragmentation typical of apoptosis. Purified mature MEG-01 MKs where examined by TEM. a, A
MK exhibiting early cytoplasmic rearrangements consistent with platelet formation (between arrows),
contained a nucleus displaying heterochromatin condensation typical of early apoptosis, shown at
higher magnification in (b). c, A MK cell bearing proplatelets shows extensive condensation and
fragmentation of the nuclear material (arrow). All scale bars represent 20 pm.
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5.6.5 Proplateletformation can be modulated by induction ofinhibition ofcaspases
Given the significant effect caspase inhibition or Fas treatment had on the total yield of
platelets, and the clear evidence of caspase activation and apoptotic morphology occurring during
proplatelet extension, we investigated if the total number of proplatelet bearing MKs was directly
modulated by the reagents. Quantification by light and epifluorescence microscopy of treated cells
confirmed that CH.l 1 and zVAD-fmk modulated the formation of proplatelet bearing MKs, in which
89 ± 3% (mean ± S.D. n = 3) of these cells stained positive for active caspases, and 95 ± 3% (mean ±
S.D. n = 3) showed signs of nuclear pyknosis (Figure 5.19). In contrast to previous experiments
where zVAD-fmk reduced total platelet production by around 50%, the effect of the caspase inhibitor
in these experiments resulted in almost total loss of the proplatelet bearing phenotype. Flowever,
these experiments were counted after an 8 h time course, in comparison to an 18 h culture for total
platelet yield, and may reflect instability of the small peptide inhibitor, which is well known to have a
short half-life and be sensitive to hydrolysis. These results strongly suggest that constitutively, or in
response to Fas ligation, mature megakaryocytes activate caspases and proceed to a proplatelet
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Figure 5.19: The number of proplatelet bearing MKs can be modulated through induction or
inhibition of caspases. Purified mature MEG-01 MKs were culture for 8 h in the presence of
reagents as indicated, and formaldehyde added to a final concentration of 0.5% to stabilise processes,
a, Entire wells were counted blind by phase microscopy for the total number of pro-platelet bearing
MKs. Data represent mean ± one S.D. of n = 3. ** represents p < 0.0001 compared to control, b, A
representative example of typical proplatelet bearing MK morphology as examined by phase
microscopy. Scale bar represents 20 pm.
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5.7 MK proplatelets maintain their A^M during constitutive and induced death
Death receptor pathways typically proceed through activation of effector caspases, such as 8
or 10, leading to Bid cleavage and subsequent mitochondrial insertion resulting in loss of A\|/M,
release of cytochrome-C, and eventual caspase-3 activation. Platelets are known to utilise oxidative
phosphorylation (Doery et al 1970) and we have previously demonstrated a loss ofA\|/M and release of
cytochrome-C to occur as an early event in blood platelet programmed cell death (section 4.2.1). If
MK apoptosis proceeded via a mitochondrial-dependent pathway, it would require newly formed
platelets to re-establish their A\|/M. As this seemed implausible we investigated the involvement of the
mitochondria.
5.7.I Caspase-dependent platelet production occurs without loss ofA if/M
Mature MEG-01 MKs were cultured under control conditions or with CH.ll for 8 h,
followed by staining with the inner-mitochondrial membrane potential sensitive dye JC-1 (Salvioli et
al 1997). Functional mitochondria can be seen localised within platelet-sized nodes along the
extended proplatelets, as evidenced by orange fluorescence, whether induced with CH.l 1, or cultured
under control conditions (Figure 5.20). Intriguingly, 94 ± 3% (mean ± S.D. n = 3) of proplatelet
bearing MKs with an intact Av|/M showed evidence of nuclear condensation on dual staining with
Hoechst 33342 (Figure 5.20). Analysis by confocal microscopy revealed residual mitochondria to be
polarised within the cell body to the MK edge with the remaining proplatelet "bridge" still attached
(Figure 5.20; arrow). This evidence supports the hypothesis by Italiano et al (1999) that platelet
specific material and organelles are actively delivered to the forming platelet tip, most likely by
attachment to open microtubule loops, and that platelets are not present as nascent pre-formed entities
within MK demarcation membranes. Therefore, extraordinarily, it seems that caspase-dependent
proplatelet extension, nuclear condensation, and eventual functional platelet release occurs with an
intact mitochondrial membrane potential.
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Figure 5.20: Functioual platelet production is associated with the maintenance of an inner-
mitochondrial membrane potential, a, b, Mature MEG-01 MKs cultured for 8 h untreated (a) or
with CH.l 1 (b) were double stained with the inner mitochondrial membrane potential sensitive dye
JC-1 (orange), and the nuclear staining vital dye Hoechst 33342 (blue). Mitochondria with an intact
A\|/M are seen localised within platelet-sized nodes along extended proplatelets, whilst the cell bodies
simultaneously display nuclear condensation, c, On examination of JC-1 stained MKs by con focal
microscopy, with limited Z-axis scanning due to cell and pro-platelet motility, mitochondria with an
intact AyM can be seen polarised within the cell body toward the remaining attached pro-platelet
(arrow). All scale bars represent 20 pm.
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5.7.2 MEG-01 MKs contain BID which is truncated in response to Fas ligation
The BH3 only domain pro-apoptotic protein Bid has been shown to be a specific proximal
substrate of caspase-8 in the Fas apoptotic signalling pathway. Full length Bid (26kDa) remains
localised in the cytoplasm, but following cleavage by caspase-8 the BH3 containing COOH-terminal
(15kDa) translocates to mitochondria, triggering cytochrome-C release (Luo et al 1998; Li et al 1998).
Given the increased apoptosis and platelet production by MKs on Fas ligation, and the concomitant
maintenance of the Av|/M, we investigated whether a defect in the Bid pathway could be mediating this
novel phenomenon. Western-blot analysis using an anti-Bid pAb recognising both the full length and
truncated active form revealed purified mature and immature MKs to contain Bid at comparable levels
to Jurkats, used as a positive control (Figure 5.21). Treatment of MKs with CH.l 1 prior to sample
analysis revealed Bid to be truncated to the active form, again with comparable amounts processed by
mature and immature MKs, or Jurkats (Figure 5.21). Therefore, maturation ofMKs does not confer a
resistance or inability to process Bid, and hence prevent Av|/M loss. However, inhibition of truncated
Bid before mitochondrial disruption, particularly by members of the Bcl-2 family, still present a
potential explanation. In addition, the somewhat basic division of MKs with a BSA gradient into









Figure 5.21: MEG-01 MKs contain Bid which is truncated in response to Fas ligation, a, Whole
cell lysates prepared from Jurkats (i), immature MEG-01 MKs (ii), and mature MEG-01 MKs (iii)
were analysed by Western-blot for expression of Bid with a pAb recognising the 26kDa full length
and 15kDa truncated form. All cells contained comparable amounts of full length Bid, based on even
protein loading, with no change as MKs mature, b, Whole cell lysates were prepared from the same
cell types, but with or without prior CH.ll treatment. Truncated Bid was evidenced in all cells
exposed to CH.ll, suggesting the maintenance of ATM is not mediated through an inability to
truncate Bid by MKs mature.
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Discussion
The key conclusion of this work is that a form of compartmentalised apoptosis of a
progenitor cell is a hitherto unrecognised mechanism for generation of multiple, functional anucleate
daughter cells. Thus, proplatelet bearing MKs exhibited clear morphological evidence of nuclear
changes of apoptosis and caspase activation in the main cell body, but bore processes that retained
mitochondrial membrane potential and yielded functional anucleate progeny (platelets) that were not
marked for immediate clearance by macrophages. Caspase inhibition reduced platelet production,
whilst ligation of MK Fas increased platelet production in a caspase-dependent manner, supporting
caspase-directed MK apoptosis as a mechanism for production of viable platelets. However, the
"compartmentalised" nature of such apoptosis was further emphasised by our previous finding that
caspase-9, a key component of the apoptosome following mitochondrial cytochrome-C release, is
present in progenitor MKs but is excluded from platelets, accounting for the caspase-independent
nature of constitutive platelet death.
Although our findings differ, they do share some parallels with the probable early role of
caspases in generation of the erythrocyte, another anucleate cell. Rather than production of multiple
anucleate daughter cells from a single progenitor (Stenberg and Levin 1989; Italiano et al 1999), the
data suggest that viable erythrocytes transiently activate caspases, resulting in cleavage of a subset of
structural proteins that may help lead to the anucleation of the erythroblast (Zermati et al 2001). The
erythroblast then continues maturation to produce a single anucleate erythrocyte (Gregory and Eaves
1978). However, this system reassuringly demonstrates that the transient activation of caspases is
able to selectively cleave structural proteins such as acinus and laminins, whilst failing to cleave
others such as DFF45/ICAD and GATA-1. Although this selectivity remains unexplained within the
erythroblast system, it further adds support to our suggestion that the apoptotic machinery can be
compartmentalised. Clearly, further work will be required to define the mechanisms by which caspase
activation in one part of the cell can lead to nuclear changes, whilst mitochondria in a different area of
the cell retain their transmembrane potential. Similarly our data also reinforce the concept that plasma
membrane changes of apoptosis may be dissociated from the caspase-directed program of nuclear
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condensation and fragmentation (Knepper-Nicolai et al 1998; Harper et al 2001). Nevertheless, as we
have emphasised, platelet production from MKs is a complex active mechanism resulting in the
specific delivery of progenitor cell cytoplasmic components into the proplatelets. Thus, it is possible
that there is specific exclusion of death pathway components upstream of mitochondria, analogous to
the exclusion of caspase-9 suggested by our data. Unfortunately, many possibilities could not be
tested directly since platelet yields from MK cultures were insufficient for blotting studies, and the
delicate nature of proplatelet-bearing MKs, which tended to lose their processes on manipulation,
excluded direct immunofluorescent localisation of caspase-9. Nevertheless, it seems clear that
evolution has achieved adaptations of the basic program of cell death by apoptosis to produce
anucleate cells of critical importance in blood.
The maintenance of A\|/M within proplatelet extensions whilst the cell body displays nuclear
condensation is fascinating. Initiation of apoptosis through death receptors, the extrinsic pathway, is
often presented within the literature to be a mitochondrial-independent process. This has tended to be
based on the evidence that in some cell systems Fas death cannot be blocked by Bcl-2, and hence is
not mediated through the mitochondria (Scaffidi et al 1998). However, this "designation" only refers
to the initial activation of a caspase, which in the case of caspase-8 and its subsequent activation of
caspase-3, obviously occurs without any mitochondrial involvement. Nevertheless, it is well
established that active caspase-8 cleaves the BH3 only protein Bid, the truncated form of which is
thought to insert into the mitochondrial membrane to mediate release of cytochrome-C (Li et al 1998;
Luo et al 1998). This does not appear to be happening in our system given the A\|/M is always
maintained in proplatelet bearing MKs. Although the importance of mitochondrial permeability
transition (PT) in initiating apoptosis remains highly controversial, even staunch opponents of the
theory admit, and have published, that loss of Av|/M does inevitably occur during apoptosis.
Principally, "Av|/M was unchanged in cells treated with anti-Fas antibody for ~2.5 h, but dropped
precipitously at ~3 h after treatment" (Matsuyama et al 2000), concluding that although PT is an event
occurring after cytochrome-C release it will inevitably occur. We clearly cannot have cytochrome-C
release given that platelets utilise oxidative phosphorylation during their lifespan of ~8 days, and
subsequently release cytochrome-C during their own constitutive death (section 4.2.2).
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Interestingly, some cell types have been demonstrated to be protected against death receptor
induced apoptosis by Bcl-2, suggesting a requirement for the secondary caspase amplification that
Bid-mediated cytochrome-C release would give. However, deficiencies in Bid, but not the presumed
initiator caspase of the Bid pathway, caspase-9, protect against Fas induced death (Zheng et al 2000),
implying that Bid is capable of mediating some as yet unknown pathway. In our opinion the data
could suggest the main objective of Bid-mediated mitochondrial disruption is the release of caspase
inhibitor antagonists such as Smac/Diablo. This may potentially explaining the disparity in Bcl-2
protection against Fas death, with cell types containing higher levels of the endogenous caspase
inhibitor XIAP requiring the Bid pathway-induced mitochondrial release of antagonist. It is not clear
whether the Bcl-2/Bcl-xL antagonism of Bid is through binding of the proform to prevent cleavage,
sequestration of the active truncated form, or interaction at the mitochondrial membrane to prevent
Bid-mediated release, mainly due to varying results dependent on the presence or absence of
detergents. Whatever mechanism is correct, expression of Bcl-xL has been demonstrated to inhibit all
of the apoptotic phenotypes induced by tBid (Li et al 1998). Interestingly, on maturation MKs have
been demonstrated to upregulate their levels of Bcl-xL by up to ten-fold (Terui et al 1998; Sanz et al
2001). Intriguingly, remnant denuded MKs have been demonstrated to contain no Bcl-xL, whilst
platelet and proplatelet-like fragments within the same culture supernatants, along with fresh blood
platelets, have been shown to be Bcl-xL positive (Sanz et al 2001). Similarly, MKs are known to
contain typical amounts of Bcl-2, however, we and others have demonstrated that platelets do not
contain Bcl-2 (Terui et al 1998). This again strongly supports the idea that MKs are capable of the
compartmentalisation of cellular components, and given the structural and functional similarity of the
Bcl-2 and Bcl-xL proteins, this appears to be an extremely specific process. Speculatively, given that
our mature MKs (albeit a rough fractionation of the MKs, and not a pure population of proplatelet
bearing cells) appear to be capable of processing comparable amounts of Bid as Jurkats or immature
MKs, could Bcl-2 be sequestering this truncated form away from the proplatelet processes to prevent
cytochrome-C release and eventual loss of AyM? Similarly, does the large excess of MK-derived
Bcl-xL, which is later found in platelets, stay associated with the mitochondria within the proplatelets
to "safeguard" against any escaped tBid, and thus prevent loss ofAyM?
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Fas signalling does not have to involve caspase-8, but instead can proceed through either
caspase-10 (Wang et al 2001), -2 (Chou et al 1998), or RIP kinase (Holler et al 2000). However,
caspase-2 has been shown to be highly insensitive to zVAD-fmk (Garcia-Calvo et al 1998), whilst
RIP-kinase has been shown to induce a necrotic-like cell death without chromosomal condensation
(Holler et al 2000), and thus both are inconsistent with our observations. Caspase-10 is the only
known mammalian caspase to share homologous DEDs to caspase-8 (Fernandes-Alnemri et al 1996),
and has been demonstrated to be able to efficiently act in the absence of caspase-8 as an apical
initiator of death receptor apoptosis (Wang et al 2001). It has also been shown that caspase-10 has
different apoptotic substrates to caspase-8, and hence may play a different role in death receptor
signalling (Wang et al 2001). However, whether caspase-10 can cleave Bid has not been reported,
and thus does not help explain our observations.
Although the combined data in this chapter strongly suggest a role for apoptosis and caspase
activation in platelet genesis, any specific caspase substrates that could enable the gross
morphological changes witnessed for platelet formation remain unknown. Caspases are well known
to target many cytoskeletal proteins and regulators such as actin, spectrin, p21-activated kinase 2
(PAK.2) and gelsolin, but most tend to result in a disruption of cellular architecture resulting in
rounding of the cells, and dissociation of adhesion to the underlying matrix. However, membrane
blebbing, as mentioned in the previously chapters discussion, is a caspase-directed event requiring a
force generation through the actin-myosin system, and results in membrane bound bodies into which
fragmented DNA has been specifically localised (Coleman et al 2000; Sebbagh et al 2000). Given
that MKs potentially have the ability, like the erythrocyte example, to "limit" or moderate a more
typical uncontrollable caspase cascade, could caspase cleavage of a more limited set of cytoskeletal
substrates directly aid or activate regulators of cytoskeletal rearrangements to allow, for example, the
actin-generated contractile force required for branching of proplatelets (Italiano et al 1999), or to aid
in polymerisation of tubulin monomers to the base of the microtubule containing proplatelet, allowing
elongation (Italiano et al 1999).
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Protein kinase C alpha (PKCa) has been implicated to be required for proplatelet extension,
based on its inhibition with pharmacological agents and isotype specific ribozymes (Rojnuckarin and
Kaushansky 2001). PKCa was shown to localise to aggregates of F-actin that form at the base of
proplatelet extensions, whilst PKCa inhibition prevented these aggregates form forming. Various
proteins have been identified to function in actin rearrangement in association with PKC, including
the myristoylated alanine-rich C-kinase substrate (MARCKS) family (Rosen et al 1990), pleckstrin
(Ma and Abrams 1999), and the Wiskott-Aldrich syndrome proteins WASP and N-WASP (Miki et al
1996; 1997). Functions of PKC during apoptosis remain controversial with many reports claiming a
caspase-directed activation (Ghayur et al 1996), whilst others suggest PKC activation inhibits cell
death (Sarker et al 2001). The data appears to vary with the cell types, death stimuli, and PKC
subspecies studied, however, the report "closest" to our system has demonstrated PKCa to be
activated in a zVAD-fmk-inhibitable manner in HL-60 cells following induction of apoptosis by a
range of agents (Shao et al 1997). However, PKC has been implicated to be able to modulate
signalling from the death receptor induced DISC complex. High levels of active PKC have been
shown to inhibit recruitment of FADD and hence caspase-8 to the DISC, thus preventing the caspase
cascade (Gomez-Angelats and Cidlowski 2001). Speculatively, if the level of PKC activation was in a
more controlled manner, could it affect signalling from the DISC to, say, prevent Bid cleavage, or to
modulate the initiator or effector caspases activated, thus eliciting a different cellular response of
caspase-driven proplatelet extension and apoptosis, rather than immediate "high level" caspase
activation and apoptotic death?
Another fascinating outcome of this study was the opportunity to work with the bone core
bioreactor system in collaboration with Prof. David Jones of the University of Marburg, Germany.
His prime interest is the study of osteoblast reabsorption, and osteoclast replication of bone that is
continually turned over throughout our life. Thus, a system was developed to allow the maintenance,
and hence study of ex vivo bone core samples in the lab. However, the haematopoietic potential of the
system had not been studied. As discussed in the results, production of platelets from the core
replicated the data seen with the cell lines and primary MKs. In addition, the core also appeared to
produce mononuclear and neutrophil-like cells ten days post surgical excision. As stated this is very
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much a preliminary study, but the potential of this system for the study of general haematopoiesis is
huge. A persistently highlighted weakness of more typical "culture plate" experiments is the lack of
the complex matrix substratum, and three dimensional cell-cell interactions that exist within the bone
marrow. Hence using the bone core a plethora ofmore physiological experiments could be conducted
on, for example, cytokine driven differentiation, chemotherapy agents, immunosuppressants, etc, etc,
without the incessant and sometimes preventable use of laboratory animals.
Essential thrombocythaemia is a myeloproliferative disease characterised by a marked
alteration in megakaryocytopoiesis resulting in high levels of circulating platelets, whilst many non¬
immune mediated thrombocytopenias result in low circulating platelets numbers, both are of unknown
aetiology. Our findings suggest that in vivo these abnormalities of circulating platelet numbers, of
critical importance in disorders of haemostasis and in thrombotic diseases such as stroke and
myocardial infarction, could reflect abnormalities in the control of MK apoptosis. Insufficient MK
apoptosis, or a "non-compartmentalised" apoptosis could result in lack of platelet formation, or the
direct clearance of the MKs before or during platelet formation (the logistics ofMO phagocytosis of a
mature MK would be interesting!). Some in vivo evidence exists to support a physiological basis for
our findings. Transgenic mice over expressing the anti-apoptotic Bcl-2 (Ogilvy et al 1999), or ablated
for the pro-apoptotic Bim (Bouillet et al 1999) show a 50% reduction in circulating platelets, but show
no defect in MK numbers. In addition, mice deficient in components of the Fas death pathway exhibit
thrombocytopenia, which has largely been attributed to autoimmune thrombocytopenia (Rieux-Laucat
et al 1995; Le Deist et al 1996). Interestingly, the few TEM studies that have demonstrated MKs
producing platelets in vivo have more often than not observed MO to be in the vicinity, and in some
cases with processes extending around the remnant denuded nucleus (Radley and Haller 1983). Given
that a recent paper has demonstrated nitric oxide (NO) to induce platelet-like particle formation
through an apoptotic-like process (Battinelli et al 2001), and that MO-NO (Duffield et al 2000), and
MO-Fas directed killing (Brown and Savill 1999) has been observed in many systems, could tissue
MO within the bone marrow be "directing" the apoptosis of the MKs, and thus be ready to clear the
remnant bodies and large amounts of micro vesicular debris observed during in vitro platelet
production. Indeed, one might speculate the possibility exists that pharmacological manipulation of
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MK apoptosis, and the Fas pathway in particular, might provide a novel therapeutic strategy for the
management and control of thrombostasis. Furthermore, the recent clinical trials of caspase inhibitors
for the clinical treatment of blood sepsis (Hotchkiss et al 2000), reperfusion ischemia (Cursio et al
1999), and neurological conditions (Robertson et al 2000) may reveal an unwanted side effect to be
thrombocytopenia.
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Chapter 6 - General Discussion
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The study effectively started at "end of the line" for the MK / platelet system, looking at the
ultimate changes on platelet aging and phagocytosis, worked backward to elucidate earlier potential
mechanisms and effectors of platelet death, and ended with a study on the birth of platelets! Although
much of this work has been discussed in the individual chapters, such discussion has tended to focus
on the three studies in relative isolation. However, the combined data (in reverse order!) reveals a
fascinating and seminal insight into the possibility that cell death may be a prime effector mechanism
in the maintenance of thrombostasis.
To summarise, MKs differentiate and mature within the bone marrow until a terminal stage is
reached whereby either constitutively, or by Fas directed killing, MKs initiate an adapted and
putatively "compartmentalised" form of apoptosis. Unidentified caspases are activated resulting in
membrane rearrangements and early stages of chromatin condensation. The MK extends proplatelets
along with the occurrence of more extensive nuclear condensation and fragmentation. Platelet
specific material is delivered through the proplatelets, including alpha/dense granules, functional
mitochondria with A\|/M intact, Bcl-xL, and caspase-3, all localising to the forming platelets.
However, the key component of the apoptosome, caspase-9, is excluded or degraded by the MK,
resulting in platelets devoid of the enzyme. Platelets are released from the proplatelet tips into
circulation and typically survive for 7-10 days. Through an unknown mechanism platelets initiate
their own intrinsic death program resulting in an increase in proapoptotic Bak and Bax. This is
associated with a mitochondrial dysfunction that now results in loss of Av|/M and release of
cytochrome-C. However, due to the absence of caspase-9 cytochrome-C cannot initiate the formation
of the apoptosome complex, and hence subsequent activation of the effector caspase-3 does not occur.
In spite of this, platelets undergo morphological and surface changes indicative of a cell death
program by other uncharacterised caspase-independent mechanisms. This ultimately results in a
"recognition competent" form able to be selectively removed, whereas activated or fresh platelets are
not, by a range of phagocytes, including vascular endothelial derived cells, utilising a scavenger
receptor-mediated mechanism.
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Therefore, although of limited in vivo relevance, the combined data present the possibility
that control of circulating platelet numbers could be maintained in part by two opposing and different
cell death programs. Firstly, increased caspase-dependent cell death in MKs leads to increased
platelet formation and hence release into circulation, thus raising platelet numbers. Secondly,
increased caspase-independent cell death within the platelet produces a recognition competent cell
able to be removed by phagocytes, hence lowering platelet number. Many, many, future experiments
are needed to help understand the detailed molecular mechanisms mediating these events, and thus
whether any potential for clinical intervention exists, and as such this thesis under one man power has
only scratched the surface, leaving numerous "open avenues" of research potential.
From the "platelet work" we have the potential to investigate the chymotrypsin sensitive
recognition molecule, or other changes on the platelet surface. This could be initiated by some simple
surface biotinylations and Western blotting to attempt to identify any global surface changes on the
platelet. Further investigations could use a "molecule fishing" technique, based on incubating surface
biotinylated aged platelet membrane-derived microvesicles with MO, washing away unbound
material, followed by analysis of extracted protein by Westerns with an anti-biotin Ab. Hence, any
biotin positive proteins found would have been enriched for due to their binding to MO. Furthermore,
it may prove useful to feed platelets aged for less time, and thus where a mixed population of
edible/non-edible exists, to MO. Subsequent analysis of these MO by TEM may provide insight into
whether only platelets aged to the vacuolated and condensed morphology reported are eaten, or
whether an earlier phenotype is recognition competent. Thus, it may be possible to look for platelets
with this phenotype in vivo in patients with conditions that may potentially have increased aged
platelets, i.e. thrombocythaemias, acute splenectomy, high blood LDL. Similarly, production of
monoclonal antibodies or the screening of large panels of current antibodies may identify a surface
marker that is either gained or lost on aging, again allowing screening for these platelets in vivo, or
alternatively the blocking of an epitope crucial for phagocytosis.
Much work could also be directed at the haemostatic properties of the senescent platelets.
Initial work shows that mixing fresh platelets with small numbers of aged rapidly accelerates
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coagulation on readdition of Ca2+ by around two-fold. In addition, using a novel in house developed
flow system one could investigate what interaction effete platelets have with vascular endothelial cells
under flow conditions, especially given that HUVECS can phagocytose them. Interestingly, a paper
from Marguet and colleagues (1999) has demonstrated that in addition to the exposure of PS by dying
cells, during phagocytosis the phagocyte itself must also expose PS. Thus, if PS bearing aged
platelets are phagocytosed by PS bearing endothelial cells, or splenic macrophages, what are the
thrombogenic implications of such an event? Speculatively, do patients with thrombocythaemia, who
are well characterised to be at high risk from thrombosis, have excess numbers of circulating effete
platelets which "overload" the clearance system? Could this increase in clearance demand result in
the raised levels of PS exposed by platelet and vasculature, initiating a thrombogenic event? A similar
argument may also apply to patients who suffer from sickle cell anaemia, which is characterised by PS
exposure on the red cells and thrombosis, particularly infarction of the spleen.
The effectors of the morphological and biochemical changes witnessed during platelet death
have yet to be elucidated. Interestingly, the death pathway as we have reported is very reminiscent of
a form of cell death known as "aborted apoptosis" whereby a standard apoptosis program is initiated,
but is blocked at the level of caspase activation and is finally terminated by alternative caspase-
independent routes (Nicotera et al 1999). In this respect the increases in proapoptotic Bak and Bax
within aged platelets is likely to cause the mitochondrial dysfunctional and release of cytochrome-C
detected, but whether this can directly activate non-caspase death effectors, or whether loss of
respiratory potential in general can activate factors is unknown. Interestingly, expression of Bax alone
in a caspase-inhibited system has been shown to be capable of inducing a form of cell death
characterised by loss of mitochondrial potential, cytosolic vacuolation, and increased membrane
permeability to Hoechst, but without DNA degradation (Xiang et al 1996). However, no mechanism
or effectors of these changes have been proposed. Many other non-caspase proteases have been
implicated to act in support roles to caspases, or essential cofactors in a wide range of apoptotic
systems. These include cathepsins, calpains, serine proteases, granzyntes, and the proteosome
complex (Leist and Jaattela 2001), with many shown to be able to cleave some of the "classic"
caspase substrates. Much work could be directed at investigating the roles of these other proteases in
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platelet death (and the apoptosis field in general), by combining genetic approaches with meticulous
titration of the pharmacological inhibitors, which are often highly non-specific at concentrations
widely used (Johnson 2000).
The novel findings and unanswered questions arising from the MK work alone are numerous.
Clearly a fundamental difference must exist between MKs and other cell types given the gross
morphological changes witnessed on induction of apoptosis via Fas ligation. As referred to in the
introduction and previous discussions, many cytoskeletal components are targeted by caspases in most
cell types, so what is the key event or substrate cleaved that makes so much difference in the MK?
PKCa has been shown to be required for proplatelet formation (Rojnuckarin and Kaushansky 2001),
and has also been demonstrated to be activated in many other cell types during apoptosis (Emoto et al
1995; Webb et al 2000), none of which extend such projections. On a minimalistic level the early
emergence of proplatelet projections, before the platelet-sized nodes form, appear morphologically
similar to the multiple processes extended by mature dendritic cells (DCs) (O'Doherty et al 1993).
Such projections in the DCs have been demonstrated to be dependent on the activation of Rho and
Rac (Kobayashi et al 2001), members of the Ras-related superfamily of small GTPases well known to
be important in membrane rearrangement, filopodia, and lamellipodia formation (Nobes and Hall
1995). A potentially easy pharmacological investigation using inhibitors of this family may prove
fruitful, but commercial availability of such reagents is limited, and accessibility to them has tended to
be through academic institutions.
A major limitation of much potential in vitro work is the relatively low frequency at which
either primary or cell line MKs extend proplatelets, even when Fas induced. Hence, any basic
biochemical approach using Western blotting will not use a protein lysate that is "all proplatelet"
derived. Theoretically a purification strategy able to even partially enrich this delicate phenotype
would greatly aid in furthering the work. Initial attempts using velocity sedimentation with BSA
gradients to retard the "spindly" branched proplatelet cells have only been of a limited success, with
around 15% purity - not enough. A second approach could be to try and subclone the MEG-01 cell
line itself. Work in this has demonstrated there to be a wide variation in the level of Fas expression on
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the cells, with perhaps only the high expressing cells responding to CH. 11 stimulation. Therefore the
potential exists to sort these cells either immunomagnetically or with a FACS, followed by expansion
of these high level Fas progenitors. Alternatively the cell line could be sorted and cloned for MKs
expressing high levels of markers associated with maturity, such as CD42a and/or CD41/61.
The use of in vivo models to support and extend this work may prove technically difficult.
Although much in vivo evidence from genetic ablation of the apoptotic machinery circumstantially
supports a role in platelet formation, the major phenotype of thrombocytopenia almost always occurs
in association with anti-platelet antibodies, due to defective thymocyte selection (Hashimoto et al
2000), and thus the potential for increased immune mediated clearance of platelets. Theoretically
primary MKs could be grown ex vivo from mice genetically ablated in caspase-3, caspase-9, or
caspase-8, thus avoiding any autoimmune issues. However, the homozygotes for caspase-3 and -9 die
perinatally and are born at a very low frequency (Kuida et al 1996, 1998; Hakem et al 1998), the
caspase-8 k/o is lethal in utero (Varfolomeev et al 1998), and the recovery of haematopoietic colony-
forming cells from these embryos is very low. The potential does exist to do a bone marrow adoptive
transfer experiment. Bone marrow from, for example, the gld mice deficient in active Fas ligand
could be transferred into an irradiated control background recipient, whereby the Fas ligand negative
cells home to the marrow and repopulate it. Such an experiment may give an insight into whether Fas
ligand directed killing is important in constitutive platelet production in vivo. Similarly, one could
study the rates of platelet recovery between gld and control mice following acute platelet loss, such as
the administration of anti-platelet antibodies, to examine whether the Fas system is perhaps involved
in a more acute platelet recovery response. Unfortunately many possibilities are limited by current
animal licence procedures, and the timescale to make amendments to current licences.
This work presented in this thesis not only reveals an important insight into the mechanisms
of thrombopoiesis, but also into fundamental evolutionary aspects of cell death in general. The
MK/platelet system is both phylogenically and developmentally old, with MKs detectable within the
murine yolk sack as early as 7 d postcoitum (Xu et al 2001). These rapid maturing MKs have been
proposed to give rise to large amounts of platelets, thus preventing haemorrhage in the developing
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blood vessels. Interestingly, the major wave of apoptosis during murine development occurs in the
brain around 12 d postcoitum (Kuida et al 1996, 1998; Hakem et al 1998), and therefore the early
wave of platelet production may speculatively be one of the earliest apoptotic events during
development. The question of how or why did the two ancient processes of thrombopoiesis and
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Apoptosis is a physiological program for the deletion
of cells in which caspases govern events leading to safe
clearance by phagocytes. However, a growing weight of
evidence now suggests that not all forms of programmed
cell death are caspase-dependent. We now report a com¬
plete and constitutive but caspase-independent pro¬
gram for the specific phagocytic clearance of intact ef¬
fete platelets, anucleated blood cells of critical
importance in health and disease. Platelets aged in vitro
not only exhibited increased expression of proapoptotic
Bak and Bax but also evidenced constitutive diminution
of function such as decreased aggregation to ADP,
which was accelerated by culture in the absence of
plasma. This abrogation of cell function in plasma-de¬
prived platelets was associated with morphological and
biochemical features similar to those of granulocyte ap¬
optosis, that is, cytoplasmic condensation, plasma mem¬
brane changes including exposure of phosphatidyl-
serine and the granule protein P-selectin, and
recognition by phagocyte scavenger receptors. How¬
ever, and in contrast with constitutive death of other
inflammatory blood cells by apoptosis, these events
were not affected by caspase inhibitors, nor was there
evidence of caspase-3 activation either by hydrolysis of
analog peptide substrates orWestern blot analysis, serv¬
ing to emphasize that neither programmed cell death
nor clearance by phagocytes need involve caspases.
Apoptosis has attracted intense scrutiny as a self-contained
and physiological program for deletion of unwanted cells (1, 2).
Caspase activation has emerged as a key effector mechanism
responsible for many of the classical phenomena of apoptosis
(3-5) including the first biochemical marker of this type of cell
death, endonuclease activation (6, 7). Furthermore, caspases
have been persuasively implicated in directing plasma mem¬
brane changes that lead to the key physiological outcome of
apoptosis, the nonphlogistic recognition and uptake of the in¬
tact dying cell by phagocytes (8).
However, the study of caspase-mediated cell death by apop-
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tosis has been dominated by experiments that have frequently
relied on artificially induced death in transformed cells and
that have rarely paid attention to their recognition and clear¬
ance by phagocytes. Nevertheless, these criticisms have been
addressed in studies ofprimary blood cells freshly isolated from
healthy human donors (9). For example, neutrophil granulo¬
cytes purified by methods designed to minimize artifactual
activation (10) undergo constitutive apoptosis that clearly di¬
rects specific recognition by phagocytes (11, 12). Furthermore,
not only is there evidence that "machinery" caspases such as
caspase-3 are activated as neutrophils aged in culture undergo
constitutive apoptosis (13-15), but it is also possible to inhibit
both apoptosis and recognition by phagocytes using broad spec¬
trum caspase inhibitors such as zVAD-fmk1 (16, 17). Indeed, in
this system, zVAD-fmk inhibits even the very earliest plasma
membrane changes that lead to binding of aged neutrophils by
phagocytes (17).
The platelet is another blood cell with a short in vivo half-life
(18). Platelets are critical for normal hemostasis, but disorders
of platelet number and function are common, giving rise to a
range ofbleeding or thrombotic disorders, including stroke and
myocardial infarction. Given their importance, it is remarkable
that there has been very little study of the constitutive death
program that likely accounts for platelet deletion in vivo. An
important preliminary study (19) suggested that platelets may
undergo an apoptotic program because increases in the expres¬
sion of proapoptotic members of the Bcl-2 family of death-
regulating proteins were observed following treatment with
ionomycin, a calcium ionophore that induces apoptosis in a
range of cell types, most notably lymphocytic cells (20, 21).
Interestingly, this study showed that ionomycin-induced in¬
creases in Bax and Bak, as well as the cell surface expression of
PS, were unaffected by zVAD-fmk and were hence
caspase-independent.
To investigate whether platelets exhibited a constitutive
death program, freshly isolated platelets were cultured for up
to 24 h at 37 °C. In the presence of plasma we observed an
increase in levels of proapoptotic Bax and Bak, which, in keep¬
ing with an earlier report (19), was consistent with the sugges¬
tion that platelets might engage a death program. In support of
this, we also observed a constitutive loss of aggregation and
spreading functions. By depriving platelets of plasma, a puta-
1 The abbreviations used are: zVAD-fmk, carbobenzoxy-Val-Ala-Asp-
fluoromethylketone; CM-Orange, «4-chloromethyl)benzoyl)aminotetra-
methylrhodamine; FITC, fluorescien isothiocyanate; HBSS, Hanks' bal¬
anced salt solution; LDH, lactate dehydrogenase; mAb, monoclonal
antibody; Mr/:, monocyte-derived macrophage; PBS, phosphate-buffered
saline; PPP, platelet poor plasma; PRP, platelet-rich plasma; TEM,
transmission electron microscopy; PS, phosphatidylserine.
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tive source of survival factors, not only was loss of function
accelerated, but there was also revelation of a cell death pro¬
gram characterized by cytoplasmic condensation, retention of
plasma membrane integrity, display at the cell surface of phos-
phatidylserine and P-selectin, and specific recognition by phag¬
ocyte scavenger receptors. However, there was no evidence of
caspase-3 activation, emphasizing that constitutive cell death
in platelets represents a complete but caspase-independent
program leading to phagocyte clearance of intact effete cells.
EXPERIMENTAL PROCEDURES
Materials—All chemicals were of analytical reagent grade and pur¬
chased from Sigma unless stated otherwise. Percoll was obtained from
Amersham Pharmacia Biotech; sodium citrate solution was from
Pharma Hameln GmbH (Hanover, Germany); HBSS without Ca2 ' and
Mg2+, pH 6.4, RPMI 1640, Iscove's modified Dulbecco's medium, and
supplements (penicillin, streptomycin, glutamine, and fetal bovine se¬
rum) were from Life Technologies, Inc.; FITC and/or phycoerythrin-
conjugated mAbs to CD61 (clone BL-E6) and CD62P (clone CRC81)
were from Caltag Laboratories (TCS Biologicals Ltd., Botolph Clayton,
UK); anti-CD42a (clone GRP-P) was from Serotec Ltd (Kidlington, UK);
unconjugated anti-CD62P clone CRC81 and Gl-4 were from Caltag
Laboratories and Ancell Corporation (Bayport, MN), respectively;
FITC-conjugated annexin-V was from BioWhittaker UK Ltd (Woking¬
ham, UK); pan interleukin-l/3-converting enzyme (Ab-1, catalog num¬
ber PC84), caspase-l-pNA substrate (400025), -AFC substrate (688225),
caspase-3-pNA substrate (235400), -AMC substrate (235425), acetyl-
leucyl-leucylnorleucinal, calpeptin, zVAD-fmk, and Asp-Glu-Val-Asp-
fluoromethylketone were from Calbiochem Novachem (Nottingham,
UK); anti-human caspase-3 polyclonal antibody (catalog number
65906E) and anti-cytochrome c mAbs (clones 6H2.B4 and 7H8.2C12)
were from PharMingen (Becton Dickinson, Cowley, UK); PermeaFix
was from Orthodiagnostics; and JC-1 (catalog number T3168) and CM-
Orange (catalog number C2927) were from Molecular Probes (Leiden,
The Netherlands).
Platelet Isolation and Culture—Freshly drawn venous blood was
obtained from aspirin-free healthy donors, and PRP was prepared fol¬
lowing citration and centrifugation at 300 X g for 20 min. PPP was
prepared from PRP by centrifugation at 1200 X g. Washed platelets
were prepared by diluting PRP with 5 volumes of HBSS, pH 6.4,
containing EDTA (4 mM) into a round-bottom capped polystyrene cen¬
trifuge tube before centrifugation at 280 x g for 20 min. Platelets were
resuspended and washed in HBSS, pH 6.4, before finally resuspending
in either PPP, Iscove's Dulbecco's modified Eagle's medium, or HBSS,
pH 6.4. Platelets were maintained at 37 °C in a closed (capped) tube at
3 X 108/ml.
Following isolation, for those experiments involving phagocytic rec¬
ognition of aged platelets, platelets were first incubated in HBSS at 5 x
109/ml for 10 min with 1.8 /xM CM-Orange. Unincorporated dye was
removed with two washes ofHBSS, pH 6.4, before resuspending at 5 x
108/ml in HBSS, pH 6.4. Platelet preparations were routinely checked
by microscopy for the presence of aggregates, which if found resulted in
the experiment being discarded.
Platelet Aggregation Experiments—Platelet aggregation studies were
performed in a PAP4 aggregometer (Bio-Data Corporation) in which
0.5-ml aliquots of platelets, resuspended in PPP, were incubated for 2
min while stirring at 37 °C before the direct addition of agonist. Prior to
aggregation experiments, washed platelets were harvested by centrif¬
ugation at 280 X g for 20 min and resuspended in autologous PPP.
Agonists used were ADP (10 /xm), thrombin (10 units/ml), platelet-
activating factor (10 /xm), and U46619 (10 /xm). In some instances,
platelets were preincubated for 1 min with the anti-aggregating reagent
MK852 (10 /xm) prior to the addition of agonist.
Platelet Adhesion and Cell Spreading on Collagen—Glass microscope
slides were coated with either collagens I or IV (100 mg/ml solutions in
PBS, pH 7.4). After 30 min the slides were washed exhaustively with
PBS before applying a volume of suspended platelets in cultured media.
Following a 20-min incubation, the slides were flicked free ofmedia and
nonadherent cells and snap-frozen with methanol and acetone (1:1).
The slides were then air-dried before staining with phalloidin-FITC in
PBS (2 /xg/ml). Slides were examined by epifluorescent microscopy
(Nikon Diaphot 300).
Sample Preparation for Transmission Electron Microscopy—Cell sus¬
pensions were prepared for electron microscopy by first washing the
platelets with PBS and fixing with 2.5% (v/v) glutaraldehyde in PBS for
at least 1 h at 4 °C. Cells were then pelleted at 280 x g before resus¬
pending in a sodium cacodylate buffer, pH 7.4, containing 2.5% glutar¬
aldehyde and leaving overnight. Samples were recentrifuged at 280 X
g, the supernatant was removed, and the cells were overlaid with a
minimal volume ofPRP-derived serum, which in turn was overlaid with
the cacodylate buffer for at least 1 h at room temperature. The pellet
was then transferred to fresh fixative and treated as normal resected
tissue for TEM.
Monocyte Isolation and Culture—Human monocytes were isolated
from freshly drawn venous blood following citration, dextran sedimen¬
tation, and plasma-Percoll density gradient centrifugation as described
previously (10, 11). Human monocyte-derived macrophages (Mc£) were
obtained by the standard technique of culturing adherentmonocytes for
5-7 days in Iscove's Dulbecco's modified Eagle's medium plus 10%
PRP-derived serum (11, 22).
Phagocytic Recognition ofAged Platelets—Platelets labeled with CM-
Orange and aged in culture were washed free of conditioned media and
resuspended in HBSS before addition to a prewashed monolayer of
adherent phagocyte cell lines cultured in 24-well plates. Typically 5 X
107 platelets were incubated with 1 X 105 phagocytes at 37 °C for 10
min for platelets aged in the absence of plasma and 30 min for platelets
aged in citrated plasma. Following the incubation period, the phagocyte
monolayer was washed free of noninteracting platelets, and any adher¬
ent platelets were removed by treatment with trypsin at 37 °C for 5 min
followed by 5 mM EDTA at 4 °C, to recover the human M(£, and trypsin/
EDTA treatment at 37 °C for 15 min for all other cell lines tested, before
flow cytometric and epifluorescent microscopic analysis.
Immunolabeling and Fluorescence-activated Cell Sorter Analysis of
Platelets—Immunofluorescent labeling of intact platelets for surface
expression of CD42a, CD61, or CD62P was typically performed by
resuspending 5 /xl of cultured platelets with 40 /xl of the appropriate
FITC-conjugated mAb (diluted 1:1000 with 10% new born calf serum in
PBS) for 10 min before adding 400 /xl of fluorescence-activated cell
sorter sheath fluid and sampling by flow cytometry using a single laser
FACScan (Becton-Dickinson, Mountain View, CA).
Intracellular immunolabeling of the Bel family of proteins was per¬
formed following fixation and permeabilization of the platelets with
PermeaFix (1 ml/5 X 108 platelets for 30 min on ice). Excess fixative was
then removed with two washes of PBS before resuspending with 10%
new born calf serum in PBS at 5 X 108/ml. 5 x 106 platelets were then
incubated overnight with neat antibodies to Bak (1 /xl), Bax (1 /xl), Bcl-2
(1 /xl), Bcl-x (1 /xl), and Mcl-1 (1 /xl) or their appropriate negative
controls. All primary antibodies were detected with FITC-conjugated
F(ab')2 fragments of sheep anti-rabbit polyclonal antibodies or goat
anti-mouse polyclonal antibodies from Sigma.
Phosphatidylserine exposure by intact platelets was determined by
resuspending 5 /xl of cultured platelets in 400 /xl of HBSS containing 10
mM Ca2+ and 10 /xg/ml of FITC-conjugated annexin-V. All labeling steps
were maintained at 4 °C.
SDS-Polyacrylamide Gel Electrophoresis and Protein Blotting—For
detection of caspase-3, platelets were lysed by resuspending in SDS
Laemmli sample buffer and immediately boiled for 5 min. For cyto¬
chrome c detection, washed platelets were resuspended in ice-cold 10
mM Hepes buffer (containing 1 mM EDTA, 1 mM 1,10-phenanthroline, 1
mM phenylmethylsulphonylfluoride, 1 mM benzamidine, 10 /xM pepsta-
tin, 10 /xM leupeptin, 10 /xM antipain, pH 8.0) and lysed following two
rounds of freeze-thaw. The lysed platelets were then centrifuged at
13,000 x g to yield a cytosolic supernatant (S13), and the pellet was
resuspended in lysis buffer before centrifuging again and dissolving the
pellet in 1% TX-100 and recentrifuging at 13,000 x g to yield soluble
protein from intactmitochondria (T13). The S13 and T13 fractions were
then precleared with a control IgG and protein G-agarose before immu-
noprecipitating cytochrome c with clone 6H2.B4 and boiling in SDS
sample buffer (Laemmli). Protein was analyzed on the basis of equal
numbers of extracted cells rather than on the amount ofprotein loaded.
Immunodetection of transblotted protein to polyvinylidene difluoride
membranes was performed as described previously (13).
Spectrophotometric Assay for Lactate Dehydrogenase—Aged washed
platelets were incubated overnight and pelleted by centrifugation at
280 X g. The supernatant was removed, and the pellet was resuspended
to the same volume in HBSS and sonicated. Stock solutions of NADH
(0.2 mM) and sodium pyruvate (1.6 mM) were freshly prepared in a Tris
(81.3 mM)/NaCl (203.3 mM) buffer, pH 7.2. The assay was initiated by
the addition ofplatelet supernatant or sonicate (40 /xl) to a quartz silica
cuvette maintained at 37 °C and containing 420 /xl of NADH and 80 /xl
of pyruvate. LDH activity was measured as the time-dependent and
pyruvate-dependent decrease in the absorbance of NADH at 339 nm.
LDH activity was expressed as /xmoles ofNADH consumed per min per
ml of platelet supernatant or sonicate.
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RESULTS
Cultured Platelets Exhibit Increased Levels of Proapoptotic
Bak and Bax—An important determinant of whether a cell will
undergo apoptosis is its intracellular balance between anti-
apoptotic members of the Bcl-2 protein family such as Bcl-2 and
Mcl-1 and proapoptotic members such as Bax and Bak (23, 24).
The possibility that platelets might be able to undergo an
apoptosis-like death has been raised by Vanags et al. (19) who
reported that ionomycin, which triggers apoptosis in many cell
types (20, 21, 25), caused an increase in the expression of
proapoptotic Bax and Bak, but not Bcl-2. To extend the findings
ofVanags et al. we decided to study a different model system in
which apoptosis-like death might occur. Granulocytes "aged" in
culture undergo constitutive death that is accelerated in the
absence of survival factors (26-28) and is correlated both with
increased levels of Bax (29, 30), but not Bak (31), and decreased
levels of Mcl-1 (32). We therefore tested the hypothesis that
prolonged culture of platelets might also lead to an increase in
the expression of proapoptotic Bcl-2 family members and a
susceptibility to apoptosis-like death.
By immunofluorescence flow cytometry we confirmed that
freshly isolated platelets expressed Bax, Bak, and Mcl-1, but
not Bcl-2 (Fig. 1). The ability of each antibody to recognize its
antigen was verified both by flow cytometry and Western blot
analysis with appropriate control cell lines.2 Interestingly, the
levels of immunodetectable Bak and Bax increased by 3.4- and
2.4-fold, respectively, as platelets were aged for 18 h in citrated
plasma (Fig. 1, B and C). No significant changes in Mcl-1 were
apparent. In keeping with studies of ionomycin stimulation of
platelets (19), these data suggest that platelets cultured for
18 h can adopt a more proapoptotic balance and further suggest
that aging in culture, as originally reported for neutrophils
(11), was likely to be a useful model for platelet cell death.
Furthermore, a tendency to apoptosis-like death during culture
was reinforced by the observations that after 18 h of culture,
aged platelets exhibited diminished mitochondrial membrane
potential as measured by JC-1 and release of cytochrome c into
the cytoplasm (data not presented).
Because plasma is a potential source of exogenous survival
factors, we went on to seek evidence that plasma deprivation,
which resulted in increased levels of Bax and Bak comparable
with those observed for platelets aged in the presence of plasma
(data not shown), might accelerate and therefore reveal a con¬
stitutive death program overlooked in previous short term cul¬
ture experiments on platelets.
Aged Platelets Exhibit Impaired Function—Platelets possess
many of the functional responses exhibited by other inflamma¬
tory blood cells and a key feature of apoptosis in leukocytes that
are cultured overnight in the presence of serum is loss of the
ability to respond to external stimuli and mount pro-inflamma¬
tory responses (33). Interestingly, abrogation of cell function is
characteristic of platelets that have been stored at 37 °C in the
presence of plasma, especially the inability to respond to weak
agonists such as ADP. With the use of an aggregometer, which
measures the light transmittance of a stirred platelet suspen¬
sion, we were able to confirm that platelets lost the ability to
aggregate but not to undergo a shape change in response to
ADP when cultured overnight in the presence of citrated
plasma (Fig. 2).
Treatment of freshly isolated (viable) platelets with 10 gM
ADP resulted in an immediate shape change, observed as a
slight decrease in light transmittance (upward deflection in
Fig. 2A), followed by an irreversible decrease in light transmit¬
tance that was indicative of a full aggregation response (Fig.






















Fig. 1. The proapoptotic balance of Bel homologs is accentu¬
ated in aged platelets. A, typical immunofluorecence flow cytometry
histograms of fixed permeabilized (PermeaFix) cells that demonstrate
that freshly isolated platelets express the proapoptotic Bel homologs
Bak and Bax but not the anti-apoptotic homolog Bcl-2. The negative
controls for mouse (Bcl-2) and rabbit (Bak, Bax, and Mcl-1) antibodies
were superimposable and no different from autofluorescent controls,
confirming an absence of nonspecific binding. B, overlays of represent¬
ative histograms showing the shift in fluorescence for Bak and Bax
expression between freshly isolated and aged platelets. Autofluores-
cence and control irrelevant staining for fresh and aged platelets were
essentially indistinguishable. C, the mean peak fluorescence for various
members of the Bel family is presented as the arithmetic mean ± 95%
confidence interval for n = 4 separate experiments (three different
donors). Each experiment was performed in duplicate on samples per¬
meabilized with PermeaFix with fresh citrated platelets (open columns)
or platelets cultured in the presence of citrated plasma for 18 h (solid
columns).
2A). By reducing the concentration of ADP to 3 pM and in
accordance with the biphasic nature of platelet aggregation
(34), we observed a reversal of the initial wave of aggregation
because of the absence of endogenous agonists such as ADP
being secreted by the weakly activated platelets (Fig. 2A). In
Negative Bak Bax Mcl-1 Negative Bcl-2
Control Control
(Rabbit) (mouse)
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Fig. 2. Agonist-induced aggregation is down-regulated in aged
platelets. Photometric measurement of stirred suspensions of freshly
isolated platelets (A) or platelets aged in citrated plasma for 24 h (B)
were monitored for changes in light transmittance over a 10-min period
following activation with ADP to a final concentration of 10 p.M (i), 3 pM
(ii), and 1 pM (Hi). The upward deflection (decreased transmittance) in
the traces immediately following the addition of ADP is indicative of
shape change, whereas increases in transmittance are indicative of
reversible (if) or full aggregation (i). The chart recorder moved from left
to right with a 1-min interval represented by the horizontal bar in B. C,
freshly isolated platelets were maintained for 4 h at 37 °C in either
citrated plasma (i) or, after being washed free of plasma, in HBSS (ii)
containing either thrombopoietin (5 ng/ml) (iui, platelet-derived growth
factor (10 ng/ml) (v), insulin-like growth factor-1 (100 ng/ml) (ui), or
bovine serum albumin (4 mg/ml) (uii). Alternatively, washed platelets
were returned to PPP (iii). ADP was then added to a final concentration
of 10 pM, and the percentage of change in light transmittance was
recorded for 10 min. Error bars represent the 95% confidence interval
for five separate experiments.
the presence of 1 pM ADP there was no evidence of aggregation,
although shape change, which is the most sensitive response of
platelets, persisted. Aggregation, but not shape change, could
also be blocked by preincubating freshly isolated platelets with
the anti-GPIIb reagent MK852 (data not presented). In com¬
parison, platelets aged over a 24-h period in plasma lost the
ability to aggregate (tiA = 12 ± 2 h) but not to undergo a shape
change in response to ADP (Fig. 2B). The inability of aged
platelets to respond was also observed with the agonist plate¬
let-activating factor and the endoperoxide analog U46619 (data
not presented).
In keeping with the hypothesis that plasma might contain
survival factors that normally retard constitutive platelet
death, we found that the loss of an aggregation response to
ADP was markedly accelerated when platelets were washed
and cultured in the absence of plasma (ti^ = 1.5 ± 0.5 h). This
rapid loss in ADP-induced aggregation by washed platelets was
prevented and returned to rates comparable with those of un¬
washed platelets maintained in plasma by reconstituting the
washed platelets with PPP lt\A = 12 ± 2 h) (Fig. 2C). This
indicated that the loss in platelet response was not dependent
on the washing procedure per se but rather on the absence of
permissive factors within plasma. Culturing washed platelets
in the presence of the megakaryocyte differentiation factor
thrombopoietin and known survival factors in other cell sys¬
tems such as platelet-derived growth factor, granulocyte-mac¬
rophage colony-stimulating factor, and insulin-like growth fac¬
tor-1, had no effect. As a control for oncotic effects we tested
bovine serum albumin at 4 mg/ml and found no protective
effect and could eliminate glucose as a confounding factor given
that its concentration in HBSS (1 mg/ml) is equivalent to
plasma concentrations (0.7-1.1 mg/ml). Initial investigations to
characterize the putative soluble plasma survival factor(s) by
dialysis have revealed the activity to be of 50 kDa or greater in
molecular size and stable to long term storage at 4 °C and
-20 °C.
Constitutive loss of platelet function on incubation at 37 °C
was further confirmed by assessing the ability of aged platelets
to adhere and spread on collagen coated surfaces with the
formation of lammelipodia and filopodia. Microscopic examina¬
tion of phalloidin-FITC-stained preparations revealed that
freshly isolated platelets readily adhered to both collagen I-
and IV-coated glass slides, whereas aged platelets, whether
cultured in the presence or absence of plasma protein, did not
(data not presented).
Aged Platelets Maintain Plasma Membrane Integrity—
Down-regulation of cell function is a feature of programmed
cell death in other blood cells (33, 35, 36) but might also have
reflected necrosis. Assessing necrosis was not straightforward
in platelets because their small size precluded the use of vital
dyes such as Trypan Blue because admission of dye could not be
confidently assessed by light microscopy. Similarly, the ab¬
sence of a nucleus precluded the use ofDNA staining vital dyes
such as Hoechst and propidium iodide. Nevertheless, flow cy¬
tometry revealed that the forward and side scatter properties of
fresh and aged platelets, whether cultured in HBSS or PPP,
were virtually superimposable (data not presented). This con¬
trasted with the deliberate impairment of plasma membrane
integrity by hypotonic lysis, thermal treatment, or mild acid
treatment that invariably resulted in the appearance of cellu¬
lar debris and the loss of platelets as assessed by forward and
side scatter (data not shown).
Further evidence against necrosis being a confounding factor
in the constitutive loss of platelet function was the use of
phalloidin-FITC as an actin-binding "vital dye" where greater
than 99% of both fresh and aged platelets excluded the dye
when assessed by flow cytometry (Fig. 3A). As a positive control
to reveal the potential level of intracellular staining, aged
platelets were permeabilized with the fixative PermeaFix prior
to staining with phalloidin-FITC. Fluorescence microscopy con¬
firmed that phalloidin-FITC had stained intracellular F-actin
of permeabilized platelets (data not presented). These data
were a strong indication that aged platelets were capable of
maintaining plasma integrity under the conditions employed in
this study.
As further confirmation ofplatelet integrity, we assessed the
level of LDH activity, an abundant intracellular enzyme of
platelets, in the supernatants of cultured platelets (Fig. 3B).
Importantly, less than 4% of total LDH activity was found in
the supernatant of platelets aged for 18 h in HBSS in the
absence of serum. To confirm that soluble LDH maintained
under comparable conditions was stable, we cultured whole cell
lysates from fresh platelets either on its own or with erythro¬
cytes. These experiments revealed that soluble LDH was stable
in culture over a 24-h period (Fig. 3B). The 75% loss in LDH
activity in the cytosol of intact aged platelets appeared likely to
reflect intracellular catabolism of retained LDH or its inacti-
vation by, for example, transglutaminases. Unfortunately,
given the high levels of LDH in plasma, we were unable to
reliably assess the release of LDH from platelets aged in
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Fig. 3. Aged platelets maintain plasma membrane integrity. A,
flow cytofluorimetric analysis for platelet membrane integrity of fresh
and aged platelets using actin-binding phalloidin-FITC as a vital dye.
Suspensions of platelets aged in the presence (Aged PRP) or absence of
plasma (Aged Washed) were washed free of conditioned media and
incubated for 10 min on ice with phalloidin-FITC at 2 pg/ml in PBS
before flow analysis. The FL1 channel (FITC) on a Becton-Dickinson
FACScan was set to the autofluorescence of unlabeled freshly isolated
washed platelets. As a positive control for phalloidin-FITC staining,
aged platelets cultured in the absence of serum were permeabilized
with PermeaFix (see "Experimental Procedures"). B, freshly isolated
platelets were resuspended in HBSS and cultured in the absence of
plasma for either 1 or 18 h before separating the cells from the condi¬
tioned supernatant and resuspending the cells in an equivalent volume
of fresh HBSS and sonicating. Clarified supernatants of fresh (i) and
aged (ii) washed platelets or their cell lysates (iii and iv, respectively)
were monitored for LDH activity. Cell lysates from fresh platelets were
also incubated for 18 h in HBSS either on their own (v) or in the
presence of erythrocytes (vi). The level of LDH in PPP is shown for
comparison (vii). Error bars represent the 95% confidence interval of
four separate experiments each done in duplicate.
plasma. Taken together with the phalloidin data, these results
provide strong evidence against the possibility that aged plate¬
lets may have undergone necrosis but rather may have under¬
gone a form of programmed cell death.
Transmission Electron Microscopy ofAged Platelets Is Sug¬
gestive of a Cell Death Program—To further eliminate the
possibility of necrosis we prepared samples for TEM. Freshly
isolated platelets, whether washed or not, exhibited character¬
istic discoid-like features ofnonactivated platelets (Fig. 4). This
was confirmed by the absence of filopodia and cell surface
protrusions or a centrally clumped body of organelles sur¬
rounded by a circumferential band of a constricting microtubu-
lar network. A cross-section through the platelets also revealed
the typical distribution of dense bodies, a-granules, mitochon¬
dria, and glycogen particles.
However, platelets aged in culture under conditions leading
to loss of function exhibited dramatic morphological changes.
Control platelets maintained in citrated plasma for 24 h exhib¬
ited few changes from the freshly isolated state, except that the
majority of cells assumed a spherical rather than a discoid
shape. However, when aged for 12 h in HBSS in the absence of
serum, when loss of function was complete, there was remark¬
able condensation of cytoplasm and granules with submem-
brane vacuolization reminiscent of that reported during apop-
tosis in megakaryocytes (37). Interestingly, cultured platelets
did not exhibit plasma membrane blebbing that is a common
feature of many cell types undergoing apoptosis, but lack of
surface blebbing is a notable feature of granulocyte apoptosis
(11). Furthermore, in keeping with evidence of granule fusion
with the plasma membrane as aging neutrophil granulocytes
progress to an intact late apoptotic state prior to secondary
necrosis (38), platelets aged for 24 h exhibited fusion of gran¬
ules with the plasma membrane. In view of these morphologi¬
cal changes suggestive of an apoptosis-like program of platelet
death with similarities to that observed in granulocytes, we
went on to seek comparable plasma membrane changes.
Aged Platelets Exhibit Cell Surface Changes ofApoptosis—
Although exposure of phosphatidylserine (PS) in the outer
membrane of platelets was originally demonstrated to be a
marker ofplatelet activation with procoagulant properties (39),
PS exposure is also recognized as a reliable marker of cells
undergoing caspase-dependent cell death (40-42). In granulo¬
cytes, PS exposure and caspase activation are tightly linked to
nuclear changes typical of apoptosis (14, 16, 17). We therefore
sought to determine by flow cytometry the level of PS exposure
using FITC-conjugated annexin-V, a high affinity probe for PS
(43). Flow cytometric analysis of control platelets aged for 24 h
in citrated plasma and labeled with annexin-V-FITC revealed a
bimodal distribution with typically no more than 8% found
positive (Fig. 5A). Although a background level of 0.2-0.5% of
fresh platelets bound annexin-V, any increases were not appar¬
ent until at least 8 h of culture where annexin-V binding
increased steadily to 8% by 24 h with minimal increases seen
thereafter. In contrast, washed platelets aged in the absence of
plasma, which again contained few annexin-V binding cells in
the first 6 h of culture, rapidly switched after 8 h to be >80%
positive by 18 h (Fig. 5A). To address the confounding possibil¬
ity that PS exposure was simply a result of the cell having
insufficient energy to maintain the "flippase" activity, washed
platelets were aged in the presence ofvarying concentrations of
glucose (1 mg/ml to 10 mg/ml). Following assessment of the
level of PS exposure by Annexin-V binding and flow cytometry,
no significant differences were seen (data not presented). The
inability of aged platelets to maintain an asymmetric distribu¬
tion for PS was strong evidence of an apoptosis-like constitutive
cell death program because activated platelets expressing PS
possess a translocase that re-establishes an asymmetric distri¬
bution, unless platelets have undergone secondary events of
aggregation (44).
Furthermore, we sought to confirm morphological evidence
of granule fusion with the plasma membrane during constitu¬
tive platelet death seen by TEM (Fig. 4) because this is an
important cell surface feature of later stages of constitutive
apoptosis in neutrophils (38). To assess for this possibility we
probed for the intracellular a and dense granule marker P-
selectin (45) (Fig. 5B). Reassuringly we found that platelets
maintained in citrated plasma did not express any cell surface
P-selectin in the first 8 h of culture, evidence against platelet
activation. Indeed, after aging for 24 h in the presence of
plasma we found that only a small proportion (—10%) of plate¬
lets expressed P-selectin. However, washed platelets cultured
in HBSS in the absence of serum rapidly mobilized intracellu¬
lar stores of P-selectin following 6 h of in vitro culture so that
all cells were positive by 7-10 h.
Constitutive Platelet Death Is Caspase-independent—Activa¬
tion of caspases is reported to be upstream of plasma mem¬
brane changes associated with apoptosis including PS exposure
(8, 16, 17, 40, 42). Although Western blot analysis confirmed
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Fig. 4. Aged platelets exhibit cytoplasmic condensation. Transmission electron micrographs of platelet preparations are shown: washed
platelets fixed immediately following isolation; aged platelets maintained in citrated plasma for 24 h; and washed platelets maintained in HBSS









Fig. 5. Aged platelets express phosphatidylserine and P-selec-
tin at their surface. Fresh washed platelets, platelets aged in HBSS
in the absence of serum protein (aged washed), and platelets aged in
citrated plasma (aged PRP) were assessed by flow cytometry for phos¬
phatidylserine exposure using annexin-V-FITC (A) and granule cell
fusion with the plasma membrane by monitoring for cell surface P-
selectin expression using a FITC-conjugated anti-P selectin mAb
CRC81 (B). The FL1-H channel (FITC) was set to the autofluorescence
of unlabeled platelets and confirmed that nonspecific binding of control
antibodies was minimal.
that caspase-3 was present as a 32-kDa species in platelets that
was reduced in aged preparations (Fig. 6), we were unable to
identify caspase-mediated cleavage to an active fragment (17
kDa) as was observed with apoptotic Jurkat T cells. Interest¬
ingly, aged platelets did reveal the presence of proteolyzed
species of molecular weights just less than the p32 parent
band, which a very recent report (46) indicates is due to cal-
pain-mediated processing to nonactivated species. In keeping
with these and other results (19, 46), and in contrast to apop¬
totic Jurkat T cells, we were also unable to detect caspase




Fig. 6. Caspase-3 is not cleaved as platelets age in culture.
Cytosolic extracts taken from fresh (iii) and aged platelets (iv) cultured
in the absence of serum were probed for caspase-3 by Western blot with
a polyclonal antibody that recognized both the 32-kDa (p32) precursor
and thel7-kDa subunit of the activated enzyme (note lack of the latter).
As positive controls, cell lysates were prepared from untreated Jurkat
T-cells (ii) that exhibited low levels (10%) of constitutive apoptosis as
judged by Giemsa stained cytospins, and those induced to undergo
apoptosis (i) following a 5-h treatment with staurosporine (2 pM) (ap¬
proximately 65% apoptosis). Positions for the 30-, 23-, and 16.5-kDa
mass markers were determined with the use of Rainbow Markers
(Sigma).
for either caspase-1 or caspase-3 (data not presented).
In further agreement with these data we also found that a
number of protease inhibitors, including the caspase inhibitors
Asp-Glu-Val-Asp-fluoromethylketone and zVAD-fmk, had no
effect on the rate ofPS exposure (Table I). Additionally, we also
found that the inhibitors had no effect on the refractiveness of
aged platelets to ADP-induced aggregation (data not pre¬
sented) whether cultured either in the presence or absence of
plasma. Similarly, phagocyte recognition of washed platelets
aged in the presence of caspase inhibitors was not different
from control, confirming the caspase-independent nature of
phagocyte clearance of aged platelets (Table I). Combined,
these results suggest that caspases do not have a major role in
the constitutive cell death of platelets and complement recent
studies on apoptosis-like events associated with platelet acti¬
vation (19, 46).
Aged Platelets Are Ingested by Phagocytes via Scavenger Re¬
ceptors—In vivo, the most important feature of the apoptotic
cell death program is that intact effete cells are recognized and
rapidly ingested by professional and semi-professional phago¬
cytes. In keeping with this, we found that platelets cultured for
18 h in the absence of plasma were readily ingested by 6-day-
old human M<j> following a 30-min phagocytosis assay as evi¬
denced by TEM (Fig. 7).
To quantitate platelet ingestion by a range of phagocytes, we
developed a flow cytometric method (Fig. 8) that was dependent
on incubating the phagocytes with platelets that had been
prelabeled with an orange fluorescing reagent (CM-Orange)
(Fig. 8A). Phagocytes were then sorted by flow cytometry where
Constitutive Platelet Cell Death 5993
Table I
Effect ofprotease inhibitors on PS exposure and recognition of aged washed platelets
Condition/inhibitor Concentration PS-positive washed platelets „ Recognition of aged washed
(after 18 h) platelets (normalized)
pM % %
Aged washed 71.2 7 100.0 4
Me2S0 control [0.1%] 70.6 ± 3.8 7 99.2 ± 4.7 4
zVAD-fmk 100 84.2 ± 8.0 5 117.4 ± 17.0 4
DEVD-fmk 10 76.0 ± 3.5 5 99.5 ± 7.9 4
Acetyl-leucine-leucylnorleucinal 100 71.8 ± 5.9 7 ND'
Calpeptin 100 77.3 ± 9.9 5 ND
"
n, number of separate experiments.
' ND, not done.
Fig. 7. Human monocyte-derived macrophages readily ingest
aged platelets. A representative TEM showing a cytoplasmic region
just beneath the plasma membrane of a human macrophage that con¬
tains distinct evidence ofhaving ingested two (solid arrow) and possibly
three (open arrow) platelets. The white scale bar represents 500 nm.
they were readily resolved from platelets by forward and side
scatter (Fig. 8B) with any shift in orange fluorescence (FL2)
attributed to interacting platelets (Fig. 8C). To discriminate
between adherence and ingestion we also labeled the phago¬
cytes prior to flow cytometry with an FITC-conjugated anti-
CD61 mAb. CD61, also known as glycoprotein Ilia, is a specific
cell surface marker for platelets (Fig. 8A) in which its expres¬
sion was not found to alter as platelets were aged in culture
whether in the presence or absence ofplasma. Interestingly, we
observed that anti-CD61 mAb routinely failed to label our
phagocyte populations, suggesting that platelets were in¬
gested, in keeping with TEM (Fig. 7) and that any adherent
platelets were removed prior to flow cytometry. Assessment of
cytospin preparations by confocal microscopy also confirmed
that platelets were contained within phagocytes (data not pre¬
sented). In contrast and as a control comparison, we confirmed
that freshly isolated platelets adhere to the surface of freshly
isolated monocytes (47) (Fig. 8D).
Although fresh platelets on microscopic examination were
observed to adhere to all phagocytic cell lines tested, only aged
platelets were found to be ingested following flow cytometric
analysis (Table II). We also observed that the degree of phag¬
ocytosis was always greater for platelets aged in the absence of
plasma survival factors than those aged in citrated plasma.
Typically, after a 30-min interaction, greater than 90% of hu¬
man Md> and Bowes melanoma cells ingested platelets aged in
the absence of plasma compared with only 30 ± 12% and 20 ±
6%, respectively, when aged in the presence of citrated plasma.
Moreover, time course experiments repeatedly showed that in a
fixed time phagocytosis assay the maximal level of ingestion by
human M<f and Bowes melanoma cells was achieved with
platelets aged for 12 h in the absence ofplasma or 24 h for those
cultured in citrated plasma.
The degree to which cell lines ingested aged platelets,
whether cultured in the presence or absence of plasma, was
found to be unaffected by various well characterized inhibitors
of recognition (Table II) (48). These included the integrin in¬
hibitor RGDS, the PS receptor-competitor phospho-l-serine,
the cationic sugars glucosamine and galactosamine, the anti-
CD36 mAb SM<f>, and the anti-CD14 mAb 61D3 (Table II).
Conclusive evidence against a role for CD36 in phagocytosis
was confirmed with the use of Bowes melanoma cells stably
transfected with CD36, which exhibited no increase in phago¬
cytosis when compared with control Bowes melanoma cell lines
(49). However, greater than 75% inhibition was observed with
fucoidan, a recognized inhibitor of the scavenger receptor path¬
way, in contrast to the lack of inhibition by dextran at the same
concentration, which served as control. Polyinositol, another
inhibitor of the scavenger receptor pathway, but not its stand¬
ard control polycytidine also inhibited recognition, although
not as effectively as fucoidan (Table II). Nevertheless, further
confirmation of a major role for the scavenger receptor was
obtained with the anti-murine scavenger receptor mAb 2F8,
which inhibited mouse peritoneal macrophage uptake of aged
platelets.
Because our studies had also shown that aged platelets ex¬
pressed P-selectin (Fig. 5B), which mediates adhesion of acti¬
vated platelets to monocytes (50), and given that fucoidan is
known to bind the lectin domain of P-selectin, we explored the
role of P-selectin in platelet recognition. By using a function-
blocking mAb (clone Gl) to P-selectin, which recognizes the
lectin domain, we found that the recognition of aged platelets
by human M<j> and Bowes melanoma cells was only weakly
affected, and no synergy with polyinositol was observed (Table
II). This suggests that although P-selectin had a minor role in
the phagocytosis of aged platelets it was not primarily respon¬
sible for mediating phagocytic recognition and clearance, a
conclusion in agreement with others (51).
DISCUSSION
Platelets play a crucial role in hemostasis and thrombosis,
with the consequence that they are of central importance in
common disorders such as myocardial infarction and stroke.
However, little is known of candidate mechanisms for safe
clearance of these anucleated blood elements. Prompted by
earlier work on constitutive apoptosis in other key blood cells,
granulocytes, we sought evidence for a constitutive death pro¬
gram available to platelets. In keeping with earlier work (19)
we confirmed that platelets expressed members of the Bcl-2
family of cell death-regulating proteins and observed that there
was an apparent proapoptotic shift in platelets aged for 18 h in
citrated plasma. We also observed that aged platelets lost the
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Fig. 8. Ingestion of aged platelets is readily quantitated with the development of a flow cytometric method. A, human platelets
prelabeled with CM-Orange (i) and aged in HBSS in the absence of plasma were confirmed to express the platelet specific marker CD61 with an
FITC-conjugated mAb (ii) whose expression remained unaltered relative to freshly isolated CM-Orange unlabeled platelets (iii). B, CM-Orange
labeled platelets (i), incubated with human macrophages (ii), orwith Bowes melanoma cells (iii) for times indicated elsewhere were readily resolved
from the phagocytes according to their forward and side scatter properties in flow cytometry. C, CM-Orange-labeled platelets that associated with
the phagocyte population are seen as a distinct subpopulation that is shifted in orange fluorescence (y axis). These platelets were predominantly
ingested given that they failed to dual label with the FITC-conjugated mAb to CD61. Similar results were found with mAbs to other platelet
markers such as CD42a. D, in contrast, freshly isolated monocytes readily bind but do not ingest freshly isolated CM-Orange-labeled platelets.
Table II
Platelet ingestion is mediated by the scavenger receptor
The level of inhibition by the following compounds on the ingestion of platelets that had been aged in either the absence or presence of plasma
protein were assessed by flow cytometry as follows: 0-5% inhibition; + , 5-20% inhibition; + -, 30-50% inhibition; + + +, 75-90% inhibition.
A typical interaction assay resulted in 40 ± 8% of M</> ingesting platelets aged in the absence of plasma after a 10-min assay and 38 ± 6% after
40 min for platelets aged in the presence of plasma, in contrast to BOWES where the level of ingestion was 30 ± 12% and 20 ± 6%, respectively.
M</> (human) BOWES (human)" tfpm HTTVFP
Platelets aged in plasma Concentration — — — — (m0use)6 (human)"
EGTA 1 mM - NDrf - ND ND ND
RGDS 1 mM - - - - - -
RGES 1 mM - - - - - -
Phospho-L-serine 1 mM - - - - - -
A-Acetyl glucosamine 20 mM - - - - - -
A-Acetyl galactosamine 20 mM - - - - - -
Poly-inositol 100 /xg/ml + + + + + + + + + + + +
Poly-cytidine 100 /xg/ml - - - - - -
Fucoidan 100 /xg/ml + + + + + + + + + + + + + + + + + +
Dextran 100 /xg/ml - ND - ND ND ND
mAb 2F8 (anti-scavenger receptor) 10 /xg/ml NAe NA NA NA + + NA
mAb G-l (P-selectin blocking Ab) 10 /xg/ml + ND + ND ND ND
mAb G-l + 100 /xg/ml poly-inositol 10 /xg/ml + + ND + + ND ND ND
mAb G-l + 1 mM EGTA 10 /xg/ml + ND + ND ND ND
mAb CRC81 (anti-P-selectin) 10 /xg/ml - ND - ND ND ND
" BOWES, Bowes melanoma cells.
6 TEPM, thioglycollate-elicited peritoneal macrophages.
c HUVEC, human umbilical vein endothelial cells.
d ND, not done.
" NA, not applicable.
ability to aggregate in response to weak agonists such as ADP
and failed to adhere and spread on collagen coated surfaces.
Given that serum is a rich source of survival factors for
granulocytes, with which platelets have much in common, we
reasoned that the physiological milieu ofplatelets, plasma, was
likely to also contain factors capable of retarding their pro¬
grammed death. We therefore sought evidence of accelerated
programmed cell death when platelets were cultured in the
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absence of plasma, finding that they not only exhibited an
accelerated loss of function but also displayed many features in
common with programmed death of granulocytes. Such
changes included morphological evidence of cytoplasmic con¬
densation and cell surface expression of the "eat me" signal
phosphatidylserine (52) and granule components such as P-
selectin. Importantly, however, there was strong evidence that
such aged platelets retained plasma membrane integrity be¬
cause there was no detectable release of the cytoplasmic
marker enzyme lactate dehydrogenase, nor did the aged cells
admit actin-binding phalloidin-FITC. Furthermore, aged plate¬
lets were recognized and ingested by all professional and semi-
professional phagocytes tested by a mechanism in which phag¬
ocyte scavenger receptors predominated.
An important conclusion to be drawn from these studies is
that constitutive death in plasma-deprived platelets represents
a caspase-independent program for phagocyte clearance of ef¬
fete cells. Not only did broad spectrum caspase inhibitors fail to
affect all phenomena associated with platelet death, including
recognition by phagocytes, but there was no evidence that
caspase pseudo-substrates were cleaved. Given earlier studies
in various models of apoptotic cell death, in which the display
of cell surface "eat me" signals such as phosphatidylserine
exposure appears to be mediated by caspases (8, 40, 42), we
believe that demonstration of a complete caspase-independent
program for cell death and clearance is an important addition
to examples of caspase-independent cell death where recogni¬
tion of such cells by phagocytes has not been previously studied
(53-56).
With regard to platelet cell death, these studies also comple¬
ment recent reports suggesting that ionomycin stimulation of
platelets, a model of activation-induced cell death, can recapit¬
ulate many of the features found in apoptosis (19, 46). Although
there is some evidence that caspases may participate in plate¬
let activation (57), Wolf et al. (46) suggest that the effects of
ionomycin on platelets are independent of caspases because
calpains disable activation by partial cleavage of their pro-
domains. Similar mechanisms could be at play in constitutive
platelet cell death given its independence from caspases de¬
spite the presence of cytochrome c in supernatants from cell
lysates, which can activate caspases (46), and the remarkably
similar evidence of partial caspase-3 cleavage on Western blot.
This possibility is now under active investigation, especially as
further studies are clearly required to characterize the caspase-
independent mechanisms by which aged platelets express PS
because this was not affected by the calpain inhibitors acetyl-
leucyl-leucylnorleucinal and calpeptin.
It will also be important to define in more detail the molec¬
ular mechanisms by which phagocyte class A scavenger recep¬
tors mediate recognition and ingestion of aged platelets, as
clearly indicated by the inhibitor studies presented in this
report. Although the role of the scavenger receptor has already
been implicated in the clearance of apoptotic thymocytes by
mouse macrophages (58) the ligands displayed by dying cells,
which lead to their recognition by scavenger receptors, are
currently unknown. Furthermore, although PS is widely rec¬
ognized as an "eat me" signal (52), it is not properly understood
why various phagocyte types will apparently ignore PS in favor
of other yet to be characterized signals for ingestion (59).
Because constitutive death in plasma-deprived platelets was
caspase-independent and could not be assessed for typical nu¬
clear changes because these cells have no nucleus, we feel it is
not appropriate to label this form of cell death as "apoptosis."
However, we believe that the data indicate that platelets can
undergo a form of programmed cell death that can be regulated
by exogenous influences, in particular plasma-derived survival
factors. In keeping with this, we observed that the return of
plasma-deprived platelets to plasma slowed the phenomena of
cell death, most notably returning the rate of loss of aggrega¬
tion and levels of PS exposure to that observed for platelets
cultured in plasma. Ongoing work is directed at the biochemi¬
cal characterization of the survival activity present in plasma
because a range of candidate cytokine survival factors could not
substitute for plasma. Nevertheless it should be emphasized
that plasma deprivation appeared merely to accelerate a con¬
stitutive death program that was already active in platelets at
37 °C and evident after 18-24 h of culture in plasma. However,
study of constitutive death in plasma-replete platelets will be
difficult because our preliminary work demonstrated progres¬
sive loss of platelets from populations cultured for >24 h,
presumably reflecting relatively rapid secondary necrosis of
that proportion of cultured platelets undergoing programmed
death each day.
In conclusion, we have provided in vitro evidence that human
platelets can undergo a constitutive program of cell death that
was caspase-independent and that resulted in the specific rec¬
ognition of effete cells by phagocytes employing the scavenger
receptor as a recognition mechanism. Although our findings
have potentially important implications for understanding
platelet kinetics and the related pathogenesis of thrombotic
and bleeding disorders, no firm conclusions on in vivo relevance
can be drawn from the current data. Nevertheless, these data
raise the exciting prospect that platelet lifespan and clearance
is amenable to exogenous regulation for therapeutic purposes.
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